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Introduction
Without pregnancy-specific protection, an estimated 45% 
of 32 million pregnancies in malaria-endemic sub-
Saharan Africa are exposed to Plasmodium falciparum 
malaria yearly,1 leading to 900 000 malaria-associated low 
birthweight deliveries2 and associated consequences for 
infant health.3 In these areas, WHO recommends 
intermittent preventive treatment in pregnancy (IPTp) 
with antimalarials. IPTp with sulfadoxine-pyrimeth-
amine, the only antimalarial currently recommended for 
this strategy, is associated with major reductions in 
maternal anaemia, low birthweight, and neonatal 
mortality.4 However, the effectiveness of sulfadoxine-
pyrimethamine IPTp is threatened by resistance to this 
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Summary
Background Resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine threatens the antimalarial 
effectiveness of intermittent preventive treatment during pregnancy (IPTp) in sub-Saharan Africa. We aimed to assess 
the associations between markers of sulfadoxine-pyrimethamine resistance in P falciparum and the effectiveness of 
sulfadoxine-pyrimethamine IPTp for malaria-associated outcomes.
Methods For this systematic review and meta-analysis, we searched databases (from Jan 1, 1990 to March 1, 2018) for 
clinical studies (aggregated data) or surveys (individual participant data) that reported data on low birthweight (primary 
outcome) and malaria by sulfadoxine-pyrimethamine IPTp dose, and for studies that reported on molecular markers of 
sulfadoxine-pyrimethamine resistance. Studies that involved only HIV-infected women or combined interventions 
were excluded. We did a random-effects meta-analysis (clinical studies) or multivariate log-binomial regression 
(surveys) to obtain summarised dose-response data (relative risk reduction [RRR]) and multivariate meta-regression to 
explore the modifying effects of sulfadoxine-pyrimethamine resistance (as indicated by Ala437Gly, Lys540Glu, and 
Ala581Gly substitutions in the dhps gene). This study is registered with PROSPERO, number 42016035540.
Findings Of 1097 records screened, 57 studies were included in the aggregated-data meta-analysis (including 
59 457 births). The RRR for low birthweight declined with increasing prevalence of dhps Lys540Glu (ptrend=0·0060) but 
not Ala437Gly (ptrend=0·35). The RRR was 7% (95% CI 0 to 13) in areas of high resistance to sulfadoxine-pyrimethamine 
(Lys540Glu ≥90% in east and southern Africa; n=11), 21% (14 to 29) in moderate-resistance areas (Ala437Gly ≥90% 
[central and west Africa], or Lys540Glu ≥30% to <90% [east and southern Africa]; n=16), and 27% (21 to 33) in low-
resistance areas (Ala437Gly <90% [central and west Africa], or Lys540Glu <30% [east and southern Africa]; n=30; 
ptrend=0·0054 [univariate], I²=69·5%). The overall RRR in all resistance strata was 21% (17 to 25). In the analysis of 
individual participant data from 13 surveys (42 394 births), sulfadoxine-pyrimethamine IPTp was associated with 
reduced prevalence of low birthweight in areas with a Lys540Glu prevalence of more than 90% and Ala581Gly 
prevalence of less than 10% (RRR 10% [7 to 12]), but not in those with an Ala581Gly prevalence of 10% or higher 
(pooled Ala581Gly prevalence 37% [range 29 to 46]; RRR 0·5% [–16 to 14]; 2326 births).
Interpretation The effectiveness of sulfadoxine-pyrimethamine IPTp is reduced in areas with high resistance to 
sulfadoxine-pyrimethamine among P falciparum parasites, but remains associated with reductions in low birthweight 
even in areas where dhps Lys540Glu prevalence exceeds 90% but where the sextuple-mutant parasite (harbouring the 
additional dhps Ala581Gly mutation) is uncommon. Therapeutic alternatives to sulfadoxine-pyrimethamine IPTp are 
needed in areas where the prevalence of the sextuple-mutant parasite exceeds 37%.
Funding US Centers for Disease Control and Prevention, the Malaria in Pregnancy Consortium (funded through a 
grant from the Bill & Melinda Gates Foundation to the Liverpool School of Tropical Medicine), Worldwide Antimalarial 
Resistance Network, European and Developing Countries Clinical Trials Partnership.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Articles
Lancet Infect Dis 2019
Published Online 
March 25, 2019 
http://dx.doi.org/10.1016/
S1473-3099(18)30732-1
See Online/Comment 
http://dx.doi.org/10.1016/ 
S1473-3099(18)30796-5
Department of Clinical 
Sciences, Liverpool School of 
Tropical Medicine, Liverpool, 
UK (A M van Eijk PhD, 
G Koshy PhD, C Khairallah MSc, 
Prof F O ter Kuile PhD); 
Department of Public Health, 
Food Studies and Nutrition, 
Syracuse University, Syracuse, 
NY, USA (D A Larsen PhD); 
Malaria Research and Training 
Centre, Department of 
Epidemiology of Parasitic 
Diseases, Faculty of Medicine, 
Pharmacy, and Dentistry, 
University of Sciences, 
Techniques, and Technologies 
of Bamako, Bamako, Mali 
(K Kayentao PhD); Rollins School 
of Public Health, Emory 
University, Atlanta, GA, USA 
(D E C Slaughter SB); Faculty of 
Infectious and Tropical 
Diseases, London School of 
Hygiene & Tropical Medicine, 
London, UK (C Roper PhD); MRC 
Centre for Outbreak Analysis 
and Modelling, Department of 
Infectious Disease 
Epidemiology, Imperial College 
London, London, UK 
(L C Okell PhD); Malaria Branch, 
US Centers for Diseases Control 
and Prevention, Atlanta, GA, 
USA (M Desai PhD, 
J Gutman MD); Department 
of Medicine, University 
of Melbourne, Melbourne, 
VIC, Australia 
(Prof S J Rogerson PhD); 
Department of Genome 
Sciences, University of 
Washington, Seattle, WA, USA 
(Prof C Hopkins Sibley PhD); 
WorldWide Antimalarial 
Resistance Network, University 
of Oxford, Oxford, UK
Articles
2 www.thelancet.com/infection   Published online March 25, 2019   http://dx.doi.org/10.1016/S1473-3099(18)30732-1
drug combination, particularly in east and southern 
Africa.
In P falciparum, sulfadoxine-pyrimethamine resistance 
results from a series of single nucleotide polymorphisms in 
the parasite’s dihydrofolate reductase (dhfr) and dihydrop-
teroate synthase (dhps) genes. At the ecological level, a high 
prevalence of quintuple-mutant P falciparum parasites, 
defined as those that harbour the five most common 
substitutions (dhfr substitutions Asn51Ile, Cys59Arg, and 
Ser108Asn, and dhps substitutions Ala437Gly and 
Lys540Glu), reduces the efficacy of sulfadoxine-pyri-
methamine as an intermittent preventive treatment against 
malaria in infants and children,5,6 undermines the ability of 
sulfadoxine-pyrimethamine to clear existing P falciparum 
infections in asymptomatic pregnant women,7,8 and shor-
tens the post-treatment prophylactic period following IPTp.7 
Sextuple-mutant P falciparum parasites, which harbour the 
additional dhps Ala581Gly mutation, are associated with 
enhanced sulfadoxine-pyrimethamine resistance in vitro, 
sulfa doxine-pyrimethamine treatment failure in patients 
with acute malaria,9–11 and failure of the drug combination to 
inhibit parasite growth or prevent malaria-associated fetal 
growth restriction in pregnant women.12–15
Despite these effects, there are no guidelines on the 
use of molecular prevalence data to inform the use of 
sulfadoxine-pyrimethamine for IPTp.16 The ecological 
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Research in context
Evidence before this study
We searched the Malaria in Pregnancy Library, PubMed, Web of 
Science, and Scopus for studies (published in English, 
up to March 1, 2018) in sub-Saharan Africa of the ecological 
relationship between molecular markers of 
sulfadoxine-pyrimethamine resistance and the effectiveness of 
sulfadoxine-pyrimethamine intermittent preventive treatment 
in pregnancy (IPTp) for preventing low birthweight, preterm 
birth, maternal malaria infection, and maternal anaemia. The 
following search terms were used: “Malaria AND pregnan* AND 
(intermittent OR IPT) AND Review”. We found one prospective 
multi-country study (done in eight sites), two meta-analyses, 
and one modelling study. In the prospective study, prevalence of 
molecular markers of sulfadoxine-pyrimethamine resistance was 
strongly correlated with clearance of existing infections by the 
drug, and with duration of post-treatment prophylaxis, but 
showed no clear trend with regard to reductions in low 
birthweight, maternal anaemia, or plasmodium infections from 
this treatment. In this study, few areas with a high prevalence of 
the highly resistant sextuple-mutant Plasmodium falciparum 
parasite were investigated. One meta-analysis showed, based on 
three studies, no protective effect of sulfadoxine-pyrimethamine 
IPTp (vs placebo or no intervention) against low birthweight in 
areas with more than 50% dhps Lys540Glu mutation prevalence. 
By contrast, the other meta-analysis (nine studies) showed no 
reduced effectiveness of the treatment in areas with high 
sulfadoxine-pyrimethamine resistance. The modelling study did 
not directly investigate the relationship between the effect of 
sulfadoxine-pyrimethamine resistance and the effectiveness of 
sulfadoxine-pyrimethamine, but suggested that, even 
accounting for resistance, extending sulfadoxine-pyrimethamine 
IPTp to all women attending antenatal clinics would have a 
sizeable and cost-effective impact on maternal and infant health. 
Although this inference was valid in most malaria-endemic 
settings in sub-Saharan Africa, the single exception was highly 
resistant areas where sextuple-mutant parasites are common.
Added value of this study
This is the most comprehensive study of the effect of 
sulfadoxine-pyrimethamine resistance on the effectiveness of 
IPTp, involving 57 studies, 13 surveys, and more than 
100 000 births. The aggregated data meta-analysis indicated 
substantial heterogeneity in effect size between studies, 
which might explain the contradictory findings between the 
two previous smaller reviews and the ongoing controversy 
about the continued use of sulfadoxine-pyrimethamine IPTp in 
areas of high resistance. We report for the first time a clear trend 
towards reduced effectiveness of sulfadoxine-pyrimethamine 
IPTp for low birthweight and P falciparum infection with 
increasing prevalence of molecular sulfadoxine-pyrimethamine 
resistance markers. Sulfadoxine-pyrimethamine was protective 
against low birthweight in areas of high resistance where 
parasites with the dhfr and dhps quintuple-mutant haplotype 
are essentially fixed. However, three observational cohort 
studies published elsewhere showed that these beneficial 
effects were not apparent in individuals infected with the highly 
resistant sextuple-mutant parasites (harbouring the quintuple 
mutant haplotype plus dhps Ala581Gly).
Implications of all the available evidence
Overall, evidence suggests a decline in the effectiveness of 
sulfadoxine-pyrimethamine IPTp for reducing malaria 
infection, anaemia, and low birthweight with increasing 
resistance. Nevertheless, use of sulfadoxine-pyrimethamine 
IPTp remains associated with reduced risks of low birthweight, 
even in areas where sulfadoxine-pyrimethamine fails to clear a 
third of asymptomatic infections in women receiving IPTp. 
These findings support WHO’s recommendation to continue 
using sulfadoxine-pyrimethamine for IPTp in these 
high-resistance areas. However, an important exception is areas 
where sextuple mutant parasites are common (≥37% 
prevalence). In such areas, alternative preventive strategies are 
required now. The substantial heterogeneity between studies, 
even in areas with similar resistance levels, suggests that 
single observational studies of the relationship between 
sulfadoxine-pyrimethamine doses and low birthweight might 
not be informative as tools for making policy decisions. 
A decision tool using just two or three mutational markers 
in the dhps gene could be considered to guide 
sulfadoxine-pyrimethamine IPTp policy.
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relationship between molecular measures of sulfadoxine-
pyrimethamine resistance and the effect of sulfa-
doxine-pyrimethamine IPTp on clinically relevant birth 
outcomes, such as low birthweight, is not clear. Previous 
attempts to define these relationships reached conflicting 
conclusions,17,18 possibly reflecting substantial between-
study heterogeneity in the effect of sulfadoxine-
pyrimethamine treatment on low birthweight.14,18
Using all available data derived from observational 
studies, clinical trials, and national surveys in sub-
Saharan Africa, we did a meta-analysis of the ecological 
relationship between molecular markers of sulfadoxine-
pyrimethamine resistance and the effect of sulfadoxine-
pyrimethamine IPTp on low birthweight. We hypothesised 
that a higher prevalence of sulfadoxine-pyrimethamine 
resistance, as indicated by the prevalence of molecular 
markers of sulfadoxine resistance, would be associated 
with an attenuation of the sulfadoxine-pyrimethamine 
IPTp-associated reduction in low birthweight.
Methods
Search strategy and selection criteria
We did a systematic review and meta-analysis in acc-
ordance with the Preferred Reporting Items for 
Systematic reviews and Meta-Analyses statement 
(appendix, p 41). Two main sources of data regarding 
IPTp effectiveness were used: aggregated data from 
observational studies and clinical trials (henceforth 
See Online for appendix
Figure 1: Study profile
dhps=dihydropteroate synthase. IPTp=intermittent preventive treatment in pregnancy. *561 from Malaria in Pregnancy Library, 440 from PubMed, 518 from Web of 
Science, and 502 from Scopus. †63 Demographic and Health Surveys, 13 Malaria Indicator Surveys, 54 Multiple Indicator Cluster Surveys (UNICEF), and eight AIDS 
indicator surveys. ‡Resistance data were not available for Comoros and São Tomé and Príncipe. §39 surveys with individual-level data available and information on out-
comes, exposures, and potential confounders (276 383 single live births: 46% with measured birthweight available, 54% with perceived birthweight; mean birthweight 
3217 g (SD 699), small birth size 14·1% of 276 383, low birthweight 9·4% of 128 347). ¶Comprising 49 481 births (of which 98·2% were singleton livebirths) before exact 
matching, and 42 394 singleton livebirths (19 429 with measured birthweight not available and 22 965 with measured birthweight available) after exact matching.
2021 records identified through database searching* 
1097 titles and abstracts screened
269 full-text records assessed for eligibility
66 articles or studies with information on one or more outcomes of interest 
(comprising 74 mutually exclusive datapoints) included in the review
57 datapoints from 50 source articles contributed to primary outcome 
(low birthweight)
43 observational cross-sectional studies with exposure data recorded 
at the time of delivery
  4 from trials comparing sulfadoxine-pyrimethamine IPTp against 
placebo or passive case detection
  3 from the sulfadoxine-pyrimethamine IPTp arm of other trials
924 duplicates removed
828 records excluded
365 related to policy implementation or reviews
238 studies on sulfadoxine-pyrimethamine IPTp coverage or qualitative studies
143 on treatment efficacy, drug resistance, pharmacokinetics, or modelling
  34 not in pregnant women
24 in HIV-infected women
  14 on cost-effectiveness
  10 outside Africa
203 records not meeting inclusion criteria excluded
68 overlapped with other studies that were included
49 almost all participants received IPTp (no zero-dose control) 
36 outcome during pregnancy, but not at delivery
36 no information on outcomes in relation to sulfadoxine-pyrimethamine dose
12 studies with insufficient detail on the number of sulfadoxine-pyrimethamine 
doses received
1 small sample size with inclusion of twin deliveries
1 multiple cointerventions in the sulfadoxine-pyrimethamine group
138† surveys identified for period 2000–15
39§ surveys with data on outcome, exposure, 
and confounders screened
13 surveys¶ with areas with ≥80% dhps 
Lys540Glu prevalence or super resistance 
      included in primary analysis after exact
      matching
99 not included
77 no birthweight data
14 not in sub-Subharan Africa
3 no data on insecticide-treated net use
2 no resistance data‡
1 no IPTp data
2 other reasons
26 excluded
25 in areas with <80% dhps Lys540Glu prevalence
  1 with no IPTp policy
Aggregated data (observational studies and trials) Individual participant data (surveys)
Articles
4 www.thelancet.com/infection   Published online March 25, 2019   http://dx.doi.org/10.1016/S1473-3099(18)30732-1
referred to collectively as clinical studies), and individual 
participant data from nationally representative surveys 
(referred to as surveys). Clinical studies were identified by 
two independent reviewers (AMvE and GK) by searching 
trial registries and electronic databases (Malaria in 
Pregnancy Library,19 PubMed, Web of Science, and 
Scopus) for studies published between Jan 1, 1990, and 
March 1, 2018, without language restrictions, in addition 
to scanning reference lists of articles and consulting with 
experts in the field (appendix p 2). The search terms 
“Malaria AND pregnan* AND intermittent AND 
(prevent* OR prophyla* OR chemoprevent* OR 
chemoprophyla* OR IPT*) AND (sulfadoxine OR 
sulphadoxine OR pyrimethamine OR SP)” were used. 
Observational studies were included if they were done in 
sub-Saharan Africa, had information at delivery on the 
number of sulfadoxine-pyrimethamine doses received, 
and data on birthweight, maternal haemoglobin, or plas-
modium infection at delivery. Trials were included if they 
were quasi-randomised or randomised trials done in sub-
Saharan Africa, compared sulfadoxine-pyrimethamine 
IPTp against passive case detection or placebo, and 
otherwise fulfilled the same criteria as for the 
observational studies. Studies or study arms were 
excluded if they involved only HIV-infected women or if 
they combined sulfadoxine-pyrimethamine with other 
antimalarial drugs (such as artemisinin derivatives or 
azithromycin) or with other interventions (such as 
screening for malaria). Final study eligibility was agreed 
on by the reviewers. If no agreement could be reached, a 
third reviewer (FOtK) assessed the study and agreement 
was reached by consensus.
To identify surveys, one reviewer (DAL) searched all 
national-level datasets from surveys done in malaria-
endemic countries in Africa after the year 2000 (when 
WHO introduced the sulfadoxine-pyrimethamine IPTp 
policy) and with datasets publicly available (as described 
in detail elsewhere;4 search date May 31, 2015), including 
the Demographic and Health Surveys Program, UNICEF 
Multiple Indicator Cluster Surveys, and Malaria 
Indicator Surveys. Surveys were included if they 
contained data on low birthweight (perceived birth size 
and measured weight), measured IPTp use by number 
of doses among recently pregnant women, and measured 
insecticide-treated net coverage at the household level 
(appendix pp 2–3).
Data on molecular markers of sulfadoxine-pyrimeth-
amine resistance were obtained from the clinical study 
reports or from the authors of those reports. If these data 
were not available, data were obtained from existing 
population prevalence maps of P falciparum dhps mutations 
by use of the molecular surveyor tool of the Worldwide 
Antimalarial Resistance Network (WWARN) and existing 
prediction surfaces of the prevalence of sulfadoxine-
pyrimethamine resistance-associated mutations based on 
these data.16,20–22 Malaria transmission intensity data were 
obtained from the Malaria Atlas Project.
Extraction and quality assessment of IPTp 
effectiveness data
From clinical studies, extraction of summary data was 
done independently by two investigators (AMvE and GK or 
DECS). Authors of primary studies were contacted for 
missing information or if reported data did not fit the 
required format. The following information was extracted: 
first author, publication year, year of study start and end, 
study design, study and randomisation procedures (trials 
only), inclusion criteria (eg, any restrictions by gravidity), 
insecticide-treated net use, numerator and denominator 
per outcome per sulfa doxine-pyrimethamine dose, and 
details of control intervention (trials only). If available, 
sulfadoxine-pyrimethamine resistance data were extracted. 
Study quality was assessed by two reviewers (AMvE and 
GK or DECS) using an adaptation of the Newcastle-Ottawa 
Scale (appendix, p 3).23
From surveys, the following (individual patient-level) data 
were extracted: reported number of sulfadoxine-
pyrimethamine doses received; composite of low birth-
weight (<2·5 kg) if measured birthweight was available, or 
perceived small birth size (very small or small) if 
birthweight was not available (the correlation between 
perceived and measured low birthweight has been 
described elsewhere4); and measured birthweight as a 
continuous variable.4 Other data extracted included number 
of antenatal visits, tetanus vaccination, iron supple-
mentation and insecticide-treated net ownership, house-
hold socio economic status, mother’s education, mother’s 
age and parity, birth spacing, newborn sex, season of birth, 
and whether it was a single or multiple birth.
Data on the prevalence of dhps Ala437Gly, Lys540Glu, 
and Ala581Gly mutations among P falciparum parasites 
were extracted from the clinical studies in pregnant 
women, the literature, and existing molecular surveyor 
databases (appendix p 4).16,20–22 In areas where the 
Figure 2: Relative risk of low birthweight associated with each incremental 
dose of sulfadoxine-pyrimethamine IPTp in all gravidae by resistance strata
On the basis of the estimated prevalence of dhps mutations in the study areas 
(matched as described in text and appendix p 9), resistance was stratified into low 
(Ala437Gly <90% [central and west Africa], or Lys540Glu <30% [east and 
southern Africa]; 30 studies), moderate (Ala437Gly ≥90% [central and west 
Africa], or Lys540Glu ≥30% to <90% [east and southern Africa]; 16 studies), 
and high (Lys540Glu ≥90% in east and southern Africa; 11 studies). p values 
following the I² statistics represent the χ² test for heterogeneity. Weights are from 
random effects analysis. Data marker sizes indicate the weight applied to each 
study using random-effects meta-analysis. Diamonds represent summary effect 
of studies. CW=central and west Africa. dhps=dihydropteroate synthase. 
D+L=Dersimonian-Laird method for random effects models. ES=east and 
southern Africa. IPTp=intermittent preventive treatment in pregnancy. 
I-V=inverse variance method for fixed effects models. *Reference refers to the 
lowest sulfadoxine-pyrimethamine dose category (0 or 0–1 dose as indicated in 
the sulfadoxine-pyrimethamine dose category column), and the comparison 
column (included for illustration only) refers to all the other exposure groups 
pooled (eg, if the sulfadoxine-pyrimethamine categories were 0, 1, 2+, the 
comparison column would reflect the data in the 1 dose group and 2+ dose groups 
pooled; full sample sizes per dose group and average doses are shown in the 
appendix (p 13). †The high prevalence of dhps Ala581Gly in these studies was not 
accompanied by a high prevalence in dhps Lys540Glu, so this information was not 
interpreted as an indication of the presence of sextuple-mutant parasites.
For the Demographic and 
Health Surveys Program see 
http://dhsprogram.com/
For the UNICEF Multiple 
Indicator Cluster Surveys see 
http://mics.unicef.org/
For the Malaria Indicator 
Surveys see http://www.
malariasurveys.org/
For the Malaria Atlas Project 
see http://www.map.ox.ac.uk/
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High-resistance areas
Moderate-resistance areas
Low-resistance areas
I–V overall 0·88 (0·86 to 0·90)
I–V subtotal 0·95 (0·90 to 1·00)
I–V subtotal 0·81 (0·78 to 0·84)
I–V subtotal 0·90 (0·87 to 0·93)
Olliaro et al, 2008, Senegal Mlomp CW 2000–07 0,1,2+ 57/532 (10·7) 29/372 (7·8) 39·3 0·0 0·82 (0·65 to 1·04) 18 (–4 to 35)
Menendez et al, 2008, Mozambique Manhica ES 2003–05 0,2+ 49/411 (11·9) 41/382 (10·7) 62·9 0·0 0·95 (0·78 to 1·15) 5 (–15 to 22)
Yussuf et al, 2010, Tanzania Lindi ES 2009–10 0,1,2+ 55/123 (44·7) 44/123 (35·8) 79·7 0·0 0·85 (0·70 to 1·02) 15 (–2 to 30)
Minja et al, 2013, Tanzania Korogwe ES 2008–10 0–1,2+ 4/17 (23·5) 43/705 (6·1) 100·0 42·9 0·52 (0·33 to 0·80) 48 (20 to 67)
Namusoke et al, 2010, Uganda Kampala ES 2004–05 0,1,2+ 28/162 (17·3) 19/159 (11·9) 93·5 0·0 0·74 (0·49 to 1·12) 26 (–12 to 51)
Bouyou-Akotet et al, 2010, Gabon Libreville CW 2005–06 0,1+ 24/120 (20·0) 11/83 (13·3) 69·0 0·0 0·77 (0·51 to 1·17) 23 (–17 to 49)
Challis et al, 2004, Mozambique Maputo ES 2001–02 0,2+ 27/203 (13·3) 19/200 (9·5) 26·1 0·0 0·85 (0·64 to 1·11) 15 (–11 to 36)
Arinaitwe et al, 2014, Uganda Tororo ES 2011 0–1,2+ 29/227 (12·8) 25/325 (7·7) 97·3 0·2 0·78 (0·61 to 1·00) 22 (–0 to 39)
Coulibaly et al, 2014, Burkina Faso Ziniare CW 2011–12 0,1,2+ 32/155 (20·6) 106/757 (14·0) 75·3 0·0 0·74 (0·61 to 0·91) 26 (9 to 39)
Famanta et al, 2011, Mali Bamako CW 2009 0,1,2+ 16/102 (15·7) 25/257 (9·7) 15·2 0·0 0·85 (0·62 to 1·17) 15 (–17 to 38)
Desai et al, 2014, Kenya Nyanza ES 2011–12 0–1,2,3+ 10/135 (7·4) 59/734 (8·0) 93·0 5·7 0·99 (0·81 to 1·20) 1 (–20 to 19)
Feng et al, 2010, Malawi Blantyre ES 1997–99 0,1,2+ 49/215 (22·8) 84/697 (12·1) 63·6 0·0 0·68 (0·56 to 0·82) 32 (18 to 44)
Gutman et al, 2013, and 
Kalilani et al, 2014, Malawi
Southern Malawi ES 2009–11 0–1,2,3+ 28/334 (8·4) 103/1498 (6·9) 94·4 1·5 0·98 (0·83 to 1·14) 2 (–14 to 17)
Oduro et al, 2010, Ghana Navrongo CW 2006–07 0,1,2,3+ 76/391 (19·4) 342/1886 (18·1) 53·8 0·0 0·97 (0·89 to 1·05) 3 (–5 to 11)
Ndyomugyenyi et al, 2011, Uganda Kabale ES 2004–07 0,2+ 99/1577 (6·3) 107/1561 (6·9) 100·0 45·0 1·04 (0·92 to 1·19) –4 (–19 to 8)
Kayentao et al, 2014, Mali Kita CW 2009–10 0,1,2+ 18/124 (14·5) 38/420 (9·0) 15·2 0·0 0·74 (0·56 to 0·99) 26 (1 to 44)
van Eijk et al, 2004, Kenya Kisumu ES 1999–2000 0,1,2+ 112/948 (11·8) 70/925 (7·6) 42·8 0·0 0·74 (0·61 to 0·90) 26 (10 to 39)
Likwela et al, 2012, DR Congo Mikalayi CW 2007 0–1,2+ 35/363 (9·6) 2/114 (1·8) 76·9 0·0 0·43 (0·21 to 0·86) 57 (14 to 79)
Mace et al, 2014, Zambia Mansa ES 2009–10 0–1,2,3+ 17/157 (10·8) 13/266 (4·9) 83·7 0·0 0·71 (0·53 to 0·95) 29 (5 to 47)
Kilauzi et al, 2013, DR Congo Kinshasa CW 2011 0,1+ 21/204 (10·3) 32/501 (6·4) 100·0 8·1† 0·63 (0·38 to 1·05) 37 (–5 to 62)
Msyamboza et al, 2009, Malawi Chikwawa ES 2002–04 0–1,2,3+ 65/427 (15·2) 157/891 (17·6) 87·0 0·0 1·03 (0·92 to 1·15) –3 (–15 to 8)
Olorunda et al, 2013, Nigeria Ibadan CW 2010 0,1+ 22/246 (8·9) 4/84 (4·8) 92·4 2·5† 0·58 (0·24 to 1·41) 42 (–41 to 76)
Njagi et al, 2002, Kenya Bondo ES 1997–99 0,2+ 51/359 (14·2) 46/369 (12·5) 42·8 0·0 0·94 (0·78 to 1·13) 6 (–13 to 22)
Aziken et al, 2010, Nigeria Benin City CW 2009 0,1+ 61/371 (16·4) 14/370 (3·8) 84·2 47·4† 0·40 (0·28 to 0·56) 60 (44 to 72)
Kayentao et al, 2014, Mali San CW 2006 0,1,2+ 15/135 (11·1) 14/263 (5·3) 32·6 0·0 0·61 (0·37 to 0·99) 39 (1 to 63)
Tutu et al, 2011, Ghana Offinso CW 2005–07 0,1,2,3+ 62/499 (12·4) 250/2084 (12·0) 77·6 0·0 0·88 (0·80 to 0·96) 12 (4 to 20)
Gies et al, 2009, Burkina Faso Boromo CW 2004–06 0,1,2+ 19/52 (36·5) 204/1220 (16·7) 71·5 0·0 0·57 (0·48 to 0·68) 43 (32 to 52)
Cassam et al, 2007, Mozambique Gaza ES 2005–07 0,3+ 756/8650 (8·7) 488/6645 (7·3) 53·2 0·0 0·94 (0·91 to 0·98) 6 (2 to 9)
Tetteh-Ashong et al, 2005, Malawi Chikwawa ES 2005 0–1,2,3+ 6/42 (14·3) 13/186 (7·0) 94·1 0·0 0·74 (0·50 to 1·09) 26 (–9 to 50)
Mosha et al, 2014, Tanzania Rufiji, Moshi ES 2012 0–1,2+ 9/169 (5·3) 9/181 (5·0) 93·2 2·7 0·97 (0·62 to 1·52) 3 (–52 to 38)
Kayentao et al, 2014, Mali Koro CW 2006–07 0,1,2+ 13/130 (10·0) 14/221 (6·3) 44·8 0·0 0·69 (0·42 to 1·14) 31 (–14 to 58)
Ramharter et al, 2007, Gabon Lambarene CW 2005–06 0,1,2+ 11/97 (11·3) 60/596 (10·1) 57·9 0·0 0·82 (0·61 to 1·11) 18 (–11 to 39)
Tongo et al, 2011, Nigeria Ibadan CW 2007–08 0–1,2+ 68/649 (10·5) 4/147 (2·7) 92·4 2·5† 0·51 (0·31 to 0·84) 49 (16 to 69)
Parise et al, 1998, Kenya Kisumu ES 1994–96 0,2,3+ 52/340 (15·3) 53/656 (8·1) 42·8 0·0 0·80 (0·70 to 0·91) 20 (9 to 30)
Alli et al, 2013, Nigeria Kubwa CW 2010–11 0,1+ 4/158 (2·5) 0/42 (0·0) 84·2 47·4† 0·50 (0·05 to 4·78) 50 (–379 to 95)
Braun et al, 2015, Uganda Fort Portal ES 2013 0,1,2+ 8/56 (14·3) 52/552 (9·4) 100·0 12·9 0·79 (0·57 to 1·10) 21 (–10 to 43)
Hommerich et al, 2007, Ghana Agogo CW 2006 0,1,2,3+ 8/52 (15·4) 20/173 (11·6) 84·6 0·0 0·91 (0·66 to 1·25) 9 (–25 to 34)
Toure et al, 2014, Côte d’Ivoire Abidjan, Comoe CW 2009–10 0,1,2,3+ 50/436 (11·5) 61/876 (7·0) 52·1 0·9 0·80 (0·67 to 0·97) 20 (3 to 33)
Harrington et al, 2011, Tanzania Muheza ES 2002–05 0,1,2+ 6/80 (7·5) 11/292 (3·8) 100·0 13·0 0·57 (0·29 to 1·09) 43 (–9 to 71)
Suleiman et al, 2003, Sudan Wad Medani ES 1999–2001 0,2+ 19/53 (35·8) 2/57 (3·5) 13·3 0·0 0·31 (0·15 to 0·63) 69 (37 to 85)
Moleins et al, 2010, Senegal Oussouye CW 2007–08 0–1,2+ 6/55 (10·9) 6/96 (6·3) 43·0 0·0 0·76 (0·44 to 1·30) 24 (–30 to 56)
 Vanga-Bosson et al, 2011, Côte d’Ivoire National CW 2008 0,1,2,3+ 35/309 (11·3) 172/1636 (10·5) 52·1 0·9 0·88 (0·75 to 1·03) 12 (–3 to 25)
Mbaye et al, 2006, Gambia Farafenni CW 2002–04 0,2+ 46/716 (6·4) 40/738 (5·4) 46·8 0·0 0·94 (0·81 to 1·09) 6 (–9 to 19)
Ndeserua et al, 2015, Tanzania Rufiji ES 2012 0–1,2+ 12/166 (7·2) 10/184 (5·4) 75·0 0·0 0·87 (0·58 to 1·30) 13 (–30 to 42)
Kayentao et al, 2014, Mali San CW 2009–10 0,1,2+ 18/110 (16·4) 22/320 (6·9) 27·5 0·0 0·62 (0·43 to 0·87) 38 (13 to 57)
Likwela et al, 2012, DR Congo Kisangani ES 2007 0–1,2+ 16/50 (32·0) 6/87 (6·9) 74·1 5·6† 0·46 (0·30 to 0·72) 54 (28 to 70)
Feng et al, 2010, Malawi Blantyre ES 1999–2001 0,1,2+ 20/117 (17·1) 85/719 (11·8) 80·3 0·0 0·77 (0·60 to 0·99) 23 (1 to 40)
Tonga et al, 2013, Cameroon Sanaga–Maritime CW 2011–12 0,1,2+ 7/68 (10·3) 6/127 (4·7) 76·5 5·9† 0·62 (0·32 to 1·19) 38 (–19 to 68)
Bouyou-Akotet et al, 2016, Gabon Libreville, Melen CW 2011 0,1,2+ 5/58 (8·6) 14/241 (5·8) 66·7 0·0 0·82 (0·50 to 1·36) 18 (–36 to 50)
Feng et al, 2010, Malawi Blantyre ES 2002–06 0,1,2,3+ 29/234 (12·4) 212/2137 (9·9) 93·5 2·0 0·89 (0·79 to 1·00) 11 (0 to 21)
Sirima et al, 2006, Burkina Faso Koupela CW 2004 0,1,2,3+ 16/66 (24·2) 119/1054 (11·3) 48·1 0·0 0·68 (0·58 to 0·79) 32 (21 to 42)
Falade et al, 2007, Nigeria Ibadan CW 2003–04 0,1+ 16/171 (9·4) 31/595 (5·2) 63·0 0·0 0·73 (0·53 to 1·00) 27 (0 to 47)
Igboeli et al, 2017, Nigeria Enugu State CW 2013 0,1+ 8/101 (7·9) 7/315 (2·2) 96·8 52·6† 0·56 (0·36 to 0·88) 44 (12 to 64)
Kayentao et al, 2014, Mali Djenne CW 2006 0,1,2+ 10/110 (9·1) 13/245 (5·3) 32·7 0·0 0·74 (0·46 to 1·17) 26 (–17 to 54)
Kayentao et al, 2014, Mali Bougouni CW 2006–07 0,1,2+ 11/101 (10·9) 17/306 (5·6) 33·8 0·0 0·70 (0·44 to 1·09) 30 (–9 to 56)
Muhammad et al, 2016, Nigeria Nguru, Yobe CW 2014 0–1,2+ 58/104 (55·8) 10/80 (12·5) 24·5 0·0 0·47 (0·35 to 0·64) 53 (36 to 65)
Likwela et al, 2012, DR Congo Rutsuhuru ES 2007 0–1,2+ 16/177 (9·0) 39/493 (7·9) 88·1 45·6 0·94 (0·71 to 1·24) 6 (–24 to 29)
D+L subtotal  (I2 31·4%, p=0·15) 0·93 (0·87 to 1·00) 7 (0 to 13)
D+L subtotal  (I2 70·5%, p<0·0001) 0·73 (0·67 to 0·79) 27 (21 to 33)
D+L subtotal  (I2 66·7%, p=0·0001) 0·79 (0·72 to 0·87) 21 (14 to 29) 
D+L overall  (I2 69·5%, p<0·0001) 0·79 (0·75 to 0·83) 21 (17 to 25)
Reference Comparison
Site Region Study
period
Sulfadoxine-
pyrimethamine
dose category
Low birthweight
prevalence, n/N (%)*
Ala437Gly Ala581GlyLys540Glu
Mutation prevalence, % Low birthweight
relative risk
reduction per 
dose, % (95% CI)
Risk ratio
trend (95% CI)
Study 
weight,
% (D+L)
IPTp better IPTp worse
10·2 0·5 2
2·14
2·44
2·54
1·04
1·14
1·15
1·83
2·02
2·42
1·58
2·44
2·46
2·78
3·36
2·98
1·77
2·43
0·49
1·74
0·85
3·14
0·33
2·52
1·39
0·89
3·28
2·63
3·59
1·24
1·01
0·85
1·69
0·87
2·98
0·05
1·49
1·57
2·52
0·55
0·49
0·76
2·78
2·81
1·16
1·41
1·06
1·99
0·55
0·85
3·11
2·78
1·60
1·01
0·96
1·01
1·67
1·82
22·71
48·32
28·97
100·00
0·0
68·6
72·7
87·5
95·1
6·9
25·4
97·5
0·0
0·7
95·6
74·0
99·6
0·0
100·0
0·7
31·1
11·3
84·0
18·9
92·7
1·0
31·1
0·0
0·0
0·0
0·2
47·6
94·8
88·3
0·1
3·3
1·0
31·1
0·0
100·0
1·4
0·9
90·2
0·0
0·1
0·9
0·0
76·3
0·0
27·8
84·0
0·0
0·0
94·7
0·1
0·0
0·0
0·0
0·2
0·0
91·2
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prevalence of this quintuple mutant was more than 50%, 
the prevalence of the dhps Ala581Gly mutation served as 
a proxy for the sextuple mutant. Two areas were identified 
where the sextuple mutant was more than 10%: 
northeastern Tanzania, and the area crossing the borders 
of southwestern Uganda, eastern Rwanda, eastern 
Democratic Republic of the Congo, and northwestern 
Tanzania (appendix p 4). The prevalence of each point 
mutation and the P falciparum parasite prevalence in 
children aged 2–10 years (PfPR2–10; using data from the 
Malaria Atlas Project) was matched to each study by time 
(the same year for PfPR2–10 and within 2 years before or 
after for point mutations) and by location using latitude 
and longitude (within 300 km where possible).24 For 
national surveys, these prevalence data were calculated 
for the administrative boundary of the given survey using 
Malaria Atlas Project data and WWARN’s geospatial 
models (appendix p 4).22 
Definition of resistance categories
To stratify resistance into low, moderate, and high 
levels, different combinations of threshold levels (at 5% 
step increases) of the resistance-associated mutations 
in dhps were explored in the aggregated-data meta-
analysis. Because of distinct parasite populations and 
distributions of mutations in each region,25 threshold 
analysis was done separately for central and west Africa 
and for east and southern Africa. Results were then 
combined to obtain a single categorical variable that 
represented the optimal thresholds based on the R² for 
each region.
Statistical analysis
The primary outcome was low birthweight. Secondary 
outcomes included anaemia, malaria, preterm delivery, 
birthweight, haemoglobin level, and gestational age. 
Analyses of clinical studies were done with Stata 
(version 14). A two-stage random-effects meta-analysis 
was done by use of a generalised least-squares regression 
for trend estimation of summarised dose-response 
data.26,27 Effect sizes were expressed as relative risk 
reduction (RRR; 100 × [1 – relative risk]) for trend (appendix 
p 4), and were then combined across studies with use 
of a random-effects meta-analysis, with heterogeneity 
quantified using the I² statistic. Potential modifying 
effects of sulfadoxine-pyrimethamine resistance were 
examined with multi variate linear meta-regression, 
adjusting for the following prespecified covariates: 
malaria transmission, study quality, average number of 
sulfa doxine-pyrimethamine doses, and proportion of 
paucigravidae (defined as women in their first or second 
pregnancy).28 The proportion of women using insecticide-
treated nets was not found to be associated with resistance 
level in our analyses and was not included as covariate in 
the metaregression. Subgroup analyses by gravidity 
(paucigravidae vs multi gravidae) were also done. For the 
assessment of the effect of sulfadoxine-pyrimethamine 
IPTp on continuous outcomes, only the no doses group 
versus the two or more doses group were compared. 
Further sensitivity analysis was done by excluding low-
quality studies and exploring the presence and impact of 
potential small-study effects due to publication and other 
biases (appendix p 4).29
n Univariate meta-regression Multivariate meta-regression*
Coefficient (95% CI) p value τ² I², % R², % Coefficient (95% CI) p value τ² I², % R², %
dhps Ala437Gly prevalence†
All studies 57 1·001 (0·999–1·004) 0·35 0·02596 69·9 1·8 1·001 (0·999–1·004) 0·25 0·01645 57·7 37·8
Excluding low-quality studies‡ 50 1·002 (0·999–1·004) 0·13 0·02079 67·3 7·5 1·002 (1·000–1·004) 0·08 0·01323 54·1 41·1
Restricted to largest 50% of 
studies§
29 1·003 (1·000–1·005) 0·06 0·01615 73·9 13·3 1·002 (1·000–1·005) 0·09 0·01137 62·1 39·0
dhps Lys540Glu prevalence†
All studies 57 1·002 (1·001–1·003) 0·0060 0·02142 66·2 19·0 1·002 (1·001–1·003) 0·0031 0·01222 53·7 53·8
Excluding low-quality studies‡ 50 1·002 (1·000–1·003) 0·0090 0·01732 61·9 22·9 1·002 (1·000–1·003) 0·0160 0·01133 51·1 49·6
Restricted to largest 50% of 
studies§
29 1·002 (1·000–1·003) 0·0223 0·01469 70·5 21·1 1·002 (1·000–1·003) 0·0132 0·00909 58·7 51·2
Resistance strata¶
All studies 57 1·10 (1·03–1·18) 0·0054 0·02040 65·4 22·8 1·10 (1·03–1·17) 0·0043 0·01184 52·9 55·2
Excluding low-quality studies‡ 50 1·10 (1·03–1·18) 0·0075 0·01687 61·6 24·9 1·09 (1·02–1·16) 0·0095 0·01067 49·7 52·5
Restricted to largest 50% of 
studies§
29 1·10 (1·02–1·18) 0·0122 0·01386 69·7 25·6 1·10 (1·03–1·17) 0·0067 0·00802 55·9 56·9
dhps=Plasmodium falciparum dihydropteroate synthase. *Adjusted for malaria transmission intensity, average number of sulfadoxine-pyrimethamine doses, study quality, and 
proportion of paucigravidae in study. †In the meta-regression, the sulfadoxine-pyrimethamine resistance variable was introduced as a linear continuous variable reflecting 1% 
stepped increases in prevalence of the resistance marker. ‡Excludes studies with less than three of six stars for quality. §To ascertain the effect of potential bias due to small-study 
effect, the analysis was restricted to the largest 50% of studies, based on their standard error of the log relative risk for low birthweight. ¶Sulfadoxine-pyrimethamine resistance, 
defined by the prevalence of molecular markers, stratified into low (dhps Ala437Gly <90% in central and west Africa or dhps Lys540Glu <30% in east and southern Africa), moderate 
(dhps Ala437Gly ≥90% in central and west Africa, or dhps Lys540Glu ≥30% and <90% in east and southern Africa), and high (dhps Lys540Glu ≥90% in east and southern Africa).
Table: Effect of sulfadoxine-pyrimethamine resistance on the effectiveness of sulfadoxine-pyrimethamine IPTp to prevent low birthweight in women 
receiving intermittent preventive treatment during pregnancy (sub-Saharan Africa, 1997–2013, aggregated data)
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The survey analysis was done in R and restricted to the 
higher-resistance areas with more than 80% prevalence 
of dhps Lys540Glu. Only the most recent livebirth within 
the past 2 years was considered. To mitigate potential 
confounding of the effect of sulfadoxine-pyrimethamine 
dose on birthweight, exact matching was used (appendix 
p 4).4 The modifying effect of sulfadoxine-pyrimethamine 
resistance was first assessed for each survey by use of 
random-effects log-binomial regression models for low 
birthweight and linear regression for birthweight with 
the matched birth strata included as a random intercept 
using the lme4 package in R.30 IPTp exposures were 
considered as continuous variables similar to the 
aggregated meta-analysis. The effect measures were 
then further evaluated by resistance strata (quintiles) 
and compared by use of meta-regression.
This study is registered with PROSPERO, number 
42016035540.
Role of the funding source
Except for the US Centers for Disease Control and 
Prevention (CDC) and WWARN, the funders of the study 
had no role in study design, data collection, data analysis, 
data interpretation, or writing of the report. CDC and 
WWARN staff participated in the conduct of the study. 
AMvE, FOtK and DAL had full access to all the data in 
the study. AMvE and FOtK had final responsibility for the 
decision to submit for publication.
Results
For the aggregated-data meta-analysis, we identified 
2021 records through database searching. After removal of 
duplicates, 1097 articles were assessed for eligibility, of 
which 66 were included in the review: 58 observational 
studies and eight trials (figure 1). A summary of the 
included studies is provided in the appendix (p 6). Of these, 
50 source articles from 17 countries (appendix p 30) were 
included in the analysis of low birthweight, involving 
57 datapoints (henceforth referred to as studies) and 
59 457 births. The remaining 16 studies did not provide data 
on low birthweight, but contributed to the analysis 
of secondary outcomes. In central and west Africa 
(31 studies), the median prevalence of dhps Ala437Gly was 
57·9% (IQR 39·3–77·6; range 15·2–100·0), despite a low 
prevalence of dhps Lys540Glu (0·1% [IQR 0·0–0·9; 
range 0·0–18·9]), whereas, in east and southern Africa 
(26 studies), the prevalence of dhps Ala437Gly (85·4% 
[IQR 62·9–94·1; range 13·3–100·0]) was similar to that of 
dhps Lys540Glu (85·8% [IQR 47·6–94·8; range 0·0–100·0]; 
appendix pp 27, 31). The dhps Ala581Gly mutation (used as 
a proxy for the sextuple mutant) mainly occurred in areas 
with a dhps Lys540Glu prevalence of more than 80% 
in east and southern Africa (figure 2, appendix p 27). 
Among sulfadoxine-pyrimethamine recipients, the median 
number of sulfadoxine-pyrimethamine doses received 
(study-level) was 1·7 (IQR 1·3–2·4; appendix p 13). The 
number of sulfadoxine-pyrimethamine doses received by 
study participants was not correlated with the prevalence of 
dhps Ala437Gly (r=–0·0295, p=0·83) or dhps Lys540Glu 
(r=0·1594, p=0·24).
Overall, per dose of sulfadoxine-pyrimethamine, 
sulfadoxine-pyrimethamine IPTp was associated with an 
RRR for low birthweight of 21% (95% CI 17–25; 57 studies; 
figure 2). RRR was 22% (17–27; 34 studies) in paucigravidae 
and 18% (11–24; 31 studies) in multigravidae (appendix 
p 17). There was substantial heterogeneity between studies 
(I²=69·5%, p<0·0001; figure 2).
Univariate and multivariate meta-regression analyses 
showed a linear trend towards decreasing effectiveness 
of sulfadoxine-pyrimethamine IPTp (as indicated by the 
log relative risk of low birthweight moving closer to the 
null) with increasing prevalence of dhps Lys540Glu (table, 
figure 3). No differences were seen by gravidity (appendix 
Figure 3: Correlation between relative risk for low birthweight in women 
receiving IPTp and the prevalence of dhps Ala437Gly or dhps Lys540Glu 
mutations in 57 studies
Meta-regression bubble plots show the log of the relative risk estimates for low 
birthweight across each sulfadoxine-pyrimethamine dose category, obtained by 
use of generalised least-squares regression for trend estimation of summarised 
dose-response data, with 95% CI of the regression line represented by the 
shaded area. The size of the bubbles for individual studies is proportional to the 
random effects study weights. A positive slope indicates decreasing 
effectiveness of sulfadoxine-pyrimethamine IPTp for averting low birthweight 
with increasing mutation prevalence. dhps=dihydropteroate synthase. 
IPTp=intermittent preventive treatment in pregnancy.
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p 16). No significant trend was observed for dhps 
Ala437Gly (table, figure 3). Of the different thresholds 
used to stratify resistance into low, medium, and high, 
the most predictive combination was low resistance 
defined as dhps Ala437Gly less than 90% in central 
and west Africa or dhps Lys540Glu less than 30% in 
east and southern Africa (RRR 27% [95% CI 21–33]); 
moderate resistance defined as dhps Ala437Gly 90% or 
higher (central and west Africa) or dhps Lys540Glu 30% 
or higher and less than 90% in east and southern Africa 
(RRR 21% [14–29]); and high resistance defined as dhps 
Lys540Glu 90% or higher in east and southern Africa 
(RRR 7% [0–13]; p=0·0054 for linear trend; table). These 
definitions of resistance strata explained 22·8% of the 
between-study variance (R²) in univariate models and, 
combined with other covariates, 55·2% in multivariate 
models (table). Very similar results were obtained if 
alternative thresholds (<20% or <40%) for dhps Lys540Glu 
prevalence were used to define low resistance, or if a dhps 
Ala437Gly prevalence of less than 80% was used to define 
low resistance, or if the presence (≥1%) of dhps Ala581Gly 
(instead of dhps Lys540Glu ≥90%) was used to define 
high resistance (appendix p 18).
Meta-regression results were similar after the exclusion 
of low-quality studies (table). There was evidence for 
significant small-study effects (p<0·0001), but this effect 
was observed in all three resistance strata (appendix p 32), 
and restricting the analysis to the larger 50% of studies 
did not change the observed trend towards decreasing 
efficacy with increasing resistance (table). By 
region, multivariate meta-regression showed significant 
correlations between low birthweight and dhps Ala437Gly 
prevalence, dhps Lys540Glu prevalence, and resistance 
strata only in east and southern Africa (appendix p 16).
Only five studies were done in areas that had a more 
than 10% prevalence of sextuple-mutant P falciparum 
parasites (pooled dhps Ala581Gly prevalence 32% [95% CI 
17 to 48]). Substantial heterogeneity in effect size was 
found among these studies (I²=68·8%, p=0·012; 
appendix p 33): the three studies with a small sample size 
in the reference group had an RRR of 35% (14 to 51; 
pooled dhps Ala581Gly prevalence 21%), whereas the two 
remaining larger studies, both conducted in areas with 
the highest dhps Ala581Gly prevalence (pooled prevalence 
46%) had an RRR of –2% (–15 to 9; p=0·0518 for subgroup 
difference).
When outcomes other than low birthweight were 
considered, we observed a linear trend towards decreasing 
effectiveness of IPTp with increasing prevalence of dhps 
Lys540Glu for maternal moderate-to-severe anaemia 
and for malaria infection (maternal, placental, or any 
malaria) at delivery. The RRRs at delivery for moderate-to-
severe anaemia were 41% (28 to 51) in low-resistance, 
20% (1 to 35) in moderate-resistance, and 13% (3 to 22) 
in high-resistance areas (ptrend=0·0049); and for any 
malaria infection were 20% (13 to 26) in low-resistance, 
18% (10 to 26) in moderate-resistance, and 3% (–3 to 9) in 
high-resistance areas (ptrend=0·0164; appendix pp 21–26).
The analysis of individual participant data from surveys 
focused on areas with a more than 80% prevalence of the 
dhps Lys540Glu mutation, with the aim of ascertaining 
the effect of the sextuple-mutant P falciparum parasite in 
areas previously defined as super resistant (>10% dhps 
Ala581Gly prevalence).16 Of 138 publicly available surveys, 
39 met the inclusion criteria, and 13 surveys that included 
data from areas with a dhps Lys540Glu prevalence of 
more than 80% or with super resistance (all in east and 
southern Africa from 2008–15, and comprising 
Figure 4: Relative risk for low birthweight associated with number of sulfadoxine-pyrimethamine IPTp doses by resistance strata in areas with super resistance or dhps Lys540Glu of more 
than 80% in east and southern Africa
(A) Linear meta-regression bubble plot with solid line representing the regression line and shaded area representing the 95% CI. (B) Forest plot. Individual observations in all areas with a dhps 
Lys540Glu prevalence of more than 80% were divided into quintiles after excluding the surveys in the super-resistant areas. Super-resistant areas were defined as those with a dhps Ala581Gly 
prevalence of more than 10% (southwestern Uganda, northern Tanzania, and eastern Democratic Republic of the Congo).16 Overall, sulfadoxine-pyrimethamine IPTp was associated with an RRR of 
11% (95% CI 8–13) for low birthweight. The RRR was 10% (7–12) in areas with a dhps Lys540Glu prevalence of more than 90% and Ala581Gly prevalence of less than 10%. dhps=dihydropteroate 
synthase. IPTp=intermittent preventive treatment in pregnancy. RRR=relative risk reduction. *Number of surveys (total 13) that contributed to each quintile group; surveys could contribute to 
more than one group. 
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42 394 singleton livebirths) were included in the analysis 
after exact matching of probability of receiving IPTp, 
resistance, and malaria transmission intensity data 
(figure 1). Sulfadoxine-pyrimethamine IPTp in these 
areas was associated with an RRR of 11% (95% CI 8 to 13) 
for low birthweight. Even in areas with a dhps Lys540Glu 
prevalence of more than 90% and a dhps Ala581Gly 
prevalence of up to 10%, sulfadoxine-pyrimethamine 
IPTp was associated with significantly reduced risk of 
low birthweight (RRR 10% [7 to 12]; figure 4). However, in 
the two super-resistant areas, sulfadoxine-pyrimethamine 
IPTp did not protect against low birthweight (RRR 0·5% 
[–16 to 14]; figure 4). In these two areas, the pooled 
prevalence of the dhps Ala581Gly mutation across all 
contemporary molecular studies was 37% (29 to 46; 
appendix p 34).
Discussion
In our meta-analysis of aggregated data from 57 clinical 
studies, increases in the prevalence of two molecular 
markers of sulfadoxine resistance were associated with 
clear reductions in the effectiveness of sulfadoxine-
pyrimethamine IPTp to avert low birthweight and other 
outcomes such as malaria infection at delivery and 
maternal anaemia. In our parallel analysis of individual 
participant data from nationally representative surveys, 
sulfadoxine-pyrimethamine IPTp was associated with a 
significant but modest protective effect against low 
birthweight in areas where the P falciparum dhps Lys540Glu 
mutation prevalence was 90% or higher and the prevalence 
of sextuple-mutant parasites was less than 10%.16 However, 
these surveys also showed that, in areas where sextuple-
mutant parasites are common (pooled prevalence estimate 
37%), sulfadoxine-pyrimethamine IPTp did not protect 
against low birthweight. These findings are consistent 
with our understanding of the incremental increase in 
resistance to sulfadoxine-pyrimethamine with successive 
mutations in the dhfr and dhps genes, and with the previous 
studies that showed compromised efficacy of sulfadoxine-
pyrimethamine in women infected with sextuple-mutant 
P falciparum.12–15 This high resistance is currently restricted 
to a few foci in east Africa,16 but its spread would 
have important implications for the continued use of 
sulfadoxine-pyrimethamine for IPTp.
Compared with other markers of sulfadoxine-
pyrimethamine resistance, fewer data are available on 
the distribution of the dhps Ala581Gly mutation. There-
fore, the aggregated-data meta-analysis was limited in 
its ability to define and validate different thresholds for 
the dhps Ala581Gly mutation. There were only 
five studies done in areas in east and southern Africa 
with a dhps Ala581Gly prevalence of more than 10%, and 
none were done in areas with a dhps Ala581Gly 
prevalence between 13% and 43%. Within these studies, 
there was also substantial between-study heterogeneity 
in the effect of treatment on low birthweight: the 
three smaller studies, with only four to eight low 
birthweight events in the reference groups,12,15,31 showed 
a pooled effect size of 35% (95% CI 14 to 51), whereas 
the studies with larger reference groups reported an 
effect size of –2% (–15 to 9; appendix p 33).32,33 The 
results of these larger two studies, which were done in 
areas with a dhps Ala581Gly prevalence of more than 
45%, are consistent with the lack of effect on low 
birthweight in our analysis of survey data, which was 
based on much larger sample sizes and areas with an 
average dhps Ala581Gly prevalence of 37%.
Irrespective of sulfadoxine-pyrimethamine resistance, 
we observed large between-study heterogeneity in the 
treatment effect on low birthweight among the 57 clinical 
studies. This can be explained, in part, by the multicausal 
nature of low birthweight and the varying population-
attributable fractions of malaria towards low birthweight, 
which depend on transmission intensity and uptake of 
interventions such as insecticide-treated nets. In the 
current study, insecticide-treated net use was not an 
effect modifier or confounder, but malaria transmission 
intensity was correlated with resistance (lower trans-
mission levels were associated with higher resistance 
levels) and was thus a potential confounder, which is 
why it was important to adjust for malaria transmission 
in our models. Nevertheless, estimates of the effect of 
sulfadoxine-pyrimethamine resistance on the 
effectiveness of sulfadoxine-pyrimethamine IPTp for 
averting low birthweight (ie, the slope of the meta-
regression lines) were largely unaffected by the inclusion 
of four co variates—malaria transmission, study quality, 
mean number of sulfadoxine-pyrimethamine doses, and 
pro portion of paucigravidae—in the models, suggesting 
minimal confounding by these variables overall.
Although the effectiveness of IPTp for low birthweight 
decreased with increasing resistance, sulfadoxine-
pyrimethamine IPTp remained associated with a 7–10% 
reduced risk of low birthweight even in areas where the 
resistant quintuple-mutant haplotype is fixed. This small 
but resilient effect on low birthweight contrasts with the 
lack of effect (RRR 3%) on malaria infection in high-
resistance areas seen in the aggregated-data meta-analysis 
(appendix p 19), and with the previously observed 
unfavourable parasitological response in asymptomatic 
pregnant women receiving sulfadoxine-pyrimethamine 
IPTp in these areas, where clearance of parasites by day 42 
was achieved in only 50% of paucigravidae.7 That IPTp can 
decrease risk of low birthweight even in areas where its 
efficacy for clearance of infection is compromised might 
suggest that suppression, rather than radical clearance of 
parasites, is required to mitigate the adverse effects of 
malaria on placental function and growth, as observed in 
multigravidae (who acquire protective antimalarial 
immunity over successive pregnancies). Alternatively, 
sulfadoxine-pyrimethamine might have beneficial effects 
on birthweight that are independent of its antimalarial 
properties and are, therefore, unaffected by parasite 
resistance (eg, anti microbial effects,32–34 or effects related to 
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immuno modulation, similar to those described for co-
trimoxazole35).
The differences in P falciparum parasite populations 
(shown in the scatter plot of the prevalence of dhps 
Ala437Gly and Lys540Glu mutations in the appendix 
p  31) reflect the distinct geographical origins of two or 
three parasite populations in east and west Africa.25 In 
east and southern Africa, the combination of the 
resistance alleles at dhps codons 540 and 581 could 
be  considered to track sulfadoxine-pyrimethamine 
resistance. In central and west Africa, where the dhps 
Lys540Glu mutation is absent or rare, tracking dhps 
Ala437Gly might be informative. However, other 
mutations have started to emerge in west Africa, such as 
dhps Ile431Val, which has been reported on a haplotype 
bearing mutant alleles at codons 581 and 613 but a wild-
type allele at codon 540.36,37 The clinical implications of 
such new haplotypes require further study.
Our analyses have important limitations. First, the 
potential biases associated with observational data, in 
which the number of sulfadoxine-pyrimethamine doses 
is not determined by the study, have been discussed in 
detail elsewhere.4 Although the use of exact matching 
and multivariate models will have reduced the potential 
for bias in the surveys, residual confounding cannot 
be excluded. Second, national surveys are subject 
to measure ment error and information bias from 
respondent recall and self-report.4 Similar limitations 
apply to the aggregated-data analysis, which could only 
adjust for study-level covariates. For some studies, 
time-matched local resistance data were not available 
and were obtained from other sources, which are less 
precise. Some studies were considered to be of poor 
quality, with a trend towards greater effectiveness with 
decreasing study quality, but sensitivity analysis showed 
that these low-quality studies were equally distributed 
across the resistance spectrum and did not affect the 
conclusions. Similarly, there was evidence of a small-
study effect, but this effect was also observed in all 
three resistance strata, and restricting the analysis to 
the largest 50% of studies (which are least likely to 
be affected by publication bias) did not alter the 
conclusions. In addition, the meta-analysis suffered 
from design and reporting variation and small numbers 
in the extreme dose groups (zero doses and three or 
more doses). This limitation was partly mitigated by 
use of a dose-response analysis that placed less 
emphasis on the extreme dose groups.
This is the most comprehensive study of the effect of 
sulfadoxine-pyrimethamine resistance on the effective-
ness of sulfadoxine-pyrimethamine IPTp, involving 
57 clinical studies, 13 nationally representative surveys, 
and more than 100 000 births. The data show that, despite 
the substantial heterogeneity between studies with regard 
to the effectiveness of sulfadoxine-pyrimethamine IPTp 
on low birthweight, increasing prevalence of molecular 
markers of sulfadoxine resistance is correlated with a 
decrease in effectiveness of sulfadoxine-pyrimethamine 
to prevent low birth weight and malaria infections. These 
findings suggest that molecular monitoring of 
sulfadoxine-pyrimethamine resistance is a potential 
policy tool to guide the use of sulfadoxine-pyrimethamine 
IPTp. It is reassuring that a protective association of 
sulfadoxine-pyrimethamine IPTp with low birthweight 
can be detected even in high-resistance areas where 
quintuple-mutant P falciparum parasites are almost fixed. 
However, sulfadoxine-pyrimethamine IPTp is not likely to 
reduce malaria and malaria-associated low birthweight in 
areas where the prevalence of sextuple-mutant parasites, 
with the dhps Ala581Gly mutation, exceed 37% (the pooled 
estimate in the high-resistance areas). For these areas, the 
search for alternative strategies or drugs to replace 
sulfadoxine-pyrimethamine IPTp is a pressing research 
priority for the control of malaria in pregnancy.
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Supplemental Methods 
Search terms  
We used the PICOS model to design the search strategy. The following search terms were used for the 
aggregated data meta-analysis: “Malaria AND pregnan* AND intermittent AND (prevent* OR prophyla* OR 
chemoprevent* OR chemoprophyla* OR IPT*) AND (sulfadoxine OR sulphadoxine OR pyrimethamine OR 
SP)”. The electronic databases “Malaria in Pregnancy Library”,1 PubMed, Web of Science, and Scopus were 
searched. The search was conducted in English but without language restriction.  
 
Example search in Pubmed 
 
 
Eligibility criteria clinical studies 
Observational studies were included if they were conducted in sub-Saharan Africa, had information at delivery 
on the number of SP doses received, and data on birthweight, maternal haemoglobin or plasmodium infection at 
delivery. Trials were included if they were: quasi-randomized or randomized trials; conducted in sub-Saharan 
Africa; compared IPTp-SP against passive case detection or placebo and otherwise fulfilled the same criteria as 
for the observational studies. Studies or study arms were excluded if they involved only HIV-infected women, 
combined SP with other antimalarial drugs, such as artemisinin derivatives or azithromycin, or with other 
interventions such as screening for malaria. Surveys were included if they were conducted after the year 2000 
(when IPTp-SP started to be introduced as policy) with datasets publicly available by 31 May 2015; contained 
data on LBW (perceived birth size and measured weight); measured IPTp use by number of doses among 
recently pregnant women, and ITN coverage measured at the household level.  
 
PICOS Table 
Components Characteristics 
Participants/Population Women at the time of delivery in malarious areas in Africa with documentation 
(verbal or written) of the number of intermittent sulfadoxine-pyrimethamine (SP) 
doses received during pregnancy for the prevention of malaria and pregnancy 
outcome (birth weight, maternal haemoglobin, malaria). 
 
There are two components: 
a) women participating in trials and observational studies with this information 
available 
b) women participating in national surveys. 
 
Studies/surveys will be matched with SP molecular resistance data and indicators 
of malaria transmission in the same area. 
Intervention/exposure Number of SP doses received during pregnancy as part of IPTp 
  van Eijk-IPTpMeta-Supplement-17mar19 
3 
 
Comparator/control No SP (zero doses received during pregnancy) or inadequate doses of SP (0-1 
doses) 
Outcomes Primary outcome: Low birth weight (<2500 grams)  
Secondary outcomes: Placental parasitaemia (the presence of asexual parasites in 
the placenta at delivery by microscopy, Rapid diagnostic test (RDT), or 
histology), maternal parasitaemia (the presence of asexual parasites in the 
peripheral blood of mother at delivery detected by microscopy or RDT), mean 
maternal haemoglobin, maternal anaemia (any anaemia: <11 or 10 g/dl; 
moderate-to-severe anaemia: <9 or 8 or 7 g/dl), miscarriage or abortion (foetal 
loss <28 weeks gestation), stillbirth (foetal loss =28 weeks gestation), preterm 
delivery (delivery before 37 weeks of gestational age), and gestational age. 
Study design Any survey, cohort or trial among pregnant women in a malarious area in sub-
Saharan Africa published from 1990 onwards without language restriction 
 
Data extraction and quality assessment of clinical studies 
For studies where time of conduct of the study was not reported or could not be obtained, the study was assumed 
to have been conducted two years before the publication date,2,3 based on the analysis of the Malaria in 
Pregnancy library content.4 Data from reports with multiple publications were combined into a single entry, to 
avoid duplication. Two independent reviewers identified studies and agreed on final study eligibility (AMvE, 
GK), and extracted data and assessed study quality unblinded to authors of the source study (AMvE and GK or 
DECS). If no agreement could be reached a third reviewer (FtK) got involved and agreement was reached by 
consensus. 
An adaption of the Newcastle-Ottawa Scale for cohort studies was used for quality assessment both for 
observational studies and for the IPTp-SP arms of clinical trials, where the number of SP doses was used as the 
exposure variable and low birthweight (or other outcomes) as the outcome variable (see table quality 
assessment). Quality assessment was conducted by two persons (AMvE and GK or DECS); where disagreement 
occurred, a joint review of the study was conducted until agreement was reached by consensus. Follow-up or 
outcome was considered adequate if more than 80% of participants initially enrolled were included in the 
analysis. Study quality was categorized into four categories as <=2, 3, 4, >=5 stars. Studies were not excluded a-
priori based on their quality score. 
 
Quality assessment form for observational studies and trials 
 Focus area Category options† 
1 Representativeness of the 
exposed group 
a) truly representative of pregnant women in the community (e.g. random selection in 
community) * 
b) somewhat representative of the average pregnant woman in the community (e.g. selection 
in ANC) * 
c) selected group of pregnant women (e.g. women who deliver in a health unit) 
d) no description of the derivation of the group 
2 Selection of the non-exposed 
group 
a) drawn from the same community/pool as the exposed group * 
b) drawn from a different source 
c) no description of the derivation of the non-exposed group 
3 Ascertainment of exposure a) ANC record (e.g. antenatal clinic notes) 
b) structured interview  
c) combination of ANC notes and interview * 
d) observed and prospectively collected (trial or cohort study) * 
e) unsecure record 
f) written self-report 
g) no description 
4 Comparability of exposed and 
unexposed group 
a) differences examined and no differences reported in characteristics which are presented * 
b) differences in characteristics present but no effect on outcome, or multivariate analysis 
for outcome available or randomized study * 
c) differences in characteristic present, not shown if effect on outcome 
d) no description/not examined 
5 Outcome assessment (low 
birthweight, haemoglobin, 
malaria) 
a) independent blind assessment *  
b) record linkage * 
c) not clear 
d) no blind assessment  
e) no description 
6 Attrition a) complete - all subjects accounted for * 
b) Outcome not available for all subjects but unlikely to introduce bias - small number lost - 
<20%, or description provided of those lost * 
c) Outcome for less than 80% of people with exposure data and no description of those lost 
d) no statement 
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† A study could be awarded a maximum of one star for each item 
 
Prediction surfaces of SP resistance mutation prevalence  
Prevalence data of Pfdhps-A437G, K540E and A581G mutations were extracted from the clinical studies in 
pregnant women, the literature, and existing molecular surveyor databases.5-8 These mutations in Pfdhps were 
chosen over the major resistance mutations in dhfr because the Pfdhps mutations have a more geographically 
heterogeneous distribution, reflecting their more recent emergence in Africa.9 The Pfdhps-K540E prevalence 
served as a proxy for the prevalence of quintuple Pfdhps/Pfdhfr mutant genotype.10 In areas where the 
prevalence of this quintuple mutant was >50%, the prevalence of Pfdhps-A581G mutation served as a proxy for 
the sextuple mutant. In West Africa, Pfdhps-A581G may occur independent of the Pfdhps-K540E mutation. 
These mutations were not considered sextuple mutants if the Pfdhps-K540E prevalence was <=50%.7 Presence 
was defined as a prevalence of ≥1%. Raster files from existing point data maps from areas that had previously 
been defined as ‘super-resistant’ (>10% prevalence of sextuple mutant) were obtained from the authors.7 Two 
such areas were identified: in north-eastern Tanzania, and in the area crossing the borders of Southwest Uganda 
and East Rwanda, eastern Democratic Republic of Congo, and north-western Tanzania.7 
 
Matching IPTp effectiveness, resistance and malaria transmission intensity data 
The prevalence of each point mutation and the PfPR2–10  (the Plasmodium falciparum parasite rate in 2-10 year 
olds)11 was matched to each study by time (the same year for PfPR2–10 and +/- 2 years for point mutations) and 
location using latitude and longitude (within 300 km).12 Location was defined as the site of the main research 
facility in the observational studies and trials, or the midpoint between study locations. The following order of 
preference was used to match resistance with clinical data: a) resistance data provided in the clinical study 
reports or by the authors for that location and time of study (data from individuals with a recent history of SP 
intake were excluded); b) estimates from continuous surface maps from WWARN’s geospatial models for 
Pfdhps-A437G and Pfdhps-K540E;8 and c) for Pfdhps-A581G, or for studies after 2012, data were used from 
existing population prevalence maps of Pfdhps (Table S2).5-7 For national surveys, the mean prevalence of 
PfPR2–10 and Pfdhps mutations was calculated for the sub-national region of each given survey using Malaria 
Atlas Project data11 and WWARN’s geospatial models.8 All matching for surveys was performed using the 
Raster-Package of R (v3.3.2).13 
 
Assessment of heterogeneity and small-study effects clinical studies 
The extent of heterogeneity was measured using the I2 statistic,14 which is a measure of the proportion of total 
variability explained by heterogeneity rather than chance expressed as a percentage, with 0–40% representing no 
or little heterogeneity, 30–60% moderate heterogeneity, 50–90% substantial heterogeneity, and 75–100% 
considerable heterogeneity.15 To examine the presence of small-study effects (the tendency for the smaller 
studies to show larger treatment effects) due to potential publication and other bias, we used funnel plots with 
effect size (relative risk of LBW) as a function of study size (the standard error of the log relative risk). We used 
Egger's test for small study effect as statistical test for funnel plot asymmetry. To determine the impact of small-
study effects we conducted sensitivity analysis by restricting the analysis to the largest 50% of studies.16 
 
Further details of methods used to define the analytical population and mitigate for potential confounding 
of the effect of SP dose on birthweight in the individual participant data meta-analysis of survey data 
In the analysis of the survey data, only the most recent live birth in the past <2 years was considered, to 
minimize information error on exposure to SP and details of the birth outcomes. To mitigate potential 
confounding of the effect of SP dose on birthweight, exact matching was employed (MatchIt package in R 
version 2.15.149)17 for the following variables: neonatal tetanus vaccination (any or none), iron supplementation 
during pregnancy (any or none), household wealth (dichotomized at the median as rich and poor), mother’s 
education (any or none), malaria transmission intensity (low:<25% and high:>=25% pfPR2-10), antenatal care 
(any or none), and residence (urban or rural). Unmatched live births were excluded from the analyses. To further 
mitigate potential confounding factors of the effect of SP dose on birthweight, we used multivariate log 
binomial regression for LBW and linear regression for birthweight as continuous variable adjusting for the 
following covariates: household wealth quintile, mother’s age (< 18y, 18-30y or > 30y), mother’s education 
(none, some primary or completed primary), whether the child was a twin or not, parity and birth interval 
(firstborn, second born <24 months spacing, second born ≥24 months spacing, third born or later <24 months 
spacing, third born or later ≥24 months spacing), gender, any household ITN ownership during pregnancy, 
PfPR2–10, and quarter of the year.  
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Generalized least square (GLST) regression for trend estimation of summarized dose-response data 
The first step in generalized least square (GLST) regression for trend estimation of summarized dose-response 
data consisted of calculation a single summary effect estimate for each study.18,19 This was expressed as relative 
risk for the trend effect and computed using the correlated log RR estimates across each of SP dose categories. 
The exposure value for each SP dose category represented the mean number of SP doses for that category. If the 
SP dose was not reported per exact dose categories (0, 1, 2, 3, etc), but as groups (2 groups [e.g. 0 vs 2+, or 0-1 
vs 2+], 3 [e.g. 0,1,2 or 0,1,2+] or 4 groups [e.g. 0, 1, 2, 3+]), then the mean SP dose per dose category was 
calculated as the sum of the total doses received divided by the number of women contributing to each dose 
category; for example, if a study reported outcome data for the intervention group as a single pooled group of 
women who had received at least 2 doses (2+) and the study also reported that this 2+ group consisted of 70, 20 
and 10 women who received 2, 3 and 4 doses respectively, then a mean was 2.4 (240 doses/100 women) was 
used as the number of SP doses received by the 2+ dose group. Similarly, if a study only presented pooled data 
for women receiving 0 or 1 dose of SP as the ‘control’ group, and that category consisted of 40 women who had 
received 0 doses and 60 who had received 1 dose, then a mean of 0.6 SP doses (60 doses/100 women) was used 
to define exposure to SP in that group (Table S2). We also combined SP-dose groups when the sample size was 
low in a specific group with the aim to obtain at least 30-40 women in any SP-dose strata, but this was not 
achieved for all studies (e.g. Minja 2013, or in analyses by gravidity group). For the same reason, we pooled 
data from 2 studies conducted in Malawi in 2010 that used the same design and protocol.20,21 For studies with a 
continuous outcome, we used the weighted mean difference between the outcome among women who had not 
received SP versus women who had received 2 or 2+ doses of SP, and the outcomes were pooled using random 
effects meta-analysis.  
 
Meta-regression  
Meta-regression graphs of log transformed relative risks (RR) for low birthweight (LBW) are presented. Study 
specific estimates are depicted as circles proportional to their precision (inverse of the variance of the log[RR]). 
The solid line indicated fitted values by random-effects meta-regression. The RRtrend value indicated the 
reduction in risk associated with each incremental dose of SP calculated obtained using generalized least square 
(GLST) regression for trend estimation of summarized dose-response data.18,19  
 
Pooled mutation prevalence by resistance strata or study area using MetaProp 
The pooled mutation prevalence by resistance strata or study area were obtained with Metaprop: a Stata 
command to perform meta-analysis of binomial data.22 
 
Supplemental Results 
In univariate meta-regression, study quality was more predictive of the effectiveness of IPT on LBW (p=0.05) 
than study design (P=0.14), and because the two variables were correlated (i.e. trials tend to have higher quality 
scores than observational studies), only study quality (rather than both or study design alone) was considered as 
co-variate in further multivariate models. 
 
Although we intended to look at birth outcomes such as miscarriage, abortion, or stillbirth, these outcomes were 
not frequently reported and were not examined further. The dose of folic acid could not be used in the analyses 
of potential effect modifiers or confounders because this data was available from only 20 of the 57 studies 
(35.1%) included in the birth weight analysis; furthermore, some authors reported that not all included women 
received folic acid.23 The use antenatal clinic or the number of antenatal clinic visits could not be included as 
confounder or effect modifier because this was reported for only 31 of 57 studies (54.4%); for 28 studies ANC 
uptake (at least one ANC visit) was >90%, and for 3 studies this ranged from 65 to 87%. Other authors reported 
that lower SP uptake was associated with lower or later antenatal attendance.24-28  
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Supplemental Tables 
Table S1: Study characteristics of observational studies and trials with information on outcomesa by SP doses  
 
Author and Publication 
Year Country 
Time 
period Design 
# of 
sites 
LBW 
(all) % 
Pauci-
gravidae 
% b 
Definition 
pauci-
gravidae 
ITN use 
%c  HIV % d 
Folate dose 
(mg)e 
ANC   
% f PfPr2-1011 
Quality 
score 
1 Aduloju 201329 Nigeria 2011-2011 Survey 1 NA 20.7 G1 10.3 4.1 (UNAIDS) NA 100.0 39.3 2 
2 Alli 201330 Nigeria 2010-2011 Survey  1 2.0 35.0 G1 19.5 4.1 (UNAIDS) NA 100.0 50.6 3 
3 Anchang Kimbi 200931 Cameroon 2007-2007 Survey 1 NA 31.0 G1 6.6 5.6 NA NA 51.6 3 
4 Apinjoh 201532 Cameroon 2008-2010 Survey 1 NA 32.0 G1 9.8 4.0 NA 100.0 51.6 4 
5 Arinaitwe 201333 g,h Uganda 2011-2011 Survey 1 9.8 32.4 G1 87.8 0.0 5.0 NA 38.2 4 
6 Aziken 201134 Nigeria 2009-2009 Cohort 1 10.1 18.9 G1 0.0 0.0 NA 100.0 62.3 2 
7 Bouyou-Akotet 201035 Gabon 2005-2006 Survey 1 17.2 77.3 G1 37.0 5.4 (UNAIDS) NA NA 37 3 
8 Bouyou-Akotet 201636 g Gabon 2011-2011 Survey 2 6.0 19.1 G1 16.2 0.0 NA 100.0 43.5 4 
9 Braun 201537 g Uganda 2013-2013 Survey 1 9.6 31.7 G1 65.1 0.0 NA NA 24.5 4 
10 Cassam 200738 Mozambique 2005-2007 Survey 50 8.1 27.5 G1 43.7 36.4 NA 100.0 54.7 4 
11 Challis 200439 Mozambique 2001-2002 Trial (IPTp)  2 11.4 100 G1/G2 1.0 10.0 NA 100.0 43.1 5 
12 Chukwuocha 201640 Nigeria 2014-2014 Survey 1 NA 36.5 G1 19.7 3.2 (UNAIDS) NA 100.0 62.8 0 
13 Coulibaly 201441 g,h Burkina Faso 2010-2012 Survey 5 15.1 20.6 G1 80.3 0.0 0.4 NA 63.8 4 
14 Desai 201542 g,h Kenya 2011-2012 Survey 3 7.9 40.0 G1 98.0 0.0 0.4 NA 61.5 4 
15 Douamba 201443 Burkina Faso 2013-2014 Survey 1 NA 21.3 G1 g 86.6 .9 (UNAIDS) NA NA 54.5 2 
16 Falade 200744 Nigeria 2003-2004 Survey 1 6.1 23.5 G1 1.1 2.0 5.0 NA 50.5 3 
17 Famanta 201145 g Mali 2009-2009 Survey 1 11.4 27.5 G1 80.7 1.3 (UNAIDS) NA 72.8 34.9 2 
18 Fehintola 201646 Nigeria 2013-2013 Survey 2 NA 40.3 G1 27.0 4.0 NA 85.3 44.7 2 
19 Feng 201047 g Malawi 1997-1999 Survey 1 14.6 46.4 G1/G2 10.0 16.6 (UNAIDS) NA NA 27.7 2 
 Feng 201047 g Malawi 1999-2001 Survey 1 12.7 48.4 G1/G2 23.0 16.5 (UNAIDS) NA NA 27.7 2 
 Feng 201047 g Malawi 2002-2006 Survey 1 10.1 47.5 G1/G2 51.0 14.5 (UNAIDS) NA NA 24.4 2 
20 Gies 200948 Burkina Faso 2004-2006 Trial (cluster) 12 17.5 100 G1/G2 5.3 1.4 (UNAIDS) NA 95.3 51.1 5 
21 
22 
Gutman 201321/ Kalilani 
201420 g,h Malawi 2009-2011 Survey 4 7.2 31.6 G1 67.0 0.0 0.4 NA 43.5 4 
23 Harrington 201149 g Tanzania 2002-2005 Survey 1 4.6 29.2 G1 15.5 6.9 (UNAIDS) NA 100.0 17.4 4 
24 Hommerich 200725 Ghana 2006-2006 Survey 1 12.4 32.7 G1 8.0 3.0 NA NA 39.6 3 
25 Igboeli 201750 Nigeria 2013-2013 Survey 1 3.6 30.2 G1 20.0 3.4 (UNAIDS) NA 100.0 33.5 3 
26 Inyang-Etho 201151 Nigeria 2008-2008 Cohort 1 NA 24.4 G1 g 7.2 3.1 (UNAIDS) NA 100.0 35.6 3 
27 Kayentao 201452 g Mali: Koro 2006-2007 Survey 1 7.7 27.8 G1 58.7 1.3 (UNAIDS) 0.4 NA 48.2 4 
 Kayentao 201452 g Mali: San 2006-2006 Survey 1 7.3 23.6 G1 61.3 1.3 (UNAIDS) 0.4 NA 64.7 4 
 Kayentao 201452 g Mali: Bougouni 2006-2007 Survey 1 6.9 23.5 G1 35.9 1.3 (UNAIDS) 0.4 NA 52.6 4 
 Kayentao 201452 g Mali: Djenne 2006-2006 Survey 1 6.5 22.1 G1 67.9 1.3 (UNAIDS) 0.4 NA 50.5 4 
 Kayentao 201452 g,h Mali: Kita 2009-2010 Survey 1 10.3 25.8 G1 88.3 1.3 (UNAIDS) 0.4 NA 39.5 4 
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Table S1: Study characteristics of observational studies and trials with information on outcomesa by SP doses  
 
Author and Publication 
Year Country 
Time 
period Design 
# of 
sites 
LBW 
(all) % 
Pauci-
gravidae 
% b 
Definition 
pauci-
gravidae 
ITN use 
%c  HIV % d 
Folate dose 
(mg)e 
ANC   
% f PfPr2-1011 
Quality 
score 
 Kayentao 201452 g,h Mali: San 2009-2010 Survey 1 9.3 20.2 G1 94.5 1.3 (UNAIDS) 0.4 NA 66.6 4 
28 Kilauzi 201353 DRC 2011-2011 Survey 1 7.5 20.0 G1 g 43.8 1.1 (UNAIDS) NA NA 29.7 3 
29 Likwela 201254 DRC: Mikalayi 2007-2007 Survey 1 16.1 17.2 G1 6.5 1.5 (UNAIDS) NA 100.0 33.2 4 
 Likwela 201254 DRC: Kisangani 2007-2007 Survey 1 7.8 29.2 G1 4.7 1.5 (UNAIDS) NA 100.0 40.2 4 
 Likwela 201254 DRC: Rutshuru 2007-2007 Survey 1 8.2 16.4 G1 11.3 1.5 (UNAIDS) NA 100.0 36.8 4 
30 Mace 201555 g,h Zambia 2009-2010 Survey 2 7.1 36.7 G1 55.5 0.0 5.0 NA 20.6 4 
31 Mbaye 200656 The Gambia 2002-2004 Trial (IPTp) 14 5.9 0.0 G1 70.3 0.5 0.4 100.0 16.5 6 
32 Menendez 200857 Mozambique 2003-2005 Trial (IPTp) 1 11.3 25.7 G1 91.5 23.9 (UNAIDS) 0.4 100.0 47.2 6 
33 Minja 201358 Tanzania 2008-2010 Cohort 1 6.5 21.6 G1 94.9 5.8 (UNAIDS) NA 100.0 11.3 3 
34 Moleins 201026 Senegal 2007-2008 Survey 1 7.9 27.3 G1 g 45.7 0.8 (UNAIDS) NA 100.0 26.6 3 
35 Mosha 201459 Tanzania 2012-2012 Survey 2 5.1 37.4 G1 94.6 3.4 NA 100.0 18.8 4 
36 Msyamboza 200960 g Malawi 2002-2004 Cohort 26 16.8 29.4 G1 10.2 15.2 (UNAIDS) NA 87.3 27.4 4 
37 Muhammad 201661 Nigeria 2014-2014 Survey 1 37.0 62.0 G1/G2 89.7 3.2 (UNAIDS) NA 100.0 40.8 4 
38 Mwangi 201562 Kenya 2011-2013 Trial (Iron) 4 NA 18.1 G1 15.5 21.1 NA NA 61 6 
39 Mwapasa 200463 Malawi 2000-2002 Survey 1 NA 42.2 G1 22.3 0.0 5.0 NA 24.4 4 
40 Namusoke 201064 g Uganda 2004-2005 Survey 1 14.6 49.4 G1 32.0 11.0 NA 96.8 19.3 4 
41 Ndeserua 201565 Tanzania 2012-2012 Survey 1 6.3 33.1 G1 97.7 1.7 NA NA 28.2 4 
42 Nduka 20113 Nigeria 2009-2009 Survey 3 NA 35.5 G1 12.0 4 (UNAIDS) NA NA 61.6 2 
43 Ndyomugyenyi 201166 Uganda 2004-2007 Trial (IPTp) 10 6.6 21.1 G1 97.0 6.5 (UNAIDS) 5.0 100.0 24.9 6 
44 Nganda 200467 Tanzania 2003-2003 Survey 1 NA 42.3 G1 48.1 6.8 (UNAIDS) NA 100.0 17.5 3 
45 Njagi 200268 Kenya 1997-1999 Trial (IPTp) 1 13.3 100 G1/G2 50.0 22.4 (UNAIDS) 5.0 100.0 22.9 5 
46 Oduro 201027 Ghana 2006-2007 Survey 6 18.4 24.2 G1 53.6 2.2 (UNAIDS) NA 97.0 63.3 3 
47 Olliaro 200869 Senegal 2000-2007 Survey 1 9.5 21.7 G1 g 12.4 .8 (UNAIDS) NA 100.0 26.6 4 
48 Olorunda 201328 Nigeria 2010-2010 Survey 1 7.9 37.2 G1 13.9 4.1 (UNAIDS) NA 100.0 37.9 4 
49 Onyebuchi 201470 Nigeria 2012-2012 Survey 1 NA 45.2 G1/G2 100.0 3.4 (UNAIDS) NA 100.0 54.0 0 
50 Orobaton 201671 Nigeria 2014-2015 Survey 4 NA 18.3 G1 56.1 3.1 (UNAIDS) NA 56.6 33.5 0 
51 Parise 199872 Kenya 1994-1996 Trial (IPTp) 1 10.5 100 G1/G2 1.0 26.9 5.0 100.0 22.6 4 
52 Ramharter 200773 Gabon 2005-2006 Survey 3 10.2 28.7 G1 38.1 7.9 NA NA 45.9 3 
53 Rogawski 201274 Malawi 1997-2006 Survey 1 NA 47.8 G1 37.0 15.5 (UNAIDS) NA NA 27.7 4 
54 Rogerson 200075 Malawi 1997-1999 Survey 1 NA 46.0 G1 7.0 16.6 (UNAIDS) 0.25 100.0 27.7 2 
55 Sirima 200676 g Burkina Faso 2004-2004 Survey 2 12.1 31.1 G1 35.3 1.6 (UNAIDS) 0.25 NA 33.9 3 
56 Suleiman 200377 Sudan 1999-2001 Cohort 2 19.1 100 G1 1.0 0.1 (UNAIDS) NA 100.0 3.2 4 
57 Tetteh-Ashong 200578 Malawi 2005-2005 Survey 1 8.3 27.6 G1 17.6 0.1 (UNAIDS) 0.25 NA 27.4 3 
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Table S1: Study characteristics of observational studies and trials with information on outcomesa by SP doses  
 
Author and Publication 
Year Country 
Time 
period Design 
# of 
sites 
LBW 
(all) % 
Pauci-
gravidae 
% b 
Definition 
pauci-
gravidae 
ITN use 
%c  HIV % d 
Folate dose 
(mg)e 
ANC   
% f PfPr2-1011 
Quality 
score 
58 Tonga 201379 Cameroon 2011-2012 Survey 5 16.7 22.5 G1 19.3 6.0 NA NA 55.4 2 
59 Tongo 201180 Nigeria 2007-2008 Survey 2 9.0 11.6 G1 20.1 3.1 (UNAIDS) NA NA 50.8 2 
60 Toure 201424 Cote d'Ivoire 2009-2010 Survey 6 8.5 24.0 G1 16.7 4.0 NA 98.6 55.5 4 
61 Tutu 201181 Ghana 2005-2007 Survey 6 12.1 24.3 G1 26.5 2.3 (UNAIDS) NA NA 30.9 4 
62 Vanga-Bosson 201182 Cote d'Ivoire 2008-2008 Survey 6 10.6 16.1 G1 48.0 5.4 NA 97.8 65.4 5 
63 van Eijk 200423 g Kenya 1999-2000 Survey 1 9.7 50.2 G1 7.4 14.8 (UNAIDS) 5.0 100.0 7.0 5 
64 Van Spronsen 201283 Ghana 2010-2010 Survey 1 NA 34.0 G1 26.5 0.0 NA NA 57.4 1 
65 Verhoeff 199884 Malawi 1993-1994 Survey 1 NA 30.0 G1 1.0 0.0 NA 100.0 27.4 3 
66 Yussuf 201085 Tanzania 2009-2010 Survey 1 40.2 50.4 G1 91.5 4.0 NA 65.0 29.5 4 
Abbreviations (alphabetical order): dhps=dihydropteroate synthetase. G1, G2: first and second pregnancies. G3+ =3 or more previous pregnancies. NA=not available. PfPr2-10=P. 
falciparum parasite prevalence in children aged 2-10 years. NP=not published. SP=sulfadoxine-pyrimethamine. UNAIDS=Joint United Nations Programme on HIV and AIDS. 
 
Notes: 
a: Outcomes considered: Low birthweight, birth weight, maternal anaemia (<11 g/dl), maternal moderate to severe anaemia (<7-9 g/dl), haemoglobin, maternal malaria at the time of 
delivery (any test), placental malaria (any test), cord malaria, neonatal malaria, preterm delivery, gestational age  
b: The proportion of primigravidae among the study population was not reported in some studies; a best estimate was obtained from a Demographic and Health Survey (DHS) close in 
time and location for the following studies: Douambo et al. (2014):43 DHS 2010 Burkina Faso, Inyang-Etoh et al. (2011):51 DHS 2008 Nigeria, Kilauzi et al. (2013):53 DHS DRC 2007 
DRC & DHS 2013-2014 (midpoint), Moleins et al. (2010):26 DHS 2005 Senegal, and Olliaro et al. (2008):69 DHS 2005 Senegal. 
c: If ITN data was not reported in the study sample, DHS or MIS survey data were used instead matched closest in time and location. If survey data for a particular year was not 
available, the nearest value was recorded. If data from two surveys were available (i.e. the nearest survey before and after the start and completion of the study), a linear trend was 
assumed between the two coverage estimates of the two surveys. If ITN data was not available, then bed net data was used. Information on ITN or bednet use was commonly not 
reported for studies conducted prior to 2001 and if so, coverage of 1% was assumed in the analyses.  
d: Where data was not available for HIV-negative women only, the HIV status prevalence was reported as available in the study. If this was not available, HIV prevalence data among 
adult women was obtained from UNAIDS for year and country among female adults 15-49 years.86  
e: Folic acid dose used in the antenatal clinic as reported in the article 
f: Proportion of the study population who had visited an antenatal clinic during pregnancy 
g: Data was supplemented with information from the authors. 
h: These studies were part of the ‘IPTp-Mon’ study, a multi-country observational study specifically designed to address the relationship between the population level of SP resistance 
and IPTp-effectiveness.42 The study used a common protocol and data sets were available to the current study. 
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Table S2: Matching of studies with information on SP resistance markers (Pfdhps-A437G, Pfdhps-K540E and Pfdhps-A581G) 
 
IPTp study 
Author, Publication 
Year Study site, country 
Time 
period 
study 
Pfdhps 
A437G 
% 
Distance in km 
(location match) 
Years 
difference 
(study period 
match) 
Pfdhps 
K540E 
% 
Distance in km 
(location match) 
Years 
difference 
(study period 
match) 
Pfdhps 
A581G 
% 
Distance in km 
(location match) 
Years difference 
(study period 
match) N 
1 Aduloju 201329 Ado Ekiti, Nigeria 2011-2011 84.287 ~400 (Enugu) -1 (2010) 0.087 ~400 (Enugu) -1 (2010) 47.487 ~400 (Enugu) -1 (2010) 3887 
2 Alli 201330  Kubwa, Nigeria 2010-2011 84.287 ~400 (Enugu) 0 (2010) 0.087 ~400 (Enugu) 0 (2010) 47.487 ~400 (Enugu) 0 (2010) 3887 
3 Anchang Kimbi 
200931  
Mutengene, Cameroon 2007-2007 85.588 0 (Mutengene) -1 (2004-
2006) 
0.588 0 (Mutengene) -1 (2004-2006) 2.088 0 (Mutengene) -1 (2004-2006) 20088 
4 Apinjoh 201532 Mutengene, Cameroon 2008-2010 85.588 0 (Mutengene) -2 (2004-
2006) 
0.588 0 (Mutengene) -2 (2004-2006) 2.088 0 (Mutengene) -2 (2004-2006) 20088 
5 Arinaitwe 201333 Tororo, Uganda 2011-2011 97.342 0 (Tororo) 0  97.542 0 (Tororo) 0  0.242 0 (Tororo) 0  10042 
6 Aziken 201134 Benin City, Nigeria 2009-2009 84.287 ~260 (Enugu) +1 (2010) 0.087 ~260 (Enugu) +1 (2010) 47.487 ~260 (Enugu) +1 (2010) 3887 
7 Bouyou-Akotet 201035  Libreville, Gabon 2005-2006 69.089 0 0 6.989 0 0 0.089 0 0 2990 
8 Bouyou-Akotet 201636 Libreville, Melen, 
Gabon 
2011-2011 66.789 0 0 0.089 0 0 0.089 0 0 1890 
9 Braun 201537 Fort Portal, Uganda 2013-2013 10091 ~130 (Kihurura) 0 (2012-2014) 10091 ~130 (Kihurura) 0 (2012-2014) 12.991 ~130 (Kihurura) 0 (2012-2014) 6291 
10 Cassam 200738 Gaza, Maputo, 
Mozambique 
2005-2007 53.28 0 0 47.68 0 0 0.092,93 0 (Gaza, Maputo) 0 (2006-2007)  ~ 2700 
92,93 
11 Challis 200439 Matola, Boane, 
Mozambique 
2001-2002 26.194 0 (peri-urban 
Maputo) 
0 (2001) 25.494 0 (peri-urban 
Maputo) 
0 (2001) 0.095 0 (Maputo) 0 (1999-2004) 13494 
~100095 
12 Chukwuocha 201640 Owerri, Nigeria 2014-2014 96.887 ~230 (Benin City) 0 (2014-2015) 0.087 ~230 (Benin City) 0 (2014-2015) 52.687 ~230 (Benin City) 0 (2014-2015) 9587 
13 Coulibaly 201441  Ziniare, Burkina Faso 2010-2012 75.342 0 0 0.042 0 0 0.042 0 0 27342 
14 Desai 201542 Siaya, Kenya 2011-2012 93.042 0 0 95.642 0 0 5.742 0 0 5342 
15 Douamba 201443  Ouagadougou, 
Burkina Faso 
2013-2014 75.342 ~ 30 (Ziniare) -1 (2010-12) 0.042 ~ 30 (Ziniare) -1 (2010-12) 0.042 ~ 30 (Ziniare) -1 (2010-12) 27342 
16 Falade 200744 Ibadan, Nigeria 2003-2004 63.087 0 (Ibadan) 0 (2003) 0.087 0 (Ibadan) 0 (2003) 0.087 0 (Ibadan) 0 (2003) 3687 
17 Famanta 201145 Bamako, Mali 2009-2009 15.242 ~190 (Kita) 0 (2009-2010) 0.742 ~190 (Kita) 0 (2009-2010) 0.042 ~190 (Kita) 0 (2009-2010) 11742 
18 Fehintola 201646 Ile Ife, Nigeria 2013-2013 96.887 ~230 (Benin City) +1 (2014-
2015) 
0.087 ~230 (Benin City) +1 (2014-
2015) 
52.687 ~230 (Benin City) +1 (2014-2015) 9587 
19 Feng 201047 Blantyre, Malawi 1997-1999 63.68 0 0 74.08 0 0 0.096 0 (Ndirande) 0 (1997-1999) 14996 
 Feng 201047 Blantyre, Malawi 1999-2001 80.38 0 0 84.08 0 0 0.097 0 (Ndirande) 0 (1999-2001) 55097 
 Feng 201047 Blantyre, Malawi 2002-2006 93.58 0 0 95.097 0 (Ndirande) +1 (2007-
2009) 
2.097 0 (Ndirande) +1 (2007-2009) 556 
20 Gies 200948 Boromo, Burkina Faso 2004-2006 71.58 0 0 0.28 0 0 0.042 210 (Ziniare) +4 (2010) 27342 
21 
22 
Gutman 201321/ 
Kalilani 201420 
Blantyre & Machinga, 
Malawi 
2009-2011 94.442 0 0 99.642 0 0 1.542 0 0 13442 
23 Harrington 201149  Muheza, Tanzania 2002-2005 100.098 0 0 90.298  0 0 13.098 0 0 540 & 
581: 1798* 
24 Hommerich 200725  Agogo, Ghana 2006-2006 84.68 0 0 1.48 0 0 0.099 ~90 (Bekwai) +1 (2007-2008) 3599 
25 Igboeli 201750 Enugu State, Nigeria 2013-2013 96.887 ~ 260 (Benin City) +1 (2014-
2015) 
0.087 ~ 260 (Benin City) +1 (2014-
2015) 
52.687 ~ 260 (Benin City) +1 (2014-2015) 9587 
26 Inyang-Etho 201151 Calabar, Nigeria 2008-2008 84.287 ~ 260 (Enugu) +2 (2010) 0.087 ~ 260 (Enugu) +2 (2010) 47.487 ~ 260 (Enugu) +2 (2010) 3887 
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Table S2: Matching of studies with information on SP resistance markers (Pfdhps-A437G, Pfdhps-K540E and Pfdhps-A581G) 
 
IPTp study 
Author, Publication 
Year Study site, country 
Time 
period 
study 
Pfdhps 
A437G 
% 
Distance in km 
(location match) 
Years 
difference 
(study period 
match) 
Pfdhps 
K540E 
% 
Distance in km 
(location match) 
Years 
difference 
(study period 
match) 
Pfdhps 
A581G 
% 
Distance in km 
(location match) 
Years difference 
(study period 
match) N 
27 Kayentao 201452  Koro, Mali 2006-2007 44.88 0 0 0.18 0 0 0.042 ~200 (San) +3 (2010) 13042 
 Kayentao 201452  San, Mali 2006-2006 32.68 0 0 0.08 0 0 0.042 0 (San) +4 (2010) 13042 
 Kayentao 201452  Bougouni, Mali 2006-2007 33.88 0 0 0.28 0 0 0.042 ~650 (San) +3 (2010) 13042 
 Kayentao 201452 Djenne, Mali 2006-2006 32.78 0 0 0.08 0 0 0.042 ~130 (San) +4 (2010) 13042 
 Kayentao 201452 Kita, Mali 2009-2010 15.242 0 0 0.742 0 0 0.042 0 0 11742 
 Kayentao 201452  San, Mali 2009-2010 27.542 0 0 0.042 0 0 0.042 0 0 13042 
28 Kilauzi 201353 Kinshasa, DRC 2011-2011 100.091 0 (Kinshasa) +1 (2012-
2014) 
18.991 0 (Kinshasa) +1 (2012-
2014) 
8.191 0 (Kinshasa) +1 (2012-2014) 3791 
29 Likwela 201254 Mikalayi, DRC 2007-2007 76.98 0 0 11.38 0 0 0.012    
 Likwela 201254 Kisangani, DRC 2007-2007 74.18 0 0 27.8100 0 (Kisangani) 0 (2007) 5.6100 0 (Kisangani) 0 (2007) 18100 
 Likwela 201254 Rutshuru, DRC 2007-2007 88.1101 ~280 (Rukara & 
Mashesa, Rwanda) 
-1 (2005-
2006) 
91.2101 ~280 (Rukara & 
Mashesa, Rwanda) 
-1 (2005-2006) 45.6101 ~280 (Rukara & 
Mashesa, Rwanda) 
-1 (2005-2006) Mean†: 
776101 
30 Mace 201555 Mansa, Zambia 2009-2010 83.742 0 0 84.042 0 0 0.042 0 0 9742 
31 Mbaye 200656 Farafenni, The 
Gambia 
2002-2004 46.88 0 0 0.028 0 0 0.0102 ~260 (Thies & 
Tambacounda 
Senegal) 
0 (2003) 22102 
32 Menendez 200857 Manhica district, 
Mozambique 
2003-2005 62.9103 0 (Manhica) 0 (2002-2005) 68.6103 0 (Manhica) 0 (2002-2005) 0.092 50 (Magude) 0 (2004-2005) 70103‡  
~50092 
33 Minja 201358 Korogwe, Tanzania 2008-2010 10058 0 0 87.558 
 
0 0 42.958 0 0 581: 2858 
34 Moleins 201026 Oussouye, Senegal 2007-2008 43.08 0 0 0.068 0 0 0.0104 ~440 (Thies) 0 (2008) 93104 
35 Mosha 201459 Moshi & Rufiji, 
Tanzania 
2012-2012 93.28 0 0 88.3105 0-500 (Rufiji, 
Misungwi) 
-1 (2010-2011) 2.7105 0-500 (Rufiji, 
Misungwi) 
-1 (2010-2011) Mean†: 
224105 
36 Msyamboza 200960 Chikwawa, Malawi 2002-2004 87.08 0 0 92.78 0 0 0.0106 ~70 (Chileka) 0 (2003-2005) 95106 
37 Muhammad 201661 Nguru, Yobe state, 
Nigeria 
2014-2014 24.5107 ~ 1200 (Parakou, 
Benin) 
-2 (2012) 0.0107 ~ 1200 (Parakou, 
Benin) 
-2 (2012) 0.012   192107 
38 Mwangi 201562 South West Kisumu, 
Nyanza, Kenya  
2011-2013 93.042 ~70 (Siaya county) 0 (2011-2012) 95.642 ~70 (Siaya county) 0 (2011-2012) 5.742 ~70 (Siaya county) 0 (2011-2012) 5342 
39 Mwapasa 200463 Blantyre, Malawi 2000-2002 80.28 0 0 85.38 0 0 0.097 0 (Ndirande) 0 (1999-2001) 55097 
40 Namusoke 201064 Kampala, Uganda 2004-2005 93.58 0 0 95.18 0 0 0.0108 ~200 (Tororo) 0 (2003-2006) 55108§ 
41 Ndeserua 201565 Rufiji, Tanzania 2012-2012 75.0109 0 -1 (2010-
2011) 
76.3105 0 -1 (2010-2011) 0.0105 0 -1 (2010-2011) 96-
97105,109 
42 Nduka 20113 Umuahia, Afikpo, 
Okigwe, Nigeria 
2009-2009 84.287 ~130 (Enugu) +1 (2010) 0.087 ~130 (Enugu) +1 (2010) 47.487 ~130 (Enugu) +1 (2010) 3887 
43 Ndyomugyenyi 201166 Kabale district, 
Uganda 
2004-2007 100.011
0 
~70 (Bufundi) 0 (2005) 100.011
0 
~70 (Bufundi) 0 (2005) 45.0110 ~70 (Bufundi) 0 (2005) 60110 
44 Nganda 200467 Kibaha, Tanzania 2003-2003 19.8111 ~20 (Mlandizi) -1 (2002) 23.6111 ~20 (Mlandizi)  -1 (2002) 0.0111 ~20 (Mlandizi) -1 (2002) 106111 
45 Njagi 200268 Bondo, Kenya 1997-1999 42.8112 ~60 (Kisumu) 0 (1996-2000) 31.1112 ~60 (Kisumu) 0 (1996-2000) 0.0112 ~60 (Kisumu) 0 (1996-2000) 180112 
46 Oduro 201027  Navrongo, Ghana 2006-2007 53.899 0 0 (2007-2008) 0.099 0 0 (2007-2008) 0.099 0 0 (2007-2008) 3999 
47 Olliaro 200869 Mlomp, Senegal 2000-2007 39.38 0 0 0.038 0 0 0.0102 ~410 (Thies) 0 (2003 & 2008) 108104 
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Table S2: Matching of studies with information on SP resistance markers (Pfdhps-A437G, Pfdhps-K540E and Pfdhps-A581G) 
 
IPTp study 
Author, Publication 
Year Study site, country 
Time 
period 
study 
Pfdhps 
A437G 
% 
Distance in km 
(location match) 
Years 
difference 
(study period 
match) 
Pfdhps 
K540E 
% 
Distance in km 
(location match) 
Years 
difference 
(study period 
match) 
Pfdhps 
A581G 
% 
Distance in km 
(location match) 
Years difference 
(study period 
match) N 
48 Olorunda 201328 Ibadan, Nigeria 2010-2010 92.487 0 (Ibadan) -2 (2007-
2008) 
1.087 0 (Ibadan) -2 (2007-2008) 2.587 0 (Ibadan) -2 (2007-2008) 19887 
49 Onyebuchi 201470 Abakaliki, Nigeria 2012-2012 84.287 ~70 (Enugu) -2 (2010) 0.087 ~70 (Enugu) -2 (2010) 47.487 ~70 (Enugu) -2 (2010) 3887 
50 Orobaton 201671 Sokoto State, Nigeria 2014-2015 47.4107 ~620 (Parakou, 
Benin) 
-2 (2012) 0.0107 ~620 (Parakou, 
Benin) 
-2 (2012) 0.012,113   192107 
51 Parise 199872 Kisumu, Kenya 1994-1996 42.8112 0 (Kisumu) 0 (1996-2000) 31.1112 0 (Kisumu) 0 (1996-2000) 0.0112 0 (Kisumu) 0 (1996-2000) 180112 
52 Ramharter 200773 Lambarene, Libreville, 
Gabon 
2005-2006 57.9114 0 (Lambarene) 0 (2005-2007) 3.3114 0 (Lambarene) 0 (2005-2007) 0.0114 0 (Lambarene) 0 (2005-2007) 121114 
53 Rogawski 201274 Blantyre 1997-2006 80.28 0 0 85.38 0 0 0.097 0 (Ndirande) 0 (1999-2001) 55097 
54 Rogerson 200075 Blantyre, Malawi 1997-1999 63.68 0 0 74.08 0 0 0.097 0 (Ndirande) 0 (1999-2001) 55097 
55 Sirima 200676 Koupela district, 
Burkina Faso 
2004-2004 48.18 0 0 0.18 0 0 0.041 ~120 (Ziniare) +6 (2010-2011) 27341 
56 Suleiman 200377 Wad Medani, Sudan 1999-2001 13.3115 ~190 (Khartoum) -2 (1996-
1997) 
0.0115 ~190 (Khartoum) -2 (1996-1997) 0.0115 ~190 (Khartoum) -2 (1996-1997) 45115 
57 Tetteh-Ashong 200578 Chikwawa, Malawi 2005-2005 94.18 0 0 94.88 0 0 0.0106 ~70 (Chileka) 0 (2003-2005) 95106 
58 Tonga 201379 Sanaga-Maritime, 
Cameroon 
2011-2012 76.5116 ~180 (Yaounde) 0 (2010-2011) 0.0116 ~180 (Yaounde) 0 (2010-2011) 5.9116 ~180 (Yaounde) 0 (2010-2011) 51116 
59 Tongo 201180  Ibadan, Nigeria 2007-2008 92.487 0 (Ibadan) 0 (2007-2008) 1.087 0 (Ibadan) 0 (2007-2008) 2.587 0 (Ibadan) 0 (2007-2008) 19887 
60 Toure 201424 Abidjan and Comoe 
districts, Cote d’Ivoire 
2009-2010 52.1117 0 (Abidjan) -1 (2008) 0.9117 0 (Abidjan) -1 (2008) 0.9117 0 (Abidjan) -1 (2008) 94117 
61 Tutu 201181 Offinso district, Ghana 2005-2007 77.6118 ~60 (Sunyani) 0 (2005-2008) 0.0118 ~60 (Sunyani) 0 (2005-2008) 0.099 ~60 (Sunyani) 0 (2007-2008) 85118 
4999 
62 Vanga-Bosson 201182 Cote d'Ivoire 2008-2008 52.1117 0 (Abidjan) 0 (2008) 0.9117 0 (Abidjan) 0 (2008) 0.9117 0 (Abidjan) 0 (2008) 94117 
63 van Eijk 200423 Kisumu, Kenya 1999-2000 42.8112 0 (Kisumu) 0 (1996-2000) 31.1112 0 (Kisumu) 0 (1996-2000) 0.0112 0 (Kisumu) 0 (1996-2000) 180112 
64 Van Spronsen 201283 Gushegu, Ghana 2010-2010 73.08 0 0 0.78 0 0 0.099 ~ 200 (Navrongo) -2 (2008)  3999 
65 Verhoeff 199884 Chikwawa, Malawi 1993-1994 34.48 0 0 34.28 0 0 0.097 ~50 (Ndirande) +7 (1999-2001) 55097 
66 Yussuf 201085 Lindi, Tanzania 2009-2010 79.78 0 0 72.7105 ~150 
(Nachingwea) 
0 (2010-2011) 0.0105 ~150 (Nachingwea) 0 (2010-2011) 88105 
 
*581: SP-negative women. (info supplemented with tables from Okell) 
†mean of two sites: Rukara & Mashesa for Rutsuhuru (Likwela et al. 2012), Rufiji and Misungwi for Rufiji and Moshi (Mosha et al. 2014, Dr. Alifrangis, University of Copenhagen, personal 
communication) 
‡Placebo arm 
§Non-users of cotrimoxazole 
 
Matching: The following order of preference was used to match resistance with clinical data: 1) resistance data provided in the clinical study reports or by the authors of these reports for that 
location and time of study, where data from individuals with a recent history of SP intake were excluded; 2) estimates from continuous surface maps from WWARN’s geospatial models for 
Pfdhps-A437G and Pfdhps-K540E;8 and 3) for Pfdhps-A581G, or for studies after 2012, data were used from existing population prevalence maps of Pfdhps (Table S2).5-7,9  
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Prevalence was defined as the proportion of infected humans carrying at least one mutant clone with the specific haplotype. If contemporaneous molecular data was not available, but the local 
prevalence of a molecular marker was 0% in studies conducted >2 years after the clinical study, a value of 0% was assumed (e.g. Mali). If a high Pfdhps-A581G (>15%) was encountered, the 
Pfdhps-K540E prevalence of the same source study was used.  
Matches for the following studies involved distances over 300 km: 1) Aduloju et al. (2013),29 Ado Ekiti, Nigeria in 2011; reference Oguike et al. (2016),87 Enugu, Nigeria, 2010, ~400 km away; 2) 
Alli et al. (2013),30 Kubwa, Nigeria in 2010-2011; reference Oguike et al. (2016),87 Enugu, Nigeria, 2010, ~400 km away, 3) Muhammad et al. (2016),61 Nguru, Yobe State, Nigeria in 2014; 
reference Ogouyemi-Hounto et al. (2013)107 Parakou,Benin, 2012, ~1200 km away; 4) Orobaton et al. (2016),71 Sokoto, Nigeria in 2014-15; reference Ogouyemi-Hounto et al. (2013)107 ~620 km 
away. For Moshi in Tanzania in 2012 (Mosha et al. 2014)59 Mwanza was used as reference site (~600 km, 2010-2011), after consultation with local experts (Dr. Alifrangis, personal 
communication), instead of Muheza (~320 km).  
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Table S3: SP dose categories used and low birthweight across categories and mean SP doses where known, for studies with information on low birthweight 
Study (First author and 
publication year, country) Site 
Study 
Period 
SP dose 
groups 
LBW n/N (%) 
1st SP group 
(reference) 
Mean # 
SP doses 
reference 
group 
LBW n/N (%) 
2nd SP group  
Mean # 
SP doses 
2nd SP 
group 
LBW n/N (%) 
3rd SP group 
Mean # 
SP doses 
3rd SP 
group 
LBW n/N (%) 
4th SP group 
Mean # 
SP doses 
4th SP 
group Notes 
Alli 2013,30 Nigeria Kubwa 2010-2011 0,1+ 4/158 (2.5) 0 0/42 (0.0) 1.3      
Arinaitwe 2014,33 Uganda Tororo 2011-2011 01,2+ 29/227 (12.8) 0.9 25/325 (7.7) 2      
Aziken 2010,34 Nigeria Benin City 2009-2009 0,1+ 61/371 (16.4) 0 14/370 (3.8) 1.6      
Bouyou-Akotet 2010,35 Gabon Libreville 2005-2006 0,1+ 24/120 (20.0) 0 11/83 (13.3) 1.6     a 
Bouyou-Akotet 2016,36 Gabon Libreville, Melen 2011-2011 0,1,2+ 5/58 (8.6) 0 5/81 (6.2) 1 9/160 (5.6) 2.1    
Braun 2015,37 Uganda Fort Portal 2013-2013 0,1,2+ 8/56 (14.3) 0 20/186 (10.8) 1 32/366 (8.7) 2   b 
Cassam 2007,38 Mozambique Gaza 2005-2007 0,3+ 756/8650 (8.7) 0 488/6645 (7.3) 3     c 
Challis 2004,39 Mozambique Maputo 2001-2002 0,2+ 27/203 (13.3) 0 19/200 (9.5) 2      
Coulibaly 2014,42 Burkina Faso Ziniare 2011-2012 0,1,2+ 32/155 (20.6) 0 54/308 (17.5) 1 52/449 (11.6) 2    
Desai 2014,42 Kenya Nyanza 2011-2012 01,2,3+ 10/135 (7.4) 0.9 22/246 (8.9) 2 37/488 (7.6) 3.3    
Falade 2007,44 Nigeria Ibadan 2003-2004 0,1+ 16/171 (9.4) 0 31/595 (5.2) 1.8      
Famanta 2011,45 Mali Bamako 2009-2009 0,1,2+ 16/102 (15.7) 0 8/107 (7.5) 1 17/150 (11.3)    b 
Feng 2010,47 Malawi Blantyre 1997-1999 0,1,2+ 49/215 (22.8) 0 55/412 (13.3) 1 29/285 (10.2) 2.2    
Feng 2010, 47 Malawi Blantyre 1999-2001 0,1,2+ 20/117 (17.1) 0 56/426 (13.1) 1 29/293 (9.9) 2.1    
Feng 2010, 47 Malawi Blantyre 2002-2006 0,1,2,3+ 29/234 (12.4) 0 71/623 (11.4) 1 85/867 (9.8) 2 56/647 (8.7) 3.2  
Gies 2009,48 Burkina Faso Boromo 2004-2006 0,1,2+ 19/52 (36.5) 0 100/408 (24.5) 1 104/812 (12.8) 2    
Gutm'&Kali' 2014,42 Malawi Southern Malawi 2009-2011 01,2,3+ 28/334 (8.4) 0.9 70/1099 (6.4) 2 33/399 (8.3) 3.1    
Harrington 2011,49 Tanzania Muheza 2002-2005 0,1,2+ 6/80 (7.5) 0 8/156 (5.1) 1 3/136 (2.2) 2   b 
Hommerich 2007,25 Ghana Agogo 2006-2006 0,1,2,3+ 8/52 (15.4) 0 6/60 (10.0) 1 9/59 (15.3) 2 5/54 (9.3) 3 c 
Igboeli 2017,50 Nigeria Enugu State 2013-2013 0,1+ 8/101 (7.9) 0 7/315 (2.2) 2.2     d 
Kayentao 2014,52 Mali San 2006-2006 0,1,2+ 15/135 (11.1) 0 10/177 (5.6) 1 4/86 (4.7) 2    
Kayentao 2014, 52 Mali Koro 2006-2007 0,1,2+ 13/130 (10.0) 0 10/131 (7.6) 1 4/90 (4.4) 2    
Kayentao 2014,42 Mali Kita 2009-2010 0,1,2+ 18/124 (14.5) 0 14/121 (11.6) 1 24/299 (8.0) 2    
Kayentao 2014,42 Mali San 2009-2010 0,1,2+ 18/110 (16.4) 0 12/165 (7.3) 1 10/155 (6.5) 2.1    
Kayentao 2014, 52 Mali Bougouni 2006-2007 0,1,2+ 11/101 (10.9) 0 10/182 (5.5) 1 7/124 (5.6) 2    
Kayentao 2014, 52 Mali Djenne 2006-2006 0,1,2+ 10/110 (9.1) 0 6/106 (5.7) 1 7/139 (5.0) 2    
Kilauzi 2013,53 DRC Kinshasa 2011-2011 0,1+ 21/204 (10.3) 0 32/501 (6.4) 1      
Likwela 2012,54 DRC Mikalayi 2007-2007 01,2+ 35/363 (9.6) 0.5 2/114 (1.8)      e 
Likwela 2012,54 DRC Rutsuhuru 2007-2007 01,2+ 16/177 (9.0) 0.5 39/493 (7.9)      e 
Likwela 2012,54 DRC Kisangani 2007-2007 01,2+ 16/50 (32.0) 0.5 6/87 (6.9)      e 
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Table S3: SP dose categories used and low birthweight across categories and mean SP doses where known, for studies with information on low birthweight 
Study (First author and 
publication year, country) Site 
Study 
Period 
SP dose 
groups 
LBW n/N (%) 
1st SP group 
(reference) 
Mean # 
SP doses 
reference 
group 
LBW n/N (%) 
2nd SP group  
Mean # 
SP doses 
2nd SP 
group 
LBW n/N (%) 
3rd SP group 
Mean # 
SP doses 
3rd SP 
group 
LBW n/N (%) 
4th SP group 
Mean # 
SP doses 
4th SP 
group Notes 
Mace 2015,55 Zambia Mansa 2009-2010 01,2,3+ 17/157 (10.8) 0.8 9/138 (6.5) 2 4/128 (3.1)   3  
Mbaye 2006,56 Gambia Farafenni 2002-2004 0,2+ 46/716 (6.4) 0 40/738 (5.4) 2.7      
Menendez 2008,57 Mozambique Manhica 2003-2005 0,2+ 49/411 (11.9) 0 41/382 (10.7) 2      
Minja 2013,58 Tanzania Korogwe 2008-2010 01,2+ 4/17 (23.5) 0.5 43/705 (6.1) 2      
Moleins 2010,26 Senegal Oussouye 2007-2008 01,2+ 6/55 (10.9) 0.2 6/96 (6.3) 1.9      
Mosha 2014,59 Tanzania Rufiji/Moshi 2012-2012 01,2+ 9/169 (5.3) 0.8 9/181 (5.0) 2     b 
Msyamboza 2009,60 Malawi Chikwawa 2002-2004 01,2,3+ 65/427 (15.2) 0.9 118/620 (19.0) 2 39/271 (14.4) 3    
Muhammad 2016,61 Nigeria Nguru, Yobe State 2014-2014 01,2+ 58/104 (55.8) 0.9 10/80 (12.5) 2     b 
Namusoke 2010,64 Uganda Kampala 2004-2005 0,1,2+ 28/162 (17.3) 0 15/118 (12.7) 1 4/41 (9.8) 2    
Ndeserua 2015,65 Tanzania Rufiji 2012-2012 01,2+ 12/166 (7.2) 0.9 10/184 (5.4) 2      
Ndyomugyenyi 2011,66 Uganda Kabale 2004-2007 0,2+ 99/1577 (6.3) 0 107/1561 (6.9) 2      
Njagi 2002,68 Kenya Bondo 1997-1999 0,2+ 51/359 (14.2) 0 46/369 (12.5) 2      
Oduro 2010,27 Ghana Navrongo 2006-2007 0,1,2,3+ 76/391 (19.4) 0 89/515 (17.3) 1 132/640 (20.6) 2 121/731 (16.6) 3 c 
Olliaro 2008,69 Senegal Mlomp 2000-2007 0,1,2+ 57/532 (10.7) 0 7/63 (11.1) 1 22/309 (7.1) 2    
Olorunda 2013,28 Nigeria Ibadan 2010-2010 0,1+ 22/246 (8.9) 0 4/84 (4.8) 1.2      
Parise 1998,72 Kenya Kisumu 1994-1996 0,2,3+ 52/340 (15.3) 0 27/325 (8.3) 2 26/331 (7.9) 3.2    
Ramharter 2007,73 Gabon Lambarene 2005-2006 0,1,2+ 11/97 (11.3) 0 24/181 (13.3) 1 36/415 (8.7) 2   b 
Sirima 2006,76 Burkina Faso Koupela 2004-2004 0,1,2,3+ 16/66 (24.2) 0 30/163 (18.4) 1 48/362 (13.3) 2 41/529 (7.8) 3  
Suleiman 2003,77 Sudan Wad Medani 1999-2001 0,2+ 19/53 (35.8) 0 2/57 (3.5) 2      
Tetteh-Ashong 2005,78 Malawi Chikwawa 2005-2005 01,2,3+ 6/42 (14.3) 0.9 10/139 (7.2) 2 3/47 (6.4) 3    
Tonga 2013,79 Cameroon Sanaga-Maritime 2011-2012 0,1,2+ 7/68 (10.3) 0 4/75 (5.3) 1 2/52 (3.8) 2.2    
Tongo 2011,80 Nigeria Ibadan 2007-2008 01,2+ 68/649 (10.5) 0.1 4/147 (2.7) 2     b 
Toure 2014,24 Cote d'Ivoire Cote d'Ivoire 2009-2010 0,1,2,3+ 50/436 (11.5) 0 19/306 (6.2) 1 39/483 (8.1) 2 3/87 (3.4) 3 c 
Tutu 2011,81 Ghana Offinso 2005-2007 0,1,2,3+ 62/499 (12.4) 0 57/314 (18.2) 1 91/676 (13.5) 2 102/1094 (9.3) 3  
Vanga-Bosson 2011,82 Cote 
d'Ivoire National 2008-2008 0,1,2,3+ 35/309 (11.3) 0 79/653 (12.1) 1 80/792 (10.1) 2 13/191 (6.8) 3 c 
Yussuf 2010,85 Tanzania Lindi 2009-2010 0,1,2+ 55/123 (44.7) 0 18/35 (51.4) 1 26/88 (29.5) 2    
van Eijk 2004,23 Kenya Kisumu 1999-2000 0,1,2+ 112/948 (11.8) 0 48/606 (7.9) 1 22/319 (6.9) 2    
 
Note: SP dose groups 01 represent data from the combined 0 and 1 dose groups 
a. No data was provided in source manuscript on the mean number of doses for the 1+ dose group. The mean number of doses was therefore based on data from malaria 
indicator survey 2008 Gabon, from Table 5 which has data from 2006 
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b. No data was provided in source manuscript on the mean number of doses for the 2+ dose group: a mean of 2 doses was assumed for analysis  
c. No data was provided in source manuscript on the mean number of doses in the 3+ dose group: a mean of 3 doses was assumed for analysis 
d. No data was provided in source manuscript on the mean number of doses in the 1+ dose group: the mean was based on data from the DHS Nigeria 2013 
e. No data was provided in source manuscript on the mean number of doses in the 01 and 2+ dose groups: a mean of 0.5 and 2 doses were assumed respectively 
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Table S4: The effect of SP resistance on the effectiveness of IPTp on LBW by region and by gravidity, sub-Saharan Africa, 1997-2013 
  
 Univariate meta-regression  Multivariate* 
   N Coefficient (95% CI) p T
2 I2 % R2 % Coefficient (95% CI) p T2 I2 % R2 % 
West and Central Africa            
    Pfdhps-437 All studies 31 0.998 (0.994, 1.002) 0.38 0.03072 68.4 0.0 0.998 (0.995, 1.002) 0.39 0.01528 40.0 48.2 
 Excluding 7 low quality studies 27 1.001 (0.996, 1.005) 0.78 0.02282 65.2 0.0 1.001 (0.997, 1.005) 0.53 0.00647 16.1 70.4 
    Pfdhps-540 All studies 31 0.991 (0.963, 1.021) 0.55 0.03005 67.7 0.0 1.013 (0.983, 1.045) 0.38 0.01380 40.3 53.2 
 Excluding 7 low quality studies 27 0.989 (0.961, 1.017) 0.42 0.02199 63.9 0.0 1.012 (0.982, 1.044) 0.41 0.00570 14.2 74.0 
    Resistance 
 strata† 
All studies 31 0.76 (0.54, 1.07) 0.12 0.0269 65.9 8.8 0.82 (0.58, 1.16) 0.25 0.01434 40.1 51.4 
Excluding 7 low quality studies 27 0.78 (0.53, 1.15) 0.19 0.02068 63.1 5.5 0.87 (0.59, 1.29) 0.47 0.00625 15.5 71.4 
East and southern Africa            
    Pfdhps-437 All studies 26 1.002 (0.998, 1.005) 0.34 0.01453 64.4 2.1 1.004 (1.000, 1.008) 0.07 0.00688 44.4 53.6 
 Excluding 7 low quality studies 23 1.001 (0.998, 1.005) 0.43 0.01430 61.8 0.3 1.005 (1.000, 1.009) 0.0385 0.00858 43.0 40.1 
    Pfdhps-540 All studies 26 1.002 (0.999, 1.005) 0.12 0.01383 64.0 6.8 1.004 (1.002, 1.007) 0.0044 0.00363 31.8 75.5 
 Excluding 7 low quality studies 23 1.002 (0.999, 1.005) 0.11 0.01167 60.0 18.6 1.005 (1.002, 1.008) 0.0046 0.00559 28.0 61.0 
    Resistance   
 strata† 
All studies 26 1.16 (1.03, 1.30) 0.0158 0.00942 61.6 36.5 1.19 (1.08, 1.31) 0.0011 0.00159 24.9 89.3 
Excluding 7 low quality studies 23 1.15 (1.01, 1.31) 0.0321 0.00867 58.0 39.6 1.21 (1.09, 1.35) 0.0017 0.00313 19.2 78.1 
Paucigravidae            
    Pfdhps-437 All studies 34 1.000 (0.997, 1.003) 0.89 0.01500 49.1 0.0 1.000 (0.997, 1.003) 0.94 0.01782 51.5 0.0 
 Excluding 7 low quality studies 30 1.000 (0.996, 1.003) 0.86 0.01901 53.3 0.0 0.999 (0.996, 1.003) 0.77 0.02288 55.4 0.0 
    Pfdhps-540 All studies 34 1.001 (0.999, 1.003) 0.29 0.01290 46.5 7.0 1.001 (0.999, 1.003) 0.33 0.01562 48.6 0.0 
 Excluding 7 low quality studies 30 1.001 (0.999, 1.003) 0.46 0.01743 52.1 0.8 1.000 (0.998, 1.003) 0.77 0.02296 54.6 0.0 
    Resistance   
 strata† 
All studies 34 1.07 (0.98-1.16) 0.14 0.01202 45.1 13.4 1.07 (0.97-1.18) 0.19 0.01517 47.5 0.0 
Excluding 7 low quality studies 30 1.06 (0.96-1.18) 0.26 0.01667 51.2 5.1 1.06 (0.95-1.19) 0.29 0.02234 53.9 0.0 
Multigravidae            
    Pfdhsp-437 All studies 31 1.001 (0.997, 1.005) 0.60 0.02107 48.4 0.0 1.001 (0.997, 1.005) 0.66 0.01445 37.2 27.1 
 Excluding 7 low quality studies 27 1.001 (0.997, 1.005) 0.59 0.01667 45.1 0.0 1.000 (0.996, 1.005) 0.82 0.01767 43.0 0.0 
    Pfdhps-540 All studies 31 1.000 (0.998, 1.002) 0.82 0.02207 47.7 0.0 1.000 (0.998, 1.002) 1.00 0.01537 37.7 22.4 
 Excluding 7 low quality studies 27 1.000 (0.998, 1.002) 0.95 0.01796 45.4 0.0 1.000 (0.998, 1.002) 0.83 0.01804 42.8 0.0 
    Resistance    
 strata† 
All studies 31 1.01 (0.91-1.11) 0.92 0.02232 48.2 0.0 1.01 (0.92-1.11) 0.81 0.01513 37.5 23.6 
Excluding 7 low quality studies 27 1.01 (0.91-1.12) 0.90 0.01791 45.4 0.0 0.99 (0.89-1.11) 0.91 0.01802 42.9 0.0 
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 Pooled summary estimate from meta-analysis of the risk of LBW associated with each incremental dose of IPTp-SP for each subgroup (RR, 95% CI): West and Central 
Africa: 0.73 (0.67, 0.79) I2 67.5%; East and southern Africa: 0.85 (0.80, 0.90) I2 63.1%; Paucigravidae: 0.78 (0.73, 0.83) I2 47.5% RRR 22% (17-27); Multigravidae: 0.82 
(0.76, 0.89) I2 46.8% RRR 18% (11-24). 
*Multivariate meta-regression: adjusted for malaria transmission intensity, number of SP courses, proportion of paucigravidae (only in models by region) and study 
quality 
†Low resistance: Pfdhps-A437G <90% in Central and West Africa or Pfdhps-K540E <30% in East and southern Africa; moderate: Pfdhps-A437G ≥90% in Central and 
West Africa or Pfdhps-K540E ≥30% and Pfdhps-K540E <90% in East and southern Africa; high: Pfdhps-K540E ≥90% in East and southern Africa 
 
 
  
  van Eijk-IPTpMeta-Supplement-17mar19 
18 
 
 
Table S5: Sensitivity analysis of the effect of the thresholds used to categorise SP resistance into low, moderate and high on the primary endpoint (LBW) 
 N RRR % Metaregression † 
 by resistance strata 
by resistance 
strata Univariate Multivariate† 
 All (L|M|H) All (L|M|H) Coefficient (95% CI) p-value Tau
2 I2 % R
2 
% 
Coefficient (95% 
CI) p-value Tau
2 I2 % R2 % 
Definition 1 (primary analysis)             
   All studies 57 (30|16|11) 21 (27|21|7) 1.10 (1.03, 1.18) 0.0054 0.02040 65.4 22.8 1.10 (1.03, 1.17) 0.0043 0.01184 52.9 55.2 
   Excluding 7 low quality studies 50 (27|13|10) 20 (26|18|6) 1.10 (1.03, 1.18) 0.0075 0.01687 61.6 24.9 1.09 (1.02, 1.16) 0.0095 0.01067 49.7 52.5 
           
Alternative lower threshold for Pfdhps-A437G to define low and moderate resistance in East and southern Africa        
Definition 2 (sensitivity analysis)             
   All studies 57 (27|19|11) 21 (26|24|7) 1.09 (1.02, 1.17) 0.0140 0.02152 66.2 18.6 1.09 (1.02, 1.16) 0.0097 0.01259 54.0 52.4 
   Excluding 7 low quality studies 50 (25|15|10) 20 (26|17|6) 1.10 (1.03, 1.18) 0.0054 0.01668 61.5 25.7 1.10 (1.03, 1.17) 0.0060 0.01048 49.3 53.3 
Definition 3 (sensitivity analysis)             
   All studies  57 (22|24|11) 21 (25|26|7) 1.08 (1.00, 1.17) 0.0373 0.02307 67.9 12.8 1.07 (1.00, 1.15) 0.0433 0.01458 56.5 44.9 
   Excluding 7 low quality studies 50 (21|19|10) 20 (25|21|6) 1.09 (1.01, 1.18) 0.0203 0.01876 64.5 16.5 1.08 (1.01, 1.16) 0.0345 0.01225 52.7 45.4 
           
Alternative lower threshold for Pfdhps-K540E to define low and moderate resistance in East and southern Africa        
Definition 4 (sensitivity analysis)             
   All studies  57 (28|18|11) 21 (27|23|7) 1.10 (1.02, 1.18) 0.0090 0.02091 65.9 20.9 1.09 (1.03, 1.17) 0.0072 0.01197 53.2 54.7 
   Excluding 7 low quality studies 50 (25|15|10) 20 (25|20|6) 1.09 (1.02, 1.17) 0.0139 0.01746 62.3 22.2 1.09 (1.02, 1.16) 0.0147 0.01076 50.1 52.1 
Definition 5 (sensitivity analysis)             
   All studies  57 (33|13|11) 21 (26|24|7) 1.09 (1.02, 1.17) 0.0107 0.02093 64.7 20.8 1.09 (1.02, 1.15) 0.0101 0.01287 54.6 51.3 
   Excluding 7 low quality studies 50 (30|10|10) 20 (24|19|6) 1.09 (1.02, 1.17) 0.0119 0.01688 60.0 24.8 1.07 (1.01, 1.14) 0.0324 0.01194 52.4 46.8 
             
Alternative definition using Pfdhps-A581G to define high resistance in East and southern Africa         
Definition 6 (sensitivity analysis)             
   All studies  57 (30|18|9) 21 (27|19|9) 1.10 (1.02, 1.19) 0.0112 0.02144 66.2 18.9 1.09 (1.02, 1.17) 0.0157 0.01354 55.8 48.8 
   Excluding 7 low quality studies 50 (27|15|8) 20 (26|15|9) 1.10 (1.02, 1.19) 0.0145 0.01771 62.3 21.2 1.08 (1.00, 1.17) 0.0405 0.01237 53.4 44.9 
Definition 7 (sensitivity analysis)             
   All studies  57 (30|25|2) 21 (27|17|-2) 1.14 (1.03, 1.25) 0.0102 0.02154 64.9 18.5 1.12 (1.02, 1.23) 0.0178 0.01430 57.0 45.9 
   Excluding 7 low quality studies 50 (27|21|2) 20 (26|14|-2) 1.13 (1.03, 1.25) 0.0087 0.01876 61.1 22.4 1.12 (1.02, 1.23) 0.0227 0.01213 53.0 46.0 
Alternative definition using four categories (two categories for Pfdhps-A581G)          
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Definition 8 (sensitivity analysis) All (L|M|H|VH) All (L|M|H|VH)           
   All studies  57 (30|18|7|2) 21 (27|19|12|-2) 1.10 (1.03, 1.17) 0.0068 0.02087 66.0 21.1 1.08 (1.02, 1.15) 0.0147 0.01365 55.4 48.4 
   Excluding 7 low quality studies 50 (27|15|6|2) 20 (26|15|15|-2) 1.09 (1.02, 1.16) 0.0094 0.01737 62.4 22.7 1.07 (1.00, 1.14) 0.0354 0.01230 52.7 45.2 
Definitions 
Primary analysis 
Definition 1:  Low: Pfdhps-A437G <90% (West/Central) or Pfdhps-K540E <30% (East/southern) 
  Moderate: Pfdhps-A437G ≥90% (West/Central) or Pfdhps-K540E ≥30% & Pfdhps-K540E <90% (East/southern) 
  High: Pfdhps-K540E ≥90% (East/southern)   
 
Alternative lower threshold for Pfdhps-A437G to define low and moderate resistance in West and Central Africa 
Definition 2:  Low: Pfdhps-A437G <80% (West/Central) or Pfdhps-K540E <30% (East/southern) 
  Moderate: Pfdhps-A437G ≥80% (West/Central) or Pfdhps-K540E ≥30% & Pfdhps-K540E <90% (East/southern)  
  High: Pfdhps-K540E ≥90% (East/southern) 
Definition 3:  Low: Pfdhps-A437G <70% (West/Central) or Pfdhps-K540E <30% (East/southern) 
5906  Moderate: Pfdhps-A437G ≥70% (West/Central) or Pfdhps-K540E ≥30% & Pfdhps-K540E <90% (East/southern)  
  High: Pfdhps-K540E ≥90% (East/southern)  
 
Alternative lower threshold for Pfdhps-K540E to define low and moderate resistance in East and southern Africa 
Definition 4:  Low: Pfdhps-A437G <90% (West/Central) or Pfdhps-K540E <20% (East/Southern) 
20574  Moderate: Pfdhps-A437G ≥90% (West/Central) or Pfdhps-K540E ≥20% & Pfdhps-K540E <90% (East/southern)  
  High: Pfdhps-K540E ≥90% (East/southern)  
Definition 5:  Low: Pfdhps-A437G <90% (West/Central) or Pfdhps-K540E <40% (East/southern)  
20528  Moderate: Pfdhps-A437G ≥90% (West/Central) or Pfdhps-K540E ≥40% & Pfdhps-K540E <90% (East/southern) 
  High: Pfdhps-K540E ≥90% (East/southern) 
 
Alternative thresholds for Pfdhps-A581G to define resistance in East and southern Africa 
Definition 6: Low: Pfdhps-A437G <90% (West/Central) or Pfdhps-K540E <30% (East/southern)  
20102  Moderate: Pfdhps-A437G ≥90% (West/Central) or Pfdhps-K540E ≥30% & Pfdhps-A581G <1% (East/southern) 
  High: Pfdhps-A581G ≥1% (East/southern) 
Definition 7: Low: Pfdhps-A437G <90% (West/Central) or Pfdhps-K540E <30% (East/southern)  
20183  Moderate: Pfdhps-A437G ≥90% (West/Central) or Pfdhps-K540E ≥30% & Pfdhps-A581G <45% (East/southern) 
  High: Pfdhps-A581G ≥45% (East/southern) 
   
Alternative definition using a total of four categories including two categories for Pfdhps-A581G 
Definition 8: Low: Pfdhps-A437G <90% (West/Central) or Pfdhps-K540E <30% (East/southern)  
20652  Moderate-1: Pfdhps-A437G ≥90% (West/Central) or Pfdhps-K540E ≥30% & Pfdhps-A581G <1% (East/southern) 
  Moderate-2: Pfdhps-A581G ≥1% & Pfdhps-A581G <45% (East/southern) 
  High: Pfdhps-A581G ≥45% (East/southern) 
 
Abbreviations: L=Low resistance. M=Moderate resistance. H=High resistance. VH=very high resistance. CI=confidence interval. Pfdhps=dihydropteroate synthase P. 
falciparum. RRR=relative risk reduction. 
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†. Metaregression parameters from a model with the variable for SP-resistance introduced as a linear variable. Multivariate models adjusted for malaria transmission, number 
of SP courses received, proportion of paucigravidae, and study quality. 
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Table S6 Meta-analysis of the effectiveness of IPTp on other outcomes than low birthweight, sub-
Saharan Africa, 1997-2015 
 
Outcome 
and resistance category* 
Number of 
studies 
Pooled protective 
effectiveness† P‡ 
 I
2, % 
P-trend 
over 
resistance 
categories 
 
% Relative Risk Reduction 
(RRR) (95% CI) 
Anaemia (<11 g/dl)       
   All studies 28 14.5 (9.2, 19.5) <0.0001 83.8  
 Low resistance 10 29.9 (17.7, 40.3) <0.0001 83.6 
0.0352  Moderate resistance 11 8.5 (3.0, 13.6) 0.0028 63.3 
 High resistance 7 9.7 (-1.5, 19.7) 0.0879 89.1 
   Excluding low quality studies 22 13.8 (8.2, 19.0) <0.0001 79.9  
 Low resistance 7 25.2 (14.2, 34.8) <0.0001 75.7 
0.01793  Moderate resistance 9 7.9 (1.1, 14.3) 0.0231 70.1 
 High resistance 6 11.7 (0.0, 22.0) 0.0499 83.2 
Moderate anaemia §      
   All studies 14 21.1 (12.3, 29.0) <0.0001 34.3  
 Low resistance 3 40.9 (28.4, 51.3) <0.0001 0 
0.0049  Moderate resistance 6 19.8 (1.3, 34.9) 0.0376 0 
 High resistance 5 13.0 (3.3, 21.7) 0.0095 21.1 
   Excluding low quality studies 11 23.8 (12.8, 33.4) 0.0001 46.3  
 Low resistance 3 40.9 (28.4, 51.3) <0.0001 0 
0.0118  Moderate resistance 4 21.2 (-1.9, 39.0) 0.07 0 
 High resistance 4 13.3 (-0.3, 25.1) 0.06 40.8 
Placental malaria (any test)      
   All studies 45 17.2 (11.7, 22.3) <0.0001 71.0  
 Low resistance 22 19.4 (10.8, 27.1) <0.0001 73.5 
0.07  Moderate resistance 14 23.3 (17.9, 28.3) <0.0001 19.3 
 High resistance 9 3.4 (-4.6, 10.8) 0.40 28.1 
   Excluding low quality studies 37 17.5 (10.8, 23.7) <0.0001 73.9  
 Low resistance 18 19.4 (9.6, 28.1) 0.0002 74.7 
0.10  Moderate resistance 11 28.6 (23.4, 33.4) <0.0001 0 
 High resistance 8 1.6 (-7.3, 9.7) 0.72 22.3 
Maternal malaria (any test)      
   All studies 40 15.0 (9.1, 20.6) <0.0001 71.2  
 Low resistance 20 22.7 (14.6, 30.0) <0.0001 59.2 
0.0090  Moderate resistance 13 11.6 (0.1, 21.7) 0.0476 77.8 
 High resistance 7 2.1 (-5.0, 8.8) 0.55 13.8 
   Excluding low quality studies 32 14.7 (7.2, 21.7) 0.0002 73.7  
 Low resistance 16 21.9 (12.1, 30.6) <0.0001 65.2 
0.0251  Moderate resistance 10 11.8 (-4.1, 25.4) 0.14 78.3 
 High resistance 6 -1.1 (-8.7, 6.0) 0.77 0 
Any malaria at delivery**      
   All studies 54 16.5 (11.9, 20.9) <0.0001 74.7  
 Low resistance 29 20.0 (13.3, 26.2) <0.0001 73.6 
0.0164  Moderate resistance 16 17.9 (9.6, 25.5) 0.0001 72.6 
 High resistance 9 3.0 (-3.0, 8.6) 0.32 27.5 
   Excluding low quality studies 44 16.9 (11.5, 22.1) <0.0001 77.9  
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 Low resistance 23 20.8 (13.0, 27.9) <0.0001 76.2 
0.0228  Moderate resistance 13 19.5 (8.6, 29.1) 0.0008 77.5 
 High resistance 8 1.8 (-4.6, 7.8) 0.58 25.5 
Preterm delivery      
   All studies 26 18.1 (11.5, 24.3) <0.0001 54.6  
 Low resistance 13 24.9 (13.1, 35.0) 0.0001 60.6 
0.12  Moderate resistance 6 20.1 (4.3, 33.4) 0.0151 64.9 
 High resistance 7 10.6 (3.5, 17.3) 0.0043 6.6 
   Excluding low quality studies 21 17.1 (9.1, 24.3) 0.0001 57.6  
 Low resistance 11 23.0 (9.6, 34.4) 0.0014 61.6 
0.21  Moderate resistance 4 23.3 (-1.9, 42.3) 0.07 76.2 
 High resistance 6 8.9 (0.6, 16.6) 0.0366 7.9 
Continuous variables  
Pooled weighted mean 
difference (95% CI, 2 vs. 0 
doses) 
   
Haemoglobin (g/dl)      
   Overall 20 0.43 (0.25, 0.60) <0.0001 55.2  
 Low resistance 6 0.71 (0.51, 0.90) <0.0001 0.0 
0.0209  Moderate resistance 7 0.32 (0.14, 0.51) 0.0008 7.2 
 High resistance 7 0.28 (-0.03, 0.59) 0.08 50.5 
   Excluding low quality studies 16 0.58 (0.43, 0.74) <0.0001 7.1  
 Low resistance 5 0.74 (0.53, 0.94) <0.001 0 
0.06  Moderate resistance 5 0.53 (0.25, 0.82) 0.0003 0 
 High resistance 6 0.39 (0.05, 0.73) 0.0255 30.6 
Gestational age (weeks)      
   Overall 21 0.25 (0.11, 0.39) 0.0004 55.1  
 Low resistance 10 0.25 (0.06, 0.45) 0.0104 50.6 
0.78  Moderate resistance 5 0.38 (-0.09, 0.85) 0.11 69.8 
 High resistance 6 0.09 (-0.10, 0.27) 0.35 16.0 
   Excluding low quality studies 19 0.19 (0.06, 0.32) 0.0032 46.2  
 Low resistance 9 0.23 (0.04, 0.43) 0.0172 51.6 
0.62  Moderate resistance 4 0.25 (-0.32, 0.83) 0.39 54.8 
 High resistance 6 0.09 (-0.10, 0.27) 0.35 16.0 
Birthweight (grams)      
   Overall 41 93.1 (60.4, 125.9) <0.0001 70.1  
 Low resistance 18 100.9 (39.3, 162.4) 0.0013 78.0 
0.50  Moderate resistance 13 96.2 (54.8, 137.5) <0.001 46.1 
 High resistance 10 28.7 (-11.3, 68.6) 0.16 15.8 
   Excluding low quality studies 36 93.3 (56.8, 129.8) <0.0001 71.6  
 Low resistance 17 103.4 (39.3, 167.5) 0.0016 79.2 
0.56  Moderate resistance 10 81.0 (35.1, 127.0) 0.0005 40.9 
 High resistance 9 40.7 (-12.2, 93.7) 0.13 21.1 
Birthweight Paucigravidae 
(grams)  
    
   Overall 26 119.4 (69.9, 168.8) <0.0001 69.5  
 Low resistance 12 153.1 (60.6, 245.5) 0.0012 69.9 
0.0453  Moderate resistance 6 123.6 (84.5, 162.6) <0.0001 0.0 
 High resistance 8 25.7 (-35.2, 86.6) 0.41 35.7 
   Excluding low quality studies 22 127.9 (71.4, 184.3) <0.0001 71.3  
 Low resistance 11 167.4 (73.1, 261.7) 0.0005 69.8 0.07 
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 Moderate resistance 4 113.1 (69.7, 156.5) <0.0001 0.0 
 High resistance 7 40.6 (-41.1, 122.3) 0.33 44.9 
Birthweight Multigravidae 
(grams)  
    
   Overall 20 50.1 (6.6, 93.6) 0.0240 36.5  
 Low resistance 9 52.1 (-0.61, 104.9) 0.05 0.0 
0.94  Moderate resistance 4 75.8 (-62.7, 214.2) 0.28 60.1 
 High resistance 7 58.4 (-30.1, 146.9) 0.20 52.1 
   Excluding low quality studies 16 46.8 (-1.8, 95.4) 0.06 38.1  
 Low resistance 8 47.0 (-7.1, 101.1) 0.09 0.0 
0.98  Moderate resistance 2 141.9 (-157.9, 441.6) 0.35 70.9 
 High resistance 6 63.0 (-46.6, 172.7) 0.26 57.2 
* Low resistance: Pfdhps-A437G <90% in Central and West Africa or Pfdhps-K540E <30% in 
East and southern Africa; moderate: Pfdhps-A437G ≥90 in Central and West Africa or Pfdhps-
K540E ≥30% and Pfdhps-K540E <90% in East and southern Africa; high: Pfdhps-K540E ≥90% 
in East and southern Africa. 
†Pooled effect per incremental SP dose obtained by meta-analysis  
‡ P-value for Z-test that the risk reduction or the weighted mean difference is 0 
§ Moderate anaemia: Haemoglobin<9 g/dl or <8 g/dl or <7 g/dl 
** Any test of any blood compartment at delivery 
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Table S7: Meta-regression of the effect of SP resistance on the effectiveness of IPTp on other outcomes than low birthweight in sub-Saharan Africa, 1997-2015 
  
  Univariate meta-regression  Multivariate meta-regression* 
   N Coefficient (95% CI) p Tau
2 I2 % R2 % Coefficient (95% CI) p Tau2 I2 % R2 % 
Anaemia (<11 g/dl)            
    Pfdhps-437 All studies 28 1.003 (0.996, 1.009) 0.40 0.03031 83.9 0.0 1.001 (0.995, 1.007) 0.71 0.01590 76.3 46.4 
 Excluding low quality studies 22 1.003 (0.998, 1.008) 0.23 0.01807 80.6 0.0 1.001 (0.997, 1.005) 0.72 0.00708 64.3 60.1 
    Pfdhps-540 All studies 28 1.002 (1.000, 1.004) 0.0208 0.02346 81.7 20.9 1.001 (1.000, 1.003) 0.11 0.01191 73.6 59.8 
 Excluding low quality studies 22 1.002 (1.000, 1.003) 0.0482 0.01618 79.3 8.9 1.001 (1.000, 1.002) 0.17 0.00590 60.0 66.8 
 Resistance 
 strata† 
All studies 28 1.12 (1.01, 1.25) 0.0352 0.02582 82.6 12.9 1.08 (0.99, 1.19) 0.09 0.01159 73.2 60.9 
Excluding low quality studies 22 1.08 (0.98, 1.19) 0.10 0.01793 80.6 0.0 1.05 (0.97, 1.13) 0.22 0.00633 61.6 64.4 
Moderate anaemia ‡            
    Pfdhps-437 All studies 14 1.006 (1.001, 1.011) 0.0238 0.00415 0.0 73.9 1.008 (1.000, 1.016) 0.0399 0.00000 0.0 100.0 
 Excluding low quality studies 11 1.006 (1.000, 1.012) 0.0492 0.01001 16.7 58.1 1.009 (0.999, 1.020) 0.07 0.00000 0.0 100.0 
    Pfdhps-540 All studies 14 1.004 (1.002, 1.007) 0.0040 0.00000 0.0 100.0 1.004 (0.999, 1.009) 0.08 0.00000 0.0 100.0 
 Excluding low quality studies 11 1.004 (1.001, 1.007) 0.0112 0.00304 0.0 87.3 1.004 (0.998, 1.010) 0.14 0.00199 0.0 91.7 
 Resistance 
 strata† 
All studies 14 1.20 (1.07, 1.34) 0.0049 0.00000 0.0 100.0 1.16 (0.96, 1.39) 0.10 0.00000 0.0 100.0 
Excluding low quality studies 11 1.20 (1.05, 1.38) 0.0118 0.00264 0.0 89.0 1.15 (0.92, 1.44) 0.17 0.00264 0.0 89.0 
Placental malaria (any test)            
    Pfdhps-437 All studies 45 1.002 (1.000, 1.005) 0.06 0.02114 65.1 10.8 1.002 (1.000, 1.005) 0.09 0.01738 55.0 26.7 
 Excluding low quality studies 37 1.003 (1.000, 1.005) 0.07 0.02491 67.7 10.2 1.002 (0.999, 1.005) 0.15 0.01849 55.8 33.4 
    Pfdhps-540 All studies 45 1.001 (1.000, 1.003) 0.06 0.02122 65.1 10.4 1.002 (1.000, 1.003) 0.0291 0.01504 49.4 36.5 
 Excluding low quality studies 37 1.002 (1.000, 1.003) 0.09 0.02492 66.5 10.1 1.002 (1.001, 1.004) 0.0142 0.01401 46.1 49.5 
 Resistance 
 strata† 
All studies 45 1.07 (0.99, 1.16) 0.07 0.02174 65.9 8.3 1.09 (1.01, 1.18) 0.0273 0.01513 48.9 36.1 
Excluding low quality studies 37 1.08 (0.98, 1.18) 0.10 0.02592 68.3 6.6 1.12 (1.03, 1.23) 0.0127 0.01386 44.7 50.0 
Maternal malaria (any test)            
    Pfdhps-437 All studies 40 1.004 (1.001, 1.006) 0.0061 0.02469 65.6 20.7 1.004 (1.001, 1.007) 0.0035 0.02575 64.1 17.4 
 Excluding low quality studies 32 1.004 (1.001, 1.007) 0.0048 0.02601 62.7 31.5 1.004 (1.000, 1.007) 0.0048 0.02662 61.2 29.8 
    Pfdhps-540 All studies 40 1.002 (1.001, 1.004) 0.0057 0.02212 61.9 29.0 1.002 (1.001, 1.004) 0.0006 0.00473 33.1 84.8 
 Excluding low quality studies 32 1.002 (1.000, 1.004) 0.0386 0.03223 68.0 15.1 1.002 (1.000, 1.004) 0.0183 0.00992 38.1 73.9 
 Resistance 
 strata† 
All studies 40 1.13 (1.03, 1.24) 0.0090 0.02525 66.0 19.0 1.13 (1.06, 1.22) 0.0011 0.00832 38.3 73.3 
Excluding low quality studies 32 1.13 (1.02, 1.27) 0.0251 0.03261 69.4 14.1 1.12 (1.04, 1.22) 0.0064 0.00816 33.6 78.5 
Any malaria at delivery §            
    Pfdhps-437 All studies 54 1.003 (1.001, 1.005) 0.0093 0.01974 69.9 17.3 1.002 (1.000, 1.004) 0.0180 0.01556 59.0 35.8 
 Excluding low quality studies 44 1.003 (1.001, 1.006) 0.0116 0.02290 72.7 19.0 1.003 (1.000, 1.005) 0.0228 0.01702 61.0 40.9 
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    Pfdhps-540 All studies 54 1.002 (1.000, 1.003) 0.0068 0.01900 67.2 20.4 1.002 (1.001, 1.003) 0.0007 0.01195 51.6 50.6 
 Excluding low quality studies 44 1.002 (1.001, 1.003) 0.0081 0.02190 69.4 22.5 1.002 (1.001, 1.004) 0.0013 0.01301 54.0 54.8 
 Resistance 
 strata† 
All studies 54 1.09 (1.02, 1.16) 0.0164 0.02047 69.9 14.2 1.11 (1.04, 1.18) 0.0024 0.01375 55.4 43.2 
Excluding low quality studies 44 1.10 (1.01, 1.18) 0.0228 0.02426 73.0 14.2 1.12 (1.04, 1.20) 0.0040 0.01519 58.3 47.3 
Preterm delivery            
    Pfdhps-437 All studies 26 1.001 (0.997, 1.005) 0.59 0.02057 56.4 0.0 1.002 (0.997, 1.007) 0.53 0.02059 55.5 0.0 
 Excluding low quality studies 21 1.002 (0.997, 1.006) 0.41 0.02524 59.7 0.0 1.002 (0.996, 1.008) 0.54 0.03519 62.4 0.0 
    Pfdhps-540 All studies 26 1.001 (0.999, 1.003) 0.14 0.01630 53.6 3.2 1.001 (0.998, 1.003) 0.62 0.01919 55.1 0.0 
  Excluding low quality studies 21 1.001 (0.999, 1.004) 0.36 0.02183 58.6 0.0 1.000 (0.997, 1.004) 0.95 0.03377 62.4 0.0 
 Resistance 
 strata† 
All studies 26 1.08 (0.98, 1.19) 0.12 0.01634 53.3 2.9 1.05 (0.92, 1.20) 0.44 0.01782 53.8 0.0 
Excluding low quality studies 21 1.08 (0.96, 1.21) 0.21 0.02023 57.3 0.0 1.04 (0.88, 1.23) 0.61 0.03316 62.0 0.0 
 Continuous variables            
Birthweight (grams)            
    Pfdhps-437 All studies  41 -0.79 (-2.17, 0.60) 0.26 7026 64.3 6.0 -0.53 (-2.04, 0.98) 0.48 6455 60.3 13.5 
 Excluding low quality studies 36 -0.76 (-2.33, 0.80) 0.33 8339 64.9 4.8 -0.10 (-1.77, 1.57) 0.91 7380 61.5 15.8 
    Pfdhsp-540 All studies 41 -0.16 (-1.06, 0.75) 0.73 7659 66.6 0.0 -0.23 (-1.17, 0.70) 0.62 6630 61.4 11.2 
  Excluding low quality studies 36 -0.13 (-1.19, 0.93) 0.81 9061 67.7 0.0 0.20 (-0.92, 1.32) 0.72 7455 63.0 14.9 
 Resistance 
 strata† 
All studies 41 -15.7 (-61.9, 30.5) 0.50 7490 65.9 0.0 -22.0 (-69.8, 25.8) 0.36 6311 60.1 15.5 
Excluding low quality studies 36 -15.0 (-67.0, 37.1) 0.56 8884 67.2 0.0 -6.9 (-63.3, 49.5) 0.80 7293 61.9 16.7 
       Birthweight (grams) Paucigravidae            
    Pfdhps-437 All studies 26 -1.55 (-3.24, 0.14) 0.07 7912 58.8 22.6 -1.76 (-3.52, 0.10) 0.05 8242 59.6 19.4 
 Excluding low quality studies 22 -1.30 (-3.23, 0.62) 0.17 9788 62.5 14.0 -1.36 (-3.32, 0.60) 0.16 9599 61.9 15.6 
    Pfdhps-540 All studies 26 -0.92 (-2.13, 0.28) 0.13 8344 59.7 18.4 -1.55 (-2.83, -0.26) 0.0208 6995 56.5 31.6 
  Excluding low quality studies 22 -1.07 (-2.46, 0.31) 0.12 9062 59.7 20.3 -1.47 (-2.91, -0.02) 0.0466 7544 56.7 33.7 
 Resistance 
 strata† 
All studies 26 -58.9 (-116.5, -1.3) 0.0453 7003 54.5 31.5 -103.5 (-160.0, -47.0)  0.0010 3789 42.3 62.9 
Excluding low quality studies 22 -60.1 (-126.0, 5.9) 0.07 8225 56.9 27.7 -94.2 (-159.8, -28.6) 0.0074 4824 45.6 57.6 
       Birthweight (grams) Multigravidae            
    Pfdhps-437 All studies 20 0.11 (-1.57, 1.78) 0.89 2947 36.5 0.0 0.32 (-1.50, 2.14) 0.72 2605 32.4 0.0 
 Excluding low quality studies 16 0.21 (-1.63, 2.05) 0.81 3304 38.9 0.0 0.57 (-1.42, 2.55) 0.55 2604 32.6 0.0 
    Pfdhps-540 All studies 20 0.04 (-1.02, 1.10) 0.94 2904 35.3 0.0 0.31 (-0.96, 1.58) 0.61 2758 32.4 0.0 
  Excluding low quality studies 16 0.19 (-1.04, 1.43) 0.74 3573 37.6 0.0 0.62 (-0.79, 2.04) 0.36 2573 31.0 0.0 
 Resistance 
 strata† 
All studies 20 -2.0 (-55.3, 51.3) 0.94 2729 34.5 0.0 14.7 (-49.4, 78.8) 0.63 2482 32.5 0.0 
Excluding low quality studies 16 0.9, (-59.3, 61.0) 0.98 3057 36.5 0.0 26.5 (-47.0, 100.1) 0.45 2078 31.5 8.5 
  van Eijk-IPTpMeta-Supplement-17mar19 
26 
 
Haemoglobin (g/dl)            
    Pfdhps-437 All studies 20 -0.009 (-0.020, 0.001) 0.08 0.04726 40.3 28.3 -0.009 (-0.017, -0.001) 0.0315 0 0.0 100 
 Excluding low quality studies 16 -0.009 (-0.018, 0.000) 0.06 0 0.0 100 -0.006 (-0.018, 0.005) 0.26 0 0.0 100 
    Pfdhps-540 All studies 20 -0.005 (-0.008, -0.002) 0.0041 0.01583 14.9 76.0 -0.002 (-0.006, 0.002) 0.37 0.00624 0.0 90.6 
  Excluding low quality studies 16 -0.003 (-0.007, 0.000) 0.08 0 0.0 100 0.000 (-0.005, 0.004) 0.82 0 0.0 100 
 Resistance 
 strata† 
All studies 20 -0.23 (-0.42, -0.04) 0.0209 0.02865 23.1 55.6 -0.13 (-0.30, 0.05) 0.15 0.00078 0.0 98.8 
Excluding low quality studies 16 -0.18 (-0.36, 0.01) 0.06 0 0.0 100 -0.06 (-0.28, 0.17) 0.58 0 0.0 100 
Gestational age (weeks)            
    Pfdhps-437 All studies 21 0.001 (-0.005, 0.007) 0.70 0.05536 55.5 0.0 0.001 (-0.005, 0.007) 0.71 0.02659 34.0 44.4 
 Excluding low quality studies 19 0.000 (-0.006, 0.005) 0.86 0.03330 44.5 0.0 0.000 (-0.007, 0.007) 0.98 0.02748 37.4 0.0 
    Pfdhps-540 All studies 21 0.000 (-0.004, 0.003) 0.87 0.05308 50.6 0.0 0.001 (-0.004, 0.006) 0.66 0.02742 34.5 42.6 
  Excluding low quality studies 19 0.000 (-0.003, 0.004) 0.92 0.03630 44.6 0.0 0.000 (-0.005, 0.006) 0.86 0.02658 37.4 1.8 
 Resistance 
 strata† 
All studies 21 -0.03 (-0.22, 0.17) 0.78 0.05289 51.5 0.0 -0.03 (-0.26, 0.21) 0.80 0.02847 35.6 40.4 
Excluding low quality studies 19 -0.04 (-0.22, 0.13) 0.62 0.02779 41.8 0.0 -0.08 (-0.34, 0.19) 0.55 0.02147 35.3 20.7 
Abbreviations: N=number of studies. CI=confidence interval. 
* Multivariate metaregression: adjusted for malaria transmission intensity, number of SP courses, study quality and proportion of paucigravidae; for continuous variables number of SP courses 
not included (comparison is 0 vs. 2 doses of SP). For birthweight by gravidity, proportion of paucigravidae was not included.  
† Resistance strata: Definition of SP resistance using molecular markers: Low resistance: Pfdhps-A437G <90% in Central and West Africa or Pfdhps-K540E <30% in East and southern 
Africa; moderate: Pfdhps-A437G ≥90 in Central and West Africa or Pfdhps-K540E ≥30% and Pfdhps-K540E <90% in East and southern Africa; high: Pfdhps-K540E ≥90% in East and 
southern Africa. This variable was introduced as a continuous variable. 
‡ Haemoglobin<9 g/dl or <8 g/dl or <7 g/dl 
§ Any test of any blood compartment at delivery 
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Table S8: Prevalence of Pfdhps resistance markers by resistance category and region, 57 settings in sub-
Saharan Africa with low birthweight information, 1994-2014 
Resistance level Region N Median (interquartile range) 
    Pfdhps-A437G Pfdhps-K540E Pfdhps-A581G 
Any level West & Central 31 57.9 (39.3-77.6) 0.1 (0.0-0.9) 0.0 (0.0-0.9) 
 East & southern 26 85.4 (62.9-94.1) 85.8 (47.6-94.8) 0.0 (0.0-5.6) 
 Overall 57 74.1 (44.8-92.4) 3.3 (0.0-84.0) 0.0 (0.0-2.5) 
   Low* West & Central 27 52.1 (33.8-75.3) 0.0 (0.0-0.7) 0.0 (0.0-0.0) 
 East & southern 3 26.1 (13.3-74.1) 25.4 (0.0-27.8) 0.0 (0.0-5.6) 
 Overall 30 52.1 (32.7-74.1) 0.1 (0.0-0.9) 0.0 (0.0-0.0) 
   Moderate* West & Central 4 94.6 (92.4-98.4) 1.0 (0.5-10.0) 5.3 (2.5-30.4) 
 East & southern 12 69.3 (48.0-82.0) 73.4 (39.4-84.0) 0.0 (0.0-0.0) 
 Overall 16 80.0 (58.1-92.8) 58.1 (25.0-80.2) 0.0 (0.0-2.6) 
   High* West & Central 0 NA NA NA 
 East & southern 11 94.1 (93.0-100.0) 95.1 (92.7-99.6) 2.0 (0.0-13.0) 
 Overall 11 94.1 (93.0-100.0) 95.1 (92.7-99.6) 2.0 (0.0-13.0) 
NA: not applicable.  
* Low resistance: Pfdhps-A437G <90% in Central and West Africa or Pfdhps-K540E <30% in East and 
southern Africa; moderate: Pfdhps-A437G ≥90% in Central and West Africa or (Pfdhps-K540E ≥30% and 
Pfdhps-K540E <90%) in East and southern Africa; high: Pfdhps-K540E ≥90% in East and southern Africa.  
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Table S9: Characteristics of included surveys by country showing the number of LBW events of women exposed to varying levels of malaria prevention 
in pregnancy before matching 
Country Year Survey Year IPTp 
adopted as 
policy 
Proportion 
women 
sleeping under 
an ITN1 
Proportion 
of women 
receiving 2+ 
doses SP1 
Mean % 
prevalence 
of A437G 
Mean % 
prevalence of 
K540E 
LBW / live 
birth no IPTp 
LBW / live 
births 1 dose 
IPTp 
LBW / live 
births 2 doses 
IPTp 
LBW / live 
births 3+ doses 
iptp 
Benin 2006 DHS 2005 19.6% 3.0% 77.03% 3.16% 1,310 / 10,003 24 / 142 18 / 163 12 / 117 
Benin 2011 DHS 2005 75.8% 22.8% 72.45% 2.31% 636 / 4,816 95 / 813 148 / 1,217 137 / 935 
Burkina Faso 2003 DHS 2005 3.0% 0.0% 62.95% 0.07% 1,235 / 7,212 0/0 0/0 1/9 
Burkina Faso 2010 DHS 2005 44.5% 38.5% 58.31% 0.21% 440 / 2,947 407 / 3,223 428 / 3,306 94 / 851 
Burundi 2010 DHS No policy 49.9% NA 88.80% 87.03% 604 / 4,821 0 / 5 0 / 3 0 / 8 
Cameroon 2011 DHS 2004 19.8% 25.6% 52.71% 0.45% 615 / 4,127 110 / 1,250 118 / 1,075 87 / 1,024 
Cote d’Ivoire 2011 DHS 2005 40.2% 17.6% 60.62% 0.73% 546 / 3,626 80 / 560 91 / 662 55 / 385 
DRC 2007 DHS 2004 7.1% 6.9% 77.19% 29.92% 355 / 4,316 29 / 467 12 / 224 18 / 168 
DRC 2013 DHS 2004 60.9% 14.3% 77.66% 25.55% 663 / 7,425 163 / 2,004 69 / 977 50 / 601 
Gabon 2012 DHS 2003 28.7% 2.6% 79.51% 2.45% 526 / 3,642 12 / 83 16 / 95 10 / 68 
Ghana 2003 DHS 2003 2.7% 1.0% 79.98% 0.55% 427 / 2,592 0 / 1 0 / 5 0 / 26 
Ghana 2008 DHS 2003 27.4% 45.5% 81.04% 1.20% 135 / 966 32 / 240 42 / 335 59 / 537 
Guinea 2005 DHS 2005 1.4%  3.6% 46.04% 0.31% 486 / 3,789 2 / 14 2 / 16 6 / 98 
Guinea 2012 DHS 2005 28.0% 17.8% 39.32% 0.39% 378 / 2,927 45 / 400 57 / 543 48 / 552 
Kenya 2003 DHS 1999 5.4% 6.8% 63.83% 62.74% 438 / 3,371 37 / 271 19 / 130 11 / 123 
Kenya 2008 DHS 1999 49.0% 15.1% 95.41% 92.21% 300 / 2,205 88 / 814 38 / 319 17 / 255 
Liberia 2013 DHS 2004 37.1% 47.6% 56.80% 1.05% 428 / 1,950 177 / 861 248 / 1,533 176 / 964 
Madagascar 2008 DHS 2004 46.2% 6.7% 45.45% 0.30% 1,338 / 7,433 62 / 394 49 / 379 20 / 156 
Malawi 2004 DHS 1993 14.7% 46.5% 84.19% 89.66% 251 / 1,392 328 / 2,331 255 / 2,240 143 / 1,047 
Malawi 2010 DHS 1993 35.2% 55.0% 95.26% 95.12% 274 / 1,535 591 / 4,691 490 / 4,688 299 / 2,310 
Mali 2006 DHS 2003 28.9% 11.2% 38.03% 0.11% 1,403 / 7,458 64 / 294 77 / 526 76 / 513 
Mali 2012 DHS 2003 73.2% 19.9% 26.71% 0.11% 488 / 2,750 177 / 1,251 158 / 1,136 125 / 928 
Mozambique 2011 DHS 2006 34.3% 18.6% 76.32% 56.74% 545 / 4,187 172 / 1,431 123 / 830 89 / 757 
Namibia 2006 DHS 2005 8.8% 10.6% 66.74% 5.96% 404 / 2,621 38 / 302 11 / 121 109 / 786 
Niger 2006 DHS 2005 13.3% 0.3% 42.20% 0.30% 1,296 / 5,801 0 / 0 1 / 4 2 / 21 
Niger 2012 DHS 2005 19.9% 34.8% 41.98% 0.28% 748 / 2,762 399 / 1,875 415 / 2,022 133 / 685 
Nigeria 2008 DHS 2004 4.8% 6.5% 51.01% 1.29% 2,461 / 15,496 60 / 673 47 / 576 69 / 567 
Nigeria 2013 DHS 2004 16.4% 14.6% 50.39% 1.19% 2,275 / 14,487 236 / 1,908 207 / 1,903 148 / 1,351 
Rwanda 2005 DHS 20052 17.2% 0.9% 80.87% 83.24% 530 / 5,233 2 / 50 3 / 23 1 / 27 
Senegal 2005 DHS 2004 8.6% 13.2% 44.72% 0.03% 1,506 / 5,759 149 / 532 111 / 518 58 / 243 
Senegal 2010 DHS 2004 36.0% 38.6% 40.28% 0.05% 567 / 2,559 527 / 2,341 347 / 2,030 184 / 1,021 
Sierra Leone 2007 DHS 2004 27.2% 12.0% 48.81% 0.58% 504 / 2,845 39 / 298 40 / 290 36 / 227 
Sierra Leone 2013 DHS 2004 52.6% 45.1% 47.46% 0.42% 459 / 2,775 143 / 1,520 237 / 2,141 194 / 1,781 
Tanzania 2005 DHS 2001 15.6% 21.7% 57.43% 51.88% 355 / 3,380 134 / 1,264 73 / 830 10 / 146 
Tanzania 2010 DHS 2001 56.9% 27.2% 88.18% 81.69% 128 / 1,548 112 / 1,766 104 / 1,523 10 / 166 
Uganda 2006 DHS 2000 10.0% 17.6% 93.97% 93.71% 580 / 2,931 107 / 815 69 / 485 38 / 259 
Uganda 2011 DHS 2000 46.9% 26.7% 96.02% 93.64% 429 / 2,462 161 / 1,062 102 / 753 67 / 476 
Zambia 2007 DHS 2001 32.7% 65.7% 66.20% 50.42% 69 / 569 91 / 878 94 / 897 137 / 1,767 
Zimbabwe 2005 DHS 2004 3.2% 6.8% 29.95% 25.54% 408 / 3,587 12 / 168 4 / 79 12 / 137 
  van Eijk-IPTpMeta-Supplement-17mar19 
29 
 
 
 
 
 
 
 
Zimbabwe 2010 DHS 2004 9.6% 7.8% 60.63% 39.01% 35 / 3,643 19 / 242 9 / 125 22 / 246 
Abbreviations: DRC=Democratic Republic of the Congo. 
aCoverage estimates derived from publications 
bRwanda ended IPTp as national policy in 2008 
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Supplemental Figures 
 
Figure S1: Map of countries and sites included in the analysis  
 
Blue dots represent the location of studies included in the aggregated data meta-analysis. Green and shaded areas 
represent countries with national survey data included in the individual participant data meta-analysis. 
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Figure S2: Relationship between the prevalence of the Pfdhps-A437G and Pfdhps-K540E mutation in the 
study locations in Central and West Africa and East and southern Africa 
 
Pfdhps=Plasmodium falciparum dihydropteroate synthetase  
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Figure S3: Funnel plots of small study effect by resistance strata 
 
SE=standard error, LBW=low birth weight. Low resistance=Pfdhps-A437G <90% in Central and West Africa or Pfdhps-
K540E <30% in East and southern Africa; moderate=Pfdhps-A437G ≥90% in Central and West Africa or (Pfdhps-K540E 
≥30% and Pfdhps-K540E <90%) in East and southern Africa; high=Pfdhps-K540E ≥90% in East and southern Africa. 
Funnel plot of the effect size (X-axis, the risk ratio of LBW associated with each incremental dose of IPTp-SP) and the 
standard error of the risk ratio (Y-axis). In the top left graph for all resistance strata, the dark blue circles, dark red triangles and 
green squares represent studies in low, moderate and high resistance areas respectively. One study with zero events in the 
intervention arm was excluded in the graphs. The asymmetry suggests a potential for small-study effect with smaller studies 
(larger standard errors) showing greater treatment effects. This can be observed overall (top left) and in each of the three 
resistance strata. The two-sided p-values for asymmetry of the funnel plot by Egger’s test were P<0.0001, P<0.0001, P<0.0001 
and P=0.0103 for all strata combined, and for low, moderate and high resistance respectively.  
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Figure S4: Meta-analysis of the risk of low birthweight associated with each incremental dose of IPTp-SP in all 
gravidae by sample size in areas with a high prevalence of Pfdhps-A581G, clinical studies 
 
Pfdhps=Plasmodium falciparum dihydropteroate synthetase  
* Reference refers to the group with 0 doses SP or 0 combined with 1 dose SP, and comparison refers to the other dose 
groups combined. For full sample size per dose-group, and average dose, see Table S2. 
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Figure S5: Pooled prevalence of Pfdhps-A581G in super resistance areas, surveys study* 
 
The pooled mutation prevalence were obtained with Metaprop: a Stata command to perform meta-analysis of binomial 
data.22 
   
35 
 
Supplemental References 
1. Malaria in Pregnancy Consortium. Malaria in Pregnancy Library. 2018. http://library.mip-
consortium.org (accessed September 18, 2018). 
2. Fehintola AO, Fehintola FO, Loto OM, Fasubaa OB, Bakare B, Ogundele O. Pregnancy and fetal 
outcome of placental malaria parasitemia in Ile-Ife, Nigeria. Trop J Obstet Gynaecol 2016; 33: 310–6. 
3. Nduka FO, Nwosu E, Oguariri RM. Evaluation of the effectiveness and compliance of intermittent 
preventive treatment (IPT) in the control of malaria in pregnant women in south eastern Nigeria. Ann 
Trop Med Parasitol 2011; 105: 599–605. 
4. van Eijk AM, Hill J, Povall S, Reynolds A, Wong H, Ter Kuile FO. The Malaria in Pregnancy Library: 
a bibliometric review. Malar J 2012; 11: 362. 
5. World Wide Antimalarial Resistance Network (WWARN). Molecular Surveyor. 2018. 
http://www.wwarn.org/dhfr-dhps-surveyor/#0 (accessed September 18, 2018). 
6. London School of Hygiene and Tropical Medicine. Drug resistance maps. Mapping the distribution of 
resistance genes of malaria in Africa. 2010. http://www.drugresistancemaps.org/ (accessed September 
18, 2018). 
7. Naidoo I, Roper C. Mapping 'partially resistant', 'fully resistant', and 'super resistant' malaria. Trends 
Parasitol 2013; 29: 505–15. 
8. Flegg JA, Patil AP, Venkatesan M, et al. Spatiotemporal mathematical modelling of mutations of the 
dhps gene in African Plasmodium falciparum. Malar J 2013; 12: 249. 
9. Naidoo I, Roper C. Drug resistance maps to guide intermittent preventive treatment of malaria in 
African infants. Parasitology 2011; 138: 1469–79. 
10. Picot S, Olliaro P, de Monbrison F, Bienvenu AL, Price RN, Ringwald P. A systematic review and 
meta-analysis of evidence for correlation between molecular markers of parasite resistance and 
treatment outcome in falciparum malaria. Malar J 2009; 8: 89. 
11. Oxford Big Data Institute, University of Oxford. The Malaria Atlas Project. 2018. 
http://www.map.ox.ac.uk/ (accessed September 18, 2018). 
12. Okell LC, Griffin JT, Roper C. Mapping sulphadoxine-pyrimethamine-resistant Plasmodium 
falciparum malaria in infected humans and in parasite populations in Africa. Sci Rep 2017; 7: 7389. 
13. Hijmans RJ. Introduction to the 'raster' package (version 2.6-7). 2017. https://cran.r-
project.org/web/packages/raster/vignettes/Raster.pdf (accessed September 18, 2018). 
14. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 
2003; 327: 557–60. 
15. Deeks JJ, Higgins JP, Altman DG. Analysing data and undertaking meta-analyses. In: Higgins JP, 
Green S, editors. Cochrane handbook for systematic reviews of interventions (version 5.1.0): The 
Cochrane Collaboration; 2011. 
16. Borenstein M, Hedges LS, Higgens JPT, Rothstein HR. Chapter 30 Publication Bias.  Introduction to 
meta-analysis. Chichester, United Kingdom: John Wiley & Sons, Ltd; 2009. 
17. Eisele TP, Larsen DA, Anglewicz PA, et al. Malaria prevention in pregnancy, birthweight, and 
neonatal mortality: a meta-analysis of 32 national cross-sectional datasets in Africa. Lancet Infect Dis 
2012; 12: 942–9. 
18. Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with 
applications to meta-analysis. Am J Epidemiol 1992; 135: 1301–9. 
19. Orsini N, Li R, Wolk A, Khudyakov P, Spiegelman D. Meta-analysis for linear and nonlinear dose-
response relations: examples, an evaluation of approximations, and software. Am J Epidemiol 2012; 
175: 66–73. 
20. Kalilani L, Taylor S, Madanitsa M, et al. Waning effectiveness of intermittent preventive treatment in 
pregnancy (IPTp) with sulphadoxine-pyrimethamine (SP) in the presence of high SP Resistance in 
Malawi. Am J Trop Med Hyg 2011; 85: 354-5 (abstr). 
21. Gutman G, Mwandama D, Wiegand RE, Ali D, Mathanga DP, Skarbinski J. Effectiveness of 
intermittent preventive treatment with sulfadoxine-pyrimethamine in pregnancy on maternal and infant 
birth outcomes in Machinga District, Malawi. J Infect Dis 2013; 208: 907–16. 
22. Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. 
Arch Public Health 2014; 72: 39. 
23. van Eijk AM, Ayisi JG, ter Kuile FO, et al. Effectiveness of intermittent preventive treatment with 
sulphadoxine-pyrimethamine for control of malaria in pregnancy in western Kenya: a hospital-based 
study. Trop Med Int Health 2004; 9: 351–60. 
24. Toure OA, Kone PL, Coulibaly ML, et al. Coverage and efficacy of intermittent preventive treatment 
with sulphadoxine pyrimethamine against malaria in pregnancy in Cote d'Ivoire five years after its 
implementation. Parasit Vectors 2014; 7: 495. 
   
36 
 
25. Hommerich L, von Oertzen C, Bedu-Addo G, et al. Decline of placental malaria in southern Ghana 
after the implementation of intermittent preventive treatment in pregnancy. Malar J 2007; 6: 144. 
26. Moleins I, Agnamey P. Malaria and pregnancy: impact of ontermittent preventive treatment with 
sulfadoxine-pyrimethamine on weight at birth at the Oussouye maternity (Casamance, Senegal). Revue 
Sage-Femme 2010; 9: 123–7. 
27. Oduro AR, Fryauff DJ, Koram KA, et al. Sulfadoxine-pyrimethamine-based intermittent preventive 
treatment, bed net use, and antenatal care during pregnancy: demographic trends and impact on the 
health of newborns in the Kassena Nankana District, northeastern Ghana. Am J Trop Med Hyg 2010; 
83: 79–89. 
28. Olorunda DC, Ajayi IO, Falade CO. Do frequent antenatal care visits ensure access and adherence to 
intermittent preventive treatment of malaria in pregnancy in an urban hospital in South West Nigeria? 
Afr J Biomed Res 2013; 16: 153–61. 
29. Aduloju OP, Ade-Ojo IP, Olaogun OD, Olofinbiyi BA, Akintayo AA. Effect of intermittent preventive 
treatment of malaria on the outcome of pregnancy among women attending antenatal clinic of a 
Nigerian Teaching Hospital. Trop J Obstet Gynaecol 2013; 30: 7–15. 
30. Alli LA, Isah AY, Jamda MA, Adesokan AA. Use of intermittent preventive treatment for malaria 
among pregnant women in Kubwa, Abuja, Nigeria. Int J Trop Dis Health 2013; 3: 339–45. 
31. Anchang-Kimbi JK, Achidi EA, Nkegoum B, Sverremark-Ekstrom E, Troye-Blomberg M. Diagnostic 
comparison of malaria infection in peripheral blood, placental blood and placental biopsies in 
Cameroonian parturient women. Malar J 2009; 8: 126. 
32. Apinjoh TO, Anchang-Kimbi JK, Mugri RN, et al. Determinants of infant susceptibility to malaria 
during the first year of life in South Western cameroon. Open Forum Infect Dis 2015; 2: ofv012. 
33. Arinaitwe E, Ades V, Walakira A, et al. Intermittent preventive therapy with sulfadoxine-
pyrimethamine for malaria in pregnancy: a cross-sectional study from Tororo, Uganda. PLoS One 
2013; 8: e73073. 
34. Aziken ME, Akubuo KK, Gharoro EP. Efficacy of intermittent preventive treatment with sulfadoxine-
pyrimethamine on placental parasitemia in pregnant women in midwestern Nigeria. Int J Gynaecol 
Obstet 2011; 112: 30–3. 
35. Bouyou-Akotet MK, Nzenze-Afene S, Ngoungou EB, et al. Burden of malaria during pregnancy at the 
time of IPTp/SP implementation in Gabon. Am J Trop Med Hyg 2010; 82: 202–9. 
36. Bouyou-Akotet MK, Mawili-Mboumba DP, Kendjo E, et al. Decrease of microscopic Plasmodium 
falciparum infection prevalence during pregnancy following IPTp-SP implementation in urban cities of 
Gabon. Trans R Soc Trop Med Hyg 2016; 110: 333–42. 
37. Braun V, Rempis E, Schnack A, et al. Lack of effect of intermittent preventive treatment for malaria in 
pregnancy and intense drug resistance in western Uganda. Malar J 2015; 14: 372. 
38. Cassam Y. The effect of falciparum malaria prevalence on the effectiveness of intermittent preventive 
treatment with sulfadoxine-pyrimethamine during pregnancy in reducing low birth weight in southern 
Mozambique. Pretoria, South Africa: University of Pretoria; 2007. 
https://repository.up.ac.za/handle/2263/29732 (accessed September 18, 2018). 
39. Challis K, Osman NB, Cotiro M, Nordahl G, Dgedge M, Bergstrom S. Impact of a double dose of 
sulphadoxine-pyrimethamine to reduce prevalence of pregnancy malaria in southern Mozambique. 
Trop Med Int Health 2004; 9: 1066–73. 
40. Chukwuocha UM, Nwakwuo GC, Alinnor LO. Knowledge and utilization of preventive measures in 
the control of neonatal malaria in south-eastern Nigeria. Tanzan J Health Res 2016; 18: 1–8. 
41. Coulibaly SO, Kayentao K, Taylor S, et al. Parasite clearance following treatment with sulphadoxine-
pyrimethamine for intermittent preventive treatment in Burkina-Faso and Mali: 42-day in vivo follow-
up study. Malar J 2014; 13: 41. 
42. Desai M, Gutman J, Taylor SM, et al. Impact of sulfadoxine-pyrimethamine resistance on effectiveness 
of intermittent preventive therapy for malaria in pregnancy at clearing infections and preventing low 
birth weight. Clin Infect Dis 2016; 62: 323–33. 
43. Douamba Z, Dao NG, Zohoncon TM, et al. Mother-to-children Plasmodium falciparum asymptomatic 
malaria transmission at Saint Camille Medical Centre in Ouagadougou, Burkina Faso. Malar Res Treat 
2014; 2014: 390513. 
44. Falade CO, Yusuf BO, Fadero FF, Mokuolu OA, Hamer DH, Salako LA. Intermittent preventive 
treatment with sulphadoxine-pyrimethamine is effective in preventing maternal and placental malaria 
in Ibadan, south-western Nigeria. Malar J 2007; 6: 88. 
45. Famanta A, Diakite M, Diawara SI, et al. Prevalence of maternal and placental malaria and of neonatal 
low birth weight in a semi-urban area of Bamako (Mali). Sante 2011; 21: 3–7. 
46. Fehintola AO. Prevalence and risk factors for placental parasitaemia at delivery among pregnant 
women in Ile Ife, Nigeria. Int J Clin Med Cancer Res 2015. 
   
37 
 
47. Feng G, Simpson JA, Chaluluka E, Molyneux ME, Rogerson SJ. Decreasing burden of malaria in 
pregnancy in Malawian women and its relationship to use of intermittent preventive therapy or bed 
nets. PLoS One 2010; 5: e12012. 
48. Gies S, Coulibaly SO, Ouattara FT, D'Alessandro U. Individual efficacy of intermittent preventive 
treatment with sulfadoxine-pyrimethamine in primi- and secundigravidae in rural Burkina Faso: impact 
on parasitaemia, anaemia and birth weight. Trop Med Int Health 2009; 14: 174–82. 
49. Harrington WE, Mutabingwa TK, Kabyemela E, Fried M, Duffy PE. Intermittent treatment to prevent 
pregnancy malaria does not confer benefit in an area of widespread drug resistance. Clin Infect Dis 
2011; 53: 224–30. 
50. Igboeli NU, Ukwe CV, Aguwa CN. Effect of antimalarial prophylaxis with sulphadoxine-
pyrimethamine on pregnancy outcomes in Nsukka, Nigeria. MalariaWorld J 2017; 8: 3. 
51. Inyang-Etoh EC, Agan TU, Etuk SJ, Inyang-Etoh PC. The role of prophylactic antimalarial in the 
reduction of placental parasitemia among pregnant women in Calabar, Nigeria. Niger Med J 2011; 52: 
235–8. 
52. Kayentao K. Burden of malaria in pregnancy in Mali and impact of dosing frequency and antimalarial 
drug resistance on the effectiveness of intermittent preventive therapy in pregnancy in Africa. 
Liverpool, UK: Liverpool School of Tropical Medicine; 2014. 
https://livrepository.liverpool.ac.uk/17795/ (accessed September 18, 2018). 
53. Kilauzi AL, Mulumba JGT, Matindii BA, Tamfum JJM, Ngongo LO, Mengema B. Field utilization 
patterns of insecticide-treated net and intermittent preventive treatment with sulphadoxine-
pyrimethamine in a resource poor endemic area: Patterns' associations with adverse mother or birth 
outcomes. Ann Trop Med Public Health 2013; 6: 603–7. 
54. Likwela JL, D'Alessandro U, Lokwa BL, Meuris S, Dramaix MW. Sulfadoxine-pyrimethamine 
resistance and intermittent preventive treatment during pregnancy: a retrospective analysis of birth 
weight data in the Democratic Republic of Congo (DRC). Trop Med Int Health 2012; 17: 322–9. 
55. Mace KE, Chalwe V, Katalenich BL, et al. Evaluation of sulphadoxine-pyrimethamine for intermittent 
preventive treatment of malaria in pregnancy: a retrospective birth outcomes study in Mansa, Zambia. 
Malar J 2015; 14: 69. 
56. Mbaye A, Richardson K, Balajo B, et al. A randomized, placebo-controlled trial of intermittent 
preventive treatment with sulphadoxine-pyrimethamine in Gambian multigravidae. Trop Med Int 
Health 2006; 11: 992–1002. 
57. Menendez C, Bardaji A, Sigauque B, et al. A randomized placebo-controlled trial of intermittent 
preventive treatment in pregnant women in the context of insecticide treated nets delivered through the 
antenatal clinic. PLoS One 2008; 3: e1934. 
58. Minja DT, Schmiegelow C, Mmbando B, et al. Plasmodium falciparum mutant haplotype infection 
during pregnancy associated with reduced birthweight, Tanzania. Emerg Infect Dis 2013; 19: 1446–54. 
59. Mosha D, Chilongola J, Ndeserua R, Mwingira F, Genton B. Effectiveness of intermittent preventive 
treatment with sulfadoxine-pyrimethamine during pregnancy on placental malaria, maternal anaemia 
and birthweight in areas with high and low malaria transmission intensity in Tanzania. Trop Med Int 
Health 2014; 19: 1048–56. 
60. Msyamboza KP, Savage EJ, Kazembe PN, et al. Community-based distribution of sulfadoxine-
pyrimethamine for intermittent preventive treatment of malaria during pregnancy improved coverage 
but reduced antenatal attendance in southern Malawi. Trop Med Int Health 2009; 14: 183–9. 
61. Muhammad HU, Giwa FJ, Olayinka AT, et al. Malaria prevention practices and delivery outcome: a 
cross sectional study of pregnant women attending a tertiary hospital in northeastern Nigeria. Malaria 
Journal 2016; 15: 326. 
62. Mwangi MN, Roth JM, Smit MR, et al. Effect of daily antenatal iron supplementation on Plasmodium 
infection in Kenyan women: A randomized clinical trial. JAMA 2015; 314: 1009–20. 
63. Mwapasa V. The interactions between Plasmodium falciparum malaria and HIV-1 in pregnant 
Malawian women. Chapel Hill, Michigan: University of Michigan; 2004. 
https://deepblue.lib.umich.edu/handle/2027.42/124143 (accessed September 18, 2018). 
64. Namusoke F, Rasti N, Kironde F, Wahlgren M, Mirembe F. Malaria burden in pregnancy at Mulago 
National Referral Hospital in Kampala, Uganda. Malar Res Treat 2010: Article ID 913857. 
65. Ndeserua R, Juma A, Mosha D, Chilongola J. Risk factors for placental malaria and associated adverse 
pregnancy outcomes in Rufiji, Tanzania: a hospital based cross sectional study. Afr Health Sci 2015; 
15: 810–8. 
66. Ndyomugyenyi R, Clarke SE, Hutchison CL, Hansen KS, Magnussen P. Efficacy of malaria prevention 
during pregnancy in an area of low and unstable transmission: an individually-randomised placebo-
controlled trial using intermittent preventive treatment and insecticide-treated nets in the Kabale 
Highlands, southwestern Uganda. Trans R Soc Trop Med Hyg 2011; 105: 607–16. 
   
38 
 
67. Nganda RY, Drakeley C, Reyburn H, Marchant T. Knowledge of malaria influences the use of 
insecticide treated nets but not intermittent presumptive treatment by pregnant women in Tanzania. 
Malar J 2004; 3: 42. 
68. Njagi JK. The effects of sulfadoxine-pyrimethamine intermittent treatment and pyrethroid impregnated 
bed nets on malaria morbidity in pregnancy and birth weight in Bondo district, Kenya. Nairobi, Kenya: 
University of Nairobi; 2002. http://uonlibrary.uonbi.ac.ke/content/effects-sulfadoxine-pyrimethamine-
intermittent-treatment-and-pyrethroid-impregnated-bed-nets (accessed September 18, 2018). 
69. Olliaro PL, Delenne H, Cisse M, et al. Implementation of intermittent preventive treatment in 
pregnancy with sulphadoxine/pyrimethamine (IPTp-SP) at a district health centre in rural Senegal. 
Malar J 2008; 7: 234. 
70. Onyebuchi AK, Lawani LO, Iyoke CA, Onoh CR, Okeke NE. Adherence to intermittent preventive 
treatment for malaria with sulphadoxine-pyrimethamine and outcome of pregnancy among parturients 
in South East Nigeria. Patient Prefer Adherence 2014; 8: 447–52. 
71. Orobaton N, Austin AM, Abegunde D, et al. Scaling-up the use of sulfadoxine-pyrimethamine for the 
preventive treatment of malaria in pregnancy: results and lessons on scalability, costs and programme 
impact from three local government areas in Sokoto State, Nigeria. Malar J 2016; 15: 533. 
72. Parise ME, Ayisi JG, Nahlen BL, et al. Efficacy of sulfadoxine-pyrimethamine for prevention of 
placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency 
virus infection. Am J Trop Med Hyg 1998; 59: 813–22. 
73. Ramharter M, Schuster K, Bouyou-Akotet MK, et al. Malaria in pregnancy before and after the 
implementation of a national IPTp program in Gabon. Am J Trop Med Hyg 2007; 77: 418–22. 
74. Rogawski ET, Chaluluka E, Molyneux ME, Feng G, Rogerson SJ, Meshnick SR. The effects of malaria 
and intermittent preventive treatment during pregnancy on fetal anemia in Malawi. Clin Infect Dis 
2012; 55: 1096–102. 
75. Rogerson SJ, Chaluluka E, Kanjala M, Mkundika P, Mhango C, Molyneux ME. Intermittent 
sulfadoxine-pyrimethamine in pregnancy: effectiveness against malaria morbidity in Blantyre, Malawi, 
in 1997-99. Trans R Soc Trop Med Hyg 2000; 94: 549–53. 
76. Sirima SB, Cotte AH, Konate A, et al. Malaria prevention during pregnancy: assessing the disease 
burden one year after implementing a program of intermittent preventive treatment in Koupela District, 
Burkina Faso. Am J Trop Med Hyg 2006; 75: 205–11. 
77. Suleiman IEDE, Mohamadani AAA, Mirgani OA. Malaria propylaxis during pregnancy in 
primigravidae using sulfadoxine/pyimethamine in Wad Medani - Sudan. Gezira J Health Sci 2003; 1: 
1–9. 
78. Tetteh-Ashong E. Evaluation of a screening method to assess the efficacy of intermittent preventive 
treatment with SP in pregnant women in Malawi. Liverpool, UK: Liverpool School of Tropical 
Medicine; 2005. (accessed September 18, 2018). 
79. Tonga C, Kimbi HK, Anchang-Kimbi JK, Nyabeyeu HN, Bissemou ZB, Lehman LG. Malaria risk 
factors in women on intermittent preventive treatment at delivery and their effects on pregnancy 
outcome in Sanaga-Maritime, Cameroon. PLoS One 2013; 8: e65876. 
80. Tongo OO, Orimadegun AE, Akinyinka OO. Utilisation of malaria preventive measures during 
pregnancy and birth outcomes in Ibadan, Nigeria. BMC Pregnancy Childbirth 2011; 11: 60. 
81. Tutu EO, Browne E, Lawson B. Effect of sulphadoxine-pyrimethamine on neonatal birth weight and 
perceptions on its impact on malaria in pregnancy in an intermittent preventive treatment programme 
setting in Offinso District, Ghana. Int Health 2011; 3: 206–12. 
82. Vanga-Bosson HA, Coffie PA, Kanhon S, et al. Coverage of intermittent prevention treatment with 
sulphadoxine-pyrimethamine among pregnant women and congenital malaria in Cote d'Ivoire. Malar J 
2011; 10: 105. 
83. van Spronsen JH, Schneider TA, Atasige S. Placental malaria and the relationship to pregnancy 
outcome at Gushegu District Hospital, Northern Ghana. Trop Doct 2012; 42: 80–4. 
84. Verhoeff FH, Brabin BJ, Chimsuku L, Kazembe P, Russell WB, Broadhead RL. An evaluation of the 
effects of intermittent sulfadoxine-pyrimethamine treatment in pregnancy on parasite clearance and risk 
of low birthweight in rural Malawi. Ann Trop Med Parasitol 1998; 92: 141–50. 
85. Yussuf SM. Effect of intermitent preventive treatment (IPTp) using sulphadoxine pyrimethamine (SP) 
on birth weight, Lindi region, 2009. Dar es Salaam, Tanzania: Muhimbili University of Health and 
Allied Sciences; 2010. http://ir.muhas.ac.tz:8080/jspui/handle/123456789/1059 (accessed September 
18, 2018). 
86. UNAIDS. AIDSinfo. 2017. http://aidsinfo.unaids.org (accessed September 18, 2018). 
87. Oguike MC, Falade CO, Shu E, et al. Molecular determinants of sulfadoxine-pyrimethamine resistance 
in Plasmodium falciparum in Nigeria and the regional emergence of dhps 431V. Int J Parasitol Drugs 
Drug Resist 2016; 6: 220–9. 
   
39 
 
88. Mbacham WF, Evehe MS, Netongo PM, et al. Efficacy of amodiaquine, sulphadoxine-pyrimethamine 
and their combination for the treatment of uncomplicated Plasmodium falciparum malaria in children 
in Cameroon at the time of policy change to artemisinin-based combination therapy. Malar J 2010; 9: 
34. 
89. Bouyou-Akotet MK, Tshibola ML, Mawili-Mboumba DP, et al. Frequencies of dhfr/dhps multiple 
mutations and Plasmodium falciparum submicroscopic gametocyte carriage in Gabonese pregnant 
women following IPTp-SP implementation. Acta Parasitol 2015; 60: 218-25. 
90. Bouyou-Akotet MK, Mawili-Mboumba DP, Tchantchou TD, Kombila M. High prevalence of 
sulfadoxine/pyrimethamine-resistant alleles of Plasmodium falciparum isolates in pregnant women at 
the time of introduction of intermittent preventive treatment with sulfadoxine/pyrimethamine in Gabon. 
J Antimicrob Chemotherapy 2010; 65: 438-41. 
91. Baraka V, Delgado-Ratto C, Nag S, et al. Different origin and dispersal of sulfadoxine-resistant 
Plasmodium falciparum haplotypes between Eastern Africa and Democratic Republic of Congo. Int J 
Antimicrob Agents 2017; 49: 456-64. 
92. Raman J, Little F, Roper C, et al. Five years of large-scale dhfr and dhps mutation surveillance 
following the phased implementation of artesunate plus sulfadoxine-pyrimethamine in Maputo 
Province, Southern Mozambique. Am J Trop Med Hyg 2010; 82: 788-94. 
93. Raman J, Mauff K, Muianga P, Mussa A, Maharaj R, Barnes KI. Five years of antimalarial resistance 
marker surveillance in Gaza Province, Mozambique, following artemisinin-based combination therapy 
roll out. PLoS One 2011; 6: e25992. 
94. Pearce RJ, Pota H, Evehe MS, et al. Multiple origins and regional dispersal of resistant dhps in African 
Plasmodium falciparum malaria. PLoS Med 2009; 6: e1000055. 
95. Raman J, Sharp B, Kleinschmidt I, et al. Differential effect of regional drug pressure on dihydrofolate 
reductase and dihydropteroate synthetase mutations in southern Mozambique. Am J Trop Med Hyg 
2008; 78: 256-61. 
96. Kublin JG, Dzinjalamala FK, Kamwendo DD, et al. Molecular markers for failure of sulfadoxine-
pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis 
2002; 185: 380-8. 
97. Artimovich E, Schneider K, Taylor TE, et al. Persistence of Sulfadoxine-Pyrimethamine Resistance 
Despite Reduction of Drug Pressure in Malawi. J Infect Dis 2015; 212: 694-701. 
98. Harrington WE, Mutabingwa TK, Muehlenbachs A, et al. Competitive facilitation of drug-resistant 
Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment. Proc 
Natl Acad Sci U S A 2009; 106: 9027–32. 
99. Alam MT, de Souza DK, Vinayak S, et al. Selective sweeps and genetic lineages of Plasmodium 
falciparum drug -resistant alleles in Ghana. J Infect Dis 2011; 203: 220-7. 
100. Taylor SM, Antonia AL, Parobek CM, et al. Plasmodium falciparum sulfadoxine resistance is 
geographically and genetically clustered within the DR Congo. Sci Rep 2013; 3: 1165. 
101. Karema C, Imwong M, Fanello CI, et al. Molecular correlates of high-level antifolate resistance in 
Rwandan children with Plasmodium falciparum malaria. Antimicrob Agents Chemother 2010; 54: 477-
83. 
102. Ndiaye D, Daily JP, Sarr O, et al. Mutations in Plasmodium falciparum dihydrofolate reductase and 
dihydropteroate synthase genes in Senegal. Trop Med Int Health 2005; 10: 1176-9. 
103. Mayor A, Serra-Casas E, Sanz S, et al. Molecular markers of resistance to sulfadoxine-pyrimethamine 
during intermittent preventive treatment for malaria in Mozambican infants. J Infect Dis 2008; 197: 
1737-42. 
104. Ndiaye D, Dieye B, Ndiaye YD, et al. Polymorphism in dhfr/dhps genes, parasite density and ex vivo 
response to pyrimethamine in Plasmodium falciparum malaria parasites in Thies, Senegal. Int J 
Parasitol Drugs Drug Resist 2013; 3: 135-42. 
105. Kavishe RA, Kaaya RD, Nag S, et al. Molecular monitoring of Plasmodium falciparum super-
resistance to sulfadoxine-pyrimethamine in Tanzania. Malar J 2016; 15: 335. 
106. Bell DJ, Nyirongo SK, Mukaka M, et al. Sulfadoxine-pyrimethamine-based combinations for malaria: 
a randomised blinded trial to compare efficacy, safety and selection of resistance in Malawi. PLoS One 
2008; 3: e1578. 
107. Ogouyemi-Hounto A, Ndam NT, Fadegnon G, et al. Low prevalence of the molecular markers of 
Plasmodium falciparum resistance to chloroquine and sulphadoxine/pyrimethamine in asymptomatic 
children in Northern Benin. Malar J 2013; 12: 413. 
108. Malamba S, Sandison T, Lule J, et al. Plasmodium falciparum dihydrofolate reductase and 
dihyropteroate synthase mutations and the use of trimethoprim-sulfamethoxazole prophylaxis among 
persons infected with human immunodeficiency virus. Am J Trop Med Hyg 2010; 82: 766-71. 
   
40 
 
109. Matondo SI, Temba GS, Kavishe AA, et al. High levels of sulphadoxine-pyrimethamine resistance 
Pfdhfr-Pfdhps quintuple mutations: a cross sectional survey of six regions in Tanzania. Malar J 2014; 
13: 152. 
110. Lynch C, Pearce R, Pota H, et al. Emergence of a dhfr mutation conferring high-level drug resistance in 
Plasmodium falciparum populations from southwest Uganda. J Infect Dis 2008; 197: 1598-604. 
111. Kidima W, Nkwengulila G, Premji Z, Malisa A, Mshinda H. Dhfr and dhps mutations in Plasmodium 
falciparum isolates in Mlandizi, Kibaha, Tanzania: association with clinical outcome. Tanzania Health 
Research Bulletin 2006; 8: 50-5. 
112. Iriemenam NC, Shah M, Gatei W, et al. Temporal trends of sulphadoxine-pyrimethamine (SP) drug-
resistance molecular markers in Plasmodium falciparum parasites from pregnant women in western 
Kenya. Malar J 2012; 11: 134. 
113. van Schalkwyk DA, Burrow R, Henriques G, et al. Culture-adapted Plasmodium falciparum isolates 
from UK travellers: in vitro drug sensitivity, clonality and drug resistance markers. Malar J 2013; 12: 
320. 
114. Mombo-Ngoma G, Oyakhirome S, Ord R, et al. High prevalence of dhfr triple mutant and correlation 
with high rates of sulphadoxine-pyrimethamine treatment failures in vivo in Gabonese children. Malar 
J 2011; 10: 123. 
115. Khalil IF, Ronn AM, Alifrangis M, et al. Response of Plasmodium falciparum to cotrimoxazole 
therapy: relationship with plasma drug concentrations and dihydrofolate reductase and dihydropteroate 
synthase genotypes. Am J Trop Med Hyg 2005; 73: 174-7. 
116. Chauvin P, Menard S, Iriart X, et al. Prevalence of Plasmodium falciparum parasites resistant to 
sulfadoxine/pyrimethamine in pregnant women in Yaounde, Cameroon: emergence of highly resistant 
pfdhfr/pfdhps alleles. J Antimicrob Chemother 2015; 70: 2566–71. 
117. Ako AAB, Johansson M, Traore R, et al. Sulphadoxine-Pyrimethamine resistant haplotypes in 
asymptomatically and symptomatically malaria infected individuals in Cote d'Ivoire. Malaria 
Chemotherapy Control and Elimination 2014; 3. 
118. Duah NO, Quashie NB, Abuaku BK, Sebeny PJ, Kronmann KC, Koram KA. Surveillance of molecular 
markers of Plasmodium falciparum resistance to sulphadoxine-pyrimethamine 5 years after the change 
of malaria treatment policy in Ghana. Am J Trop Med Hyg 2012; 87: 996-1003. 
119. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews 
and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535. 
 
  
   
41 
 
Prisma checklist 
Section/topic  # Checklist item  Reported on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  Main text Page 1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study 
appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.  
Main text Page 2  
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  Main text Page 5 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).  Main text Page 5 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including 
registration number.  
Page 5 (Prospero 
CRD42016035540) 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria 
for eligibility, giving rationale.  
Main text Page 5  
Appendix Page 2 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last 
searched.  
Main text Page 5 
Appendix Page 2 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  Appendix Page 2 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).  Figure 1, Appendix Page 2 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from 
investigators.  
Main text page 5-6 
Appendix Page 2 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.  Main text page 5-6 
Appendix Page 2 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and 
how this information is to be used in any data synthesis.  
Main text page 7 
Appendix Page 4 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  Main text page 7 
Appendix Page 4 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.  Main text page 7 
Appendix Page 4 
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Section/topic  # Checklist item  Reported on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).  Main text Page 7 
Appendix Page 4 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.  Main text page 7 
Appendix Page 4 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow 
diagram.  
Figure 1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.  Appendix Table S1 & S9 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  Table S1 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates 
and confidence intervals, ideally with a forest plot.  
Figure 2 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  Figure 2-4,  
Appendix Tables S4-S7 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  Appendix Figure S3-S4 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  Appendix Tables S4-S7 
Figure S4, S5 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare 
providers, users, and policy makers).  
Main text page 9 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting 
bias).  
Main text page 10 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  Main text page 9-10 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.  Main text page 10 
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